| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AC4 A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION
|
Landfeldt, E
|
|
2009
|
12 |
7 |
p. A221-
1 p.
|
artikel
|
| 2 |
AC3 NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS AFTER MAJOR ORTHOPAEDIC SURGERY
|
Wilke, T
|
|
2009
|
12 |
7 |
p. A221-
1 p.
|
artikel
|
| 3 |
AC1 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE OF METHOD ASSUMPTIONS
|
Nguyen, NH
|
|
2009
|
12 |
7 |
p. A221-
1 p.
|
artikel
|
| 4 |
AC2 SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR—EMPIRICAL FINDINGS FROM EUROPE
|
Schäfer, C
|
|
2009
|
12 |
7 |
p. A221-
1 p.
|
artikel
|
| 5 |
CASE1 ANÁLISE DE AVALIAÇÕES ECONÔMICAS EM SAÚDE NO PROCESSO DE AVALIAÇÃO DA INCORPORAÇÃO DE TECNOLOGIAS DO MINISTÉRIO DA SAÚDE DO BRASIL
|
Vieira, FS
|
|
2009
|
12 |
7 |
p. A483-
1 p.
|
artikel
|
| 6 |
CASE4 ASSESSMENT AND APPRAISAL IN THE NETHERLANDS
|
Delwel, GO
|
|
2009
|
12 |
7 |
p. A230-
1 p.
|
artikel
|
| 7 |
CASE1 DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES: EXPERIENCE FROM HUNGARY
|
Dankó, D
|
|
2009
|
12 |
7 |
p. A228-
1 p.
|
artikel
|
| 8 |
CASE2 EXPERIÊNCIA DO VILA VELHA HOSPITAL PARA INCORPORAÇÃO DE NOVAS TECNOLOGIAS EM SAÚDE NA PRESTAÇÃO DE SERVIÇOS DE SAÚDE SUPLEMENTAR
|
Figueira, CMG
|
|
2009
|
12 |
7 |
p. A483-
1 p.
|
artikel
|
| 9 |
CASE3 INSTRUMENTOS FINANCIEROS Y VIABILIDAD SECTORIAL
|
Lazarov, L
|
|
2009
|
12 |
7 |
p. A483-A484
nvt p.
|
artikel
|
| 10 |
CASE2 REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME
|
Phillips, S
|
|
2009
|
12 |
7 |
p. A229-
1 p.
|
artikel
|
| 11 |
CASE3 THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS
|
Filko, M
|
|
2009
|
12 |
7 |
p. A229-
1 p.
|
artikel
|
| 12 |
CN4 COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL
|
Pinto, CG
|
|
2009
|
12 |
7 |
p. A222-
1 p.
|
artikel
|
| 13 |
CN3 COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
|
Tatar, M
|
|
2009
|
12 |
7 |
p. A222-
1 p.
|
artikel
|
| 14 |
CN5 COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY
|
Schuler, US
|
|
2009
|
12 |
7 |
p. A224-A225
nvt p.
|
artikel
|
| 15 |
CN2 ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM
|
Orlewska, E
|
|
2009
|
12 |
7 |
p. A222-
1 p.
|
artikel
|
| 16 |
CN1 HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER INTERVENTIONS
|
Greenberg, D
|
|
2009
|
12 |
7 |
p. A221-A222
nvt p.
|
artikel
|
| 17 |
CN8 METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA
|
Schwander, B
|
|
2009
|
12 |
7 |
p. A225-
1 p.
|
artikel
|
| 18 |
CN6 TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
|
Yood, MU
|
|
2009
|
12 |
7 |
p. A225-
1 p.
|
artikel
|
| 19 |
CN7 TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
|
Franken, M
|
|
2009
|
12 |
7 |
p. A225-
1 p.
|
artikel
|
| 20 |
CO2 ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS
|
Hoyle, M
|
|
2009
|
12 |
7 |
p. A233-
1 p.
|
artikel
|
| 21 |
CO4 AUTOMATED PHONE CALLS IMPROVED ADHERENCE TO INHALED CORTICOSTEROIDS
|
Feldstein, A
|
|
2009
|
12 |
7 |
p. A490-
1 p.
|
artikel
|
| 22 |
CO1 ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF RIGHT-CENSORING
|
Guan, S
|
|
2009
|
12 |
7 |
p. A233-
1 p.
|
artikel
|
| 23 |
CO1 GANHOS ASSOCIADOS A EXAMES CLÍNICOS ASSOCIADOS AO RASTREAMENTO MAMOGRÁFICO PARA MULHERES ACIMA DOS 40 ANOS
|
Caleffi, M
|
|
2009
|
12 |
7 |
p. A489-
1 p.
|
artikel
|
| 24 |
CO3 HOW AND WHY AUTOMATED MEDICAL DATABASES SHOULD BE USED TO CREATE BACKGROUND OCCURRENCES FOR DRUG OUTCOMES AND SAFETY STUDIES: GLAUCOMA IN THIN (UK)
|
Maguire, A
|
|
2009
|
12 |
7 |
p. A489-
1 p.
|
artikel
|
| 25 |
CO3 INDIRECT SOCIAL COST OF MULTIPLE SCLEROSIS: RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY
|
Kirzinger, S
|
|
2009
|
12 |
7 |
p. A233-A234
nvt p.
|
artikel
|
| 26 |
CO4 MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA
|
Kang, SH
|
|
2009
|
12 |
7 |
p. A234-
1 p.
|
artikel
|
| 27 |
CO2 PRESCRIPCIÓN DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES HOSPITALIZADOS
|
Jirón, M
|
|
2009
|
12 |
7 |
p. A489-
1 p.
|
artikel
|
| 28 |
CS10 ANÁLISIS DE COSTO EFECTIVIDAD Y COSTO UTILIDAD DEL INTERFERÓN BETA-1B (INFB1B) FRENTE A INTERFERÓN BETA-1A (INFB1A) PARA EL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE REMITENTE RECIDIVANTE EN COLOMBIA
|
Romero, M
|
|
2009
|
12 |
7 |
p. A487-
1 p.
|
artikel
|
| 29 |
CS14 ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSISTENCE WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRATIVE CLAIMS DATABASE OF QUEBEC (CANADA)
|
Beland, SG
|
|
2009
|
12 |
7 |
p. A490-
1 p.
|
artikel
|
| 30 |
CS19 AUDITORIA BASEADA EM EVIDÊNCIAS (ABE): IMPACTO NO CUSTO DO TRATAMENTO QUIMIOTERÁPICO APÓS 3 ANOS DE IMPLANTA¸ÃO
|
Clark, LG
|
|
2009
|
12 |
7 |
p. A491-
1 p.
|
artikel
|
| 31 |
CS13 CLINICAL EFFECTIVENESS AND COST UTILITY OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS IN MEXICO
|
Rely, K
|
|
2009
|
12 |
7 |
p. A490-
1 p.
|
artikel
|
| 32 |
CS1 COST-EFFECTIVENESS ANALYSIS OF A CERVICAL CANCER VACCINE IN FIVE LATIN AMERICAN COUNTRIES
|
Colantonio, L
|
|
2009
|
12 |
7 |
p. A484-
1 p.
|
artikel
|
| 33 |
CS7 COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
|
Godoy, MR
|
|
2009
|
12 |
7 |
p. A486-A487
nvt p.
|
artikel
|
| 34 |
CS11 COST-EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF MAJOR DEPRESSION IN MEXICO
|
Idrovo, J
|
|
2009
|
12 |
7 |
p. A487-
1 p.
|
artikel
|
| 35 |
CS2 COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN SEVEN LATIN AMERICAN COUNTRIES
|
Pichon-Riviere, A
|
|
2009
|
12 |
7 |
p. A484-
1 p.
|
artikel
|
| 36 |
CS17 COSTOS DE LA ESCLEROSIS MÚLTIPLE EN COLOMBIA
|
Romero, M
|
|
2009
|
12 |
7 |
p. A491-
1 p.
|
artikel
|
| 37 |
CS16 COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO
|
Rely, K
|
|
2009
|
12 |
7 |
p. A490-A491
nvt p.
|
artikel
|
| 38 |
CS15 ECONOMIC BURDEN ASSOCIATED WITH DOSE-TITRATION AT INITIATION TO MANAGED CARE IN PATIENTS WITH NON-PSYCHOTIC MAJOR DEPRESSIVE DISORDER
|
Camacho, F
|
|
2009
|
12 |
7 |
p. A490-
1 p.
|
artikel
|
| 39 |
CS18 ECONOMIC EVALUATION OF BARIATRIC SURGERY AS TREATMENT FOR OBESITY AND ASSOCIATED COMORBIDITIES—ESTIMATION BY DISCRETE EVENT SIMULATION
|
Cabra, HA
|
|
2009
|
12 |
7 |
p. A491-
1 p.
|
artikel
|
| 40 |
CS9 ESTIMATION OF THE BURDEN OF CARDIOVASCULAR DISEASE ATTRIBUTABLE TO MODIFIABLE RISK FACTORS AND COST-EFFECTIVENESS ANALYSIS OF PREVENTIVE INTERVENTIONS TO REDUCE THIS BURDEN IN ARGENTINA
|
Rubinstein, A
|
|
2009
|
12 |
7 |
p. A487-
1 p.
|
artikel
|
| 41 |
CS5 GASTOS ELEVADOS COM MEDICAMENTOS DO PROGRAMA DE MEDICAMENTOS EXCEPCIONAIS DO MINISTÉRIO DA SAÚDE/BRASIL
|
Brandao, CMR
|
|
2009
|
12 |
7 |
p. A486-
1 p.
|
artikel
|
| 42 |
CS12 IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN COLOMBIA
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A487-A488
nvt p.
|
artikel
|
| 43 |
CS20 RELATIONSHIP BETWEEN ADHERENCE LEVEL TO STATINS AND CLINICAL ISSUES AND HEALTH CARE COSTS IN REAL LIFE CLINICAL SETTING
|
Dragomir, A
|
|
2009
|
12 |
7 |
p. A491-
1 p.
|
artikel
|
| 44 |
CS4 THE COST AND HEALTH CONSEQUENCES OF SUBCUTANEOUS IMMUNOTHERAPY PLUS BECLOMETHASONE DIPROPIONATE IN COLOMBIAN CHILDREN WITH MODERATE AND SEVERE ASTHMA
|
Hernández, L
|
|
2009
|
12 |
7 |
p. A484-
1 p.
|
artikel
|
| 45 |
CS8 THE ECONOMIC BURDEN OF GAUCHER AND FABRY'S DISEASE IN COLOMBIA. IMPLICATIONS FOR NATIONAL HEALTH INSURANCE
|
Pinto, DM
|
|
2009
|
12 |
7 |
p. A487-
1 p.
|
artikel
|
| 46 |
CS6 THE INTRODUCTION OF PRE-ENDOSCOPY (EGD) HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITION (HDIVPPI) IN THE MANAGEMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING (UGIB)—A BUDGET IMPACT ANALYSIS
|
Barkun, A
|
|
2009
|
12 |
7 |
p. A486-
1 p.
|
artikel
|
| 47 |
CS3 UN MODELO DE COSTO-UTILIDAD DEL TRASPLANTE RENAL EN COLOMBIA
|
Rosselli, D
|
|
2009
|
12 |
7 |
p. A484-
1 p.
|
artikel
|
| 48 |
DB2 PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY—COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN
|
Quinzler, R
|
|
2009
|
12 |
7 |
p. A234-
1 p.
|
artikel
|
| 49 |
DB4 RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES
|
Sun, SX
|
|
2009
|
12 |
7 |
p. A234-A235
nvt p.
|
artikel
|
| 50 |
DB3 USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY UNDIAGNOSED DIABETES MELLITUS IN PRIMARY CARE PRACTICES
|
Marelli, C
|
|
2009
|
12 |
7 |
p. A234-
1 p.
|
artikel
|
| 51 |
DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES
|
Goeree, R
|
|
2009
|
12 |
7 |
p. A234-
1 p.
|
artikel
|
| 52 |
DE3 HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED R&D?
|
Trushin, EF
|
|
2009
|
12 |
7 |
p. A222-A223
nvt p.
|
artikel
|
| 53 |
DE2 INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE
|
Cammarota, S
|
|
2009
|
12 |
7 |
p. A222-
1 p.
|
artikel
|
| 54 |
DE1 MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS
|
Zhang, JX
|
|
2009
|
12 |
7 |
p. A342-
1 p.
|
artikel
|
| 55 |
DE1 MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS
|
Zhang, JX
|
|
2009
|
12 |
7 |
p. A222-
1 p.
|
artikel
|
| 56 |
DE4 PRESCRIPTION DRUG FORMULARIES AND COVERAGE: DOES A DRUG BY ANY OTHER NAME SMELL AS SWEET?
|
Hsu, J
|
|
2009
|
12 |
7 |
p. A223-
1 p.
|
artikel
|
| 57 |
EE7 A DISCRETE CHOICE EXPERIMENT COMPARING PUBLIC AND DECISION-MAKER STATED PREFERENCES FOR PHARMACEUTICAL SUBSIDY DECISIONS
|
Whitty, JA
|
|
2009
|
12 |
7 |
p. A230-
1 p.
|
artikel
|
| 58 |
EE8 BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME
|
Goetghebeur, MM
|
|
2009
|
12 |
7 |
p. A230-
1 p.
|
artikel
|
| 59 |
EE2 DEAR POLICYMAKER: HAVE YOU MADE UP YOUR MIND?
|
Koopmanschap, M
|
|
2009
|
12 |
7 |
p. A225-A226
nvt p.
|
artikel
|
| 60 |
EE6 INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS: A SYSTEMATIC REVIEW
|
Johri, M
|
|
2009
|
12 |
7 |
p. A230-
1 p.
|
artikel
|
| 61 |
EE3 IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK
|
Mason, AR
|
|
2009
|
12 |
7 |
p. A226-
1 p.
|
artikel
|
| 62 |
EE4 MARKET ACCESS IN GERMANY: WHERE NEXT?
|
Zoellner, YF
|
|
2009
|
12 |
7 |
p. A226-
1 p.
|
artikel
|
| 63 |
EE5 THE SEESAW OF COST-EFFECTIVENESS THRESHOLDS: HOW RELAXED REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE HURDLES FOR NEW THERAPIES
|
Liwing, J
|
|
2009
|
12 |
7 |
p. A230-
1 p.
|
artikel
|
| 64 |
EE1 USING IQWIG'S EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT—A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
|
Siebert, U
|
|
2009
|
12 |
7 |
p. A225-
1 p.
|
artikel
|
| 65 |
HP1 CONHECIMENTO DA POPULA¸ÃO BRASILEIRA DO CÂNCER DE MAMA E SEU DIAGNÓSTICO
|
Caleffi, M
|
|
2009
|
12 |
7 |
p. A488-
1 p.
|
artikel
|
| 66 |
HP6 EVALUACIÓN ECONÓMICA DE LA TERAPIA CON ESTATINAS EN PREVENCIÓN SECUNDARIA: REVISIÓN SISTEMÁTICA DE LA LITERATURA
|
González R, MJ
|
|
2009
|
12 |
7 |
p. A492-
1 p.
|
artikel
|
| 67 |
HP7 FACTORES PREDICTIVOS DEL ÉXITO EN UN PROGRAMA DE CESACIÓN TABAQUICA EN MÉXICO
|
Heredia, I
|
|
2009
|
12 |
7 |
p. A492-
1 p.
|
artikel
|
| 68 |
HP2 HEALTH TECHNOLOGY ASSESSMENT IN LATIN-AMERICA AND THE CARIBBEAN, FACILITATORS AND BARRIERS FOR INTERNATIONAL COLLABORATION: A SURVEY
|
Pichon-Riviere, A
|
|
2009
|
12 |
7 |
p. A488-
1 p.
|
artikel
|
| 69 |
HP4 INFLUÊNCIA DA AVALIA¸ÃO DE TECNOLOGIAS EM SAÚDE NOS PROCESSOS DE TOMADA DE DECISÃO NO SISTEMA ÚNICO DE SAÚDE
|
Laranjeira, FO
|
|
2009
|
12 |
7 |
p. A488-
1 p.
|
artikel
|
| 70 |
HP5 PROFILE OF HTA USERS AND APPLICABILITY OF HTA REPORTS TO INFORM DECISIONS IN LATIN-AMERICA
|
Pichon-Riviere, A
|
|
2009
|
12 |
7 |
p. A491-A492
nvt p.
|
artikel
|
| 71 |
HP8 REGULACIÓN Y PATRONES DE PRÁCTICA ACERCA DE TRATAMIENTOS ORALES DE LA DIABETES TIPO 2 EN LATINOAMÉRICA
|
Augustovski, FA
|
|
2009
|
12 |
7 |
p. A492-
1 p.
|
artikel
|
| 72 |
ISPOR 2nd Latin America Conference Author Index
|
|
|
2009
|
12 |
7 |
p. A532-A534
nvt p.
|
artikel
|
| 73 |
ISPOR 2ND LATIN AMERICA CONFERENCE DISCLOSURE INFORMATION
|
|
|
2009
|
12 |
7 |
p. A530-A531
nvt p.
|
artikel
|
| 74 |
ISPOR Twelfth Annual European Congress Author Index
|
|
|
2009
|
12 |
7 |
p. A470-A481
nvt p.
|
artikel
|
| 75 |
ISPOR TWELFTH ANNUAL EUROPEAN CONGRESS DISCLOSURE INFORMATION
|
|
|
2009
|
12 |
7 |
p. A461-A469
nvt p.
|
artikel
|
| 76 |
MC4 COMPARISON OF DATA AVAILABILITY AND QUALITY FOR PHARMACOECONOMIC ANALYSIS IN BRAZIL VERSUS THE UNITED STATES AND EUROPEAN UNION: THE CASES OF DIABETES & HYPERTENSION
|
Araujo, G
|
|
2009
|
12 |
7 |
p. A486-
1 p.
|
artikel
|
| 77 |
MC8 COMPARISON OF METHODS: FOR IDENTIFYING DEPRESSION IN PATIENTS WITH DIABETES USING PHYSIOLOGIC, SOCIAL, AND DISEASE SEVERITY MEASURES
|
Feeney, P
|
|
2009
|
12 |
7 |
p. A489-
1 p.
|
artikel
|
| 78 |
MC3 PREDICCIÓN DEL RIESGO CARDIOVASCULAR EN PACIENTES DIABÉTICOS TIPO 2 UTILIZANDO ÁRBOLES DE DECISIÓN: PRUEBA DE CONCEPTO
|
Quiroz, E
|
|
2009
|
12 |
7 |
p. A486-
1 p.
|
artikel
|
| 79 |
MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
|
Dragomir, A
|
|
2009
|
12 |
7 |
p. A488-A489
nvt p.
|
artikel
|
| 80 |
MC2 SELF-PERCEPTION OF HEALTH IN LATIN AMERICA
|
Cabieses Valdes, B
|
|
2009
|
12 |
7 |
p. A485-A486
nvt p.
|
artikel
|
| 81 |
MC5 TOWARD AN ECONOMIC FRAMEWORK FOR UNDERSTANDING PERFORMANCE-BASED RISK-SHARING AGREEMENTS FOR INNOVATIVE MEDICAL PRODUCTS
|
Garrison, LP
|
|
2009
|
12 |
7 |
p. A488-
1 p.
|
artikel
|
| 82 |
MC1 VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD EQ-5D EN CHILE: ALCANCES METODOLÓGICOS
|
Valenzuela, P
|
|
2009
|
12 |
7 |
p. A485-
1 p.
|
artikel
|
| 83 |
MH1 A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER—COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
|
Félix, J
|
|
2009
|
12 |
7 |
p. A223-
1 p.
|
artikel
|
| 84 |
MH3 ANTIPSYCHOTIC USE AND DIABETES: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS
|
Moisan, J
|
|
2009
|
12 |
7 |
p. A223-
1 p.
|
artikel
|
| 85 |
MH4 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM): EFFECTS ON QUALITY OF LIFE AND RESOURCE USE
|
Purayidathil, FW
|
|
2009
|
12 |
7 |
p. A223-A224
nvt p.
|
artikel
|
| 86 |
MH2 THE COST-EFFECTIVENESS OF OPPORTUNISTIC SCREENING AND MINIMAL CONTACT PSYCHOTHERAPY TO PREVENT DEPRESSION IN PRIMARY CARE PATIENTS
|
Van den Berg, M
|
|
2009
|
12 |
7 |
p. A223-
1 p.
|
artikel
|
| 87 |
MO4 BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS: DATA FROM THE PREMIER AND ARMADA TRIALS
|
Vanness, D
|
|
2009
|
12 |
7 |
p. A227-
1 p.
|
artikel
|
| 88 |
MO1 COHORT MODELLING—IS THE APPROACH TOO OLD FOR THE ELDERLY?
|
Ethgen, O
|
|
2009
|
12 |
7 |
p. A226-
1 p.
|
artikel
|
| 89 |
MO12 COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS
|
Lieuw On, MML
|
|
2009
|
12 |
7 |
p. A235-
1 p.
|
artikel
|
| 90 |
MO10 EARLY MODELLING: METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS
|
Taylor, MJ
|
|
2009
|
12 |
7 |
p. A235-
1 p.
|
artikel
|
| 91 |
MO7 EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C
|
Cawston, H
|
|
2009
|
12 |
7 |
p. A231-
1 p.
|
artikel
|
| 92 |
MO9 HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS
|
Heeg, BMS
|
|
2009
|
12 |
7 |
p. A235-
1 p.
|
artikel
|
| 93 |
MO2 IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES: A PILOT STUDY
|
Prenger, R
|
|
2009
|
12 |
7 |
p. A226-
1 p.
|
artikel
|
| 94 |
MO8 MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES
|
Desai, R
|
|
2009
|
12 |
7 |
p. A231-
1 p.
|
artikel
|
| 95 |
MO6 MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS: A NOVEL APPROACH
|
Skedgel, C
|
|
2009
|
12 |
7 |
p. A231-
1 p.
|
artikel
|
| 96 |
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R
|
Bischof, M
|
|
2009
|
12 |
7 |
p. A226-A227
nvt p.
|
artikel
|
| 97 |
MO5 THE USE OF SURVIVAL ANALYSES FOR COST-EFFECTIVENESS MODELS: AN EVALUATION OF METHODS USED IN NICE APPRAISALS
|
Guyot, P
|
|
2009
|
12 |
7 |
p. A231-
1 p.
|
artikel
|
| 98 |
MO11 WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE?
|
Ishak, KJ
|
|
2009
|
12 |
7 |
p. A235-
1 p.
|
artikel
|
| 99 |
PCASE1 AMPLIAÇÃO DO SERVIÇO DE HEPATOLOGIA CLÍNICA DO HOSPITAL DAS CLÍNICAS—FMUSP: DESAFIOS E OPORTUNIDADES
|
Baldassare, RM
|
|
2009
|
12 |
7 |
p. A528-
1 p.
|
artikel
|
| 100 |
PCASE4 AVALIAÇÃO DO USO RACIONAL DO BENEFICIO EM MEDICAMENTOS VISANDO A GARANTIA DE ACESSO EM UMA POPULAÇÃO CONTROLADA POR REGRAS DE ELEGIBILIDADE
|
Sousa, J
|
|
2009
|
12 |
7 |
p. A529-
1 p.
|
artikel
|
| 101 |
PCASE3 GESTÁO DE DOENÇAS: O HOSPITAL COMO FONTE DE INFORMAÇÃO DAS CARACTERÍSTICAS DAS DOENÇAS DOS CLIENTES DAS OPERADORAS DE SAÚDE
|
Figueira, CMG
|
|
2009
|
12 |
7 |
p. A529-
1 p.
|
artikel
|
| 102 |
PCASE2 REMUNERAÇÃO BASEADA EM PERFORMANCE: O QUE EXISTE DE DIFERENTE DA CONSULTA BONIFICADA UTILIZADA EM ALGUMAS UNIMEDS
|
Abicalaffe, CL
|
|
2009
|
12 |
7 |
p. A528-A529
nvt p.
|
artikel
|
| 103 |
PCN37 ABRANGÊNCIA DO RASTREAMENTO DE CÂNCER DE MAMA POR MAMOGRAFIA EM BENEFICIÁRIAS DE UMA OPERADORA DE PLANO DE SAÚDE
|
Reis Neto, JP
|
|
2009
|
12 |
7 |
p. A499-
1 p.
|
artikel
|
| 104 |
PCN13 A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA
|
Mickisch, GH
|
|
2009
|
12 |
7 |
p. A258-
1 p.
|
artikel
|
| 105 |
PCN6 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION
|
Pankiewicz, O
|
|
2009
|
12 |
7 |
p. A257-
1 p.
|
artikel
|
| 106 |
PCN7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM
|
Pankiewicz, O
|
|
2009
|
12 |
7 |
p. A257-
1 p.
|
artikel
|
| 107 |
PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
|
de Castro Carpeño, J
|
|
2009
|
12 |
7 |
p. A273-A274
nvt p.
|
artikel
|
| 108 |
PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
|
Bischoff, HG
|
|
2009
|
12 |
7 |
p. A273-
1 p.
|
artikel
|
| 109 |
PCN148 ADDRESSING DECISIONS ABOUT CLINICAL GUIDANCE AND ITS ACTIVE IMPLEMENTATION: SEQUENTIAL OR INTEGRAL ANALYSIS? AN APPLICATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER
|
Hoomans, T
|
|
2009
|
12 |
7 |
p. A285-
1 p.
|
artikel
|
| 110 |
PCN54 A DESCRIPTIVE ANALYSIS OF SUBJECTS WITH METASTATIC GASTRIC CANCER (MGC)
|
Oglesby, AK
|
|
2009
|
12 |
7 |
p. A266-
1 p.
|
artikel
|
| 111 |
PCN31 A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY
|
Ioannidis, G
|
|
2009
|
12 |
7 |
p. A262-
1 p.
|
artikel
|
| 112 |
PCN19 A LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE AND BONE MARROW TRANSPLANTATION (BMT)
|
Sladkevicius, E
|
|
2009
|
12 |
7 |
p. A259-
1 p.
|
artikel
|
| 113 |
PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY
|
Vergnenegre, A
|
|
2009
|
12 |
7 |
p. A281-
1 p.
|
artikel
|
| 114 |
PCN88 AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND
|
Kawalec, P
|
|
2009
|
12 |
7 |
p. A273-
1 p.
|
artikel
|
| 115 |
PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
|
Walzer, S
|
|
2009
|
12 |
7 |
p. A258-
1 p.
|
artikel
|
| 116 |
PCN5 ANÁLISE FARMACOECONÔMICA DE ANTIEMÉTICOS EM QUIMIOTERAPIA ALTAMENTE/MODERADAMENTE EMETOGÊNICA: A PERSPECTIVA DA FONTE PAGADORA
|
Faleiros, E
|
|
2009
|
12 |
7 |
p. A493-
1 p.
|
artikel
|
| 117 |
PCN23 ANÁLISE FARMACOECONÔMICA DO TRATAMENTO DO CÂNCER COLORRETAL METASTÁTICO COM BEVACIZUMABE NO BRASIL
|
Tonon, LM
|
|
2009
|
12 |
7 |
p. A497-
1 p.
|
artikel
|
| 118 |
PCN9 ANÁLISIS DE COSTOS DEL TRATAMIENTO EN PACIENTES CON SARCOMA DE TEJIDOS BLANDOS EN ETAPA TEMPRANA EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)
|
Rely, K
|
|
2009
|
12 |
7 |
p. A494-
1 p.
|
artikel
|
| 119 |
PCN154 ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003–2007
|
Paladio Duran, N
|
|
2009
|
12 |
7 |
p. A286-
1 p.
|
artikel
|
| 120 |
PCN36 A QUALIDADE DE VIDA DOS DOENTES ONCOLÓGICOS
|
Almeida, A
|
|
2009
|
12 |
7 |
p. A499-
1 p.
|
artikel
|
| 121 |
PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE
|
El Ouagari, K
|
|
2009
|
12 |
7 |
p. A279-
1 p.
|
artikel
|
| 122 |
PCN4 BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT. A SYSTEMATIC REVIEW
|
Palaska, PK
|
|
2009
|
12 |
7 |
p. A256-
1 p.
|
artikel
|
| 123 |
PCN128 BREAST CANCER DIAGNOSTIC PROCESS: MANAGEMENT AND COST EVALUATION IN ITALY
|
Pantaleoni, M
|
|
2009
|
12 |
7 |
p. A281-
1 p.
|
artikel
|
| 124 |
PCN35 BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA ANALYSIS FROM PAYERS' PERSPECTIVES IN BRAZIL
|
Clark, O
|
|
2009
|
12 |
7 |
p. A262-
1 p.
|
artikel
|
| 125 |
PCN34 BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL
|
Asano, E
|
|
2009
|
12 |
7 |
p. A262-
1 p.
|
artikel
|
| 126 |
PCN1 BURDEN OF THROMBOCYTOPENIA IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY, 2000–2007
|
Nalysnyk, L
|
|
2009
|
12 |
7 |
p. A256-
1 p.
|
artikel
|
| 127 |
PCN64 CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UK (UK)
|
Szabo, SM
|
|
2009
|
12 |
7 |
p. A268-
1 p.
|
artikel
|
| 128 |
PCN15 CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE
|
Guilhot, F
|
|
2009
|
12 |
7 |
p. A259-
1 p.
|
artikel
|
| 129 |
PCN24 CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILISATION OF PATIENTS RECEIVING LAPATINIB FOR BREAST CANCER IN FRANCE: THE LAPS STUDY (LAPATINIB ATU PARCOURS DE SOINS)
|
Perrocheau, G
|
|
2009
|
12 |
7 |
p. A260-
1 p.
|
artikel
|
| 130 |
PCN96 COLORECTAL CANCER SCREENING: COST-EFFECTIVENESS OF CT COLONOGRAPHY
|
Sweet, A
|
|
2009
|
12 |
7 |
p. A275-
1 p.
|
artikel
|
| 131 |
PCN8 COMORBIDITIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER
|
Fu, AZ
|
|
2009
|
12 |
7 |
p. A257-
1 p.
|
artikel
|
| 132 |
PCN6 COMPARA¸ÃO DE CUSTOS E TEMPO PARA PROGRESSÃO ENTRE PEMETREXEDE (P) E DOCETAXEL (D) NO TRATAMENTO DE SEGUNDA LINHA DO CÂNCER DE PULMÃO NÃO PEQUENAS CÉLULAS (NSCLC): DADOS DO MUNDO REAL
|
Clark, O
|
|
2009
|
12 |
7 |
p. A493-
1 p.
|
artikel
|
| 133 |
PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSIS
|
Rugo, H
|
|
2009
|
12 |
7 |
p. A260-
1 p.
|
artikel
|
| 134 |
PCN74 COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID THERAPY FOR RENAL CELL CARCINOMA (RCC) PATIENTS WITH BONE METASTASES IN FRENCH, GERMAN, AND THE UK POPULATIONS
|
Botteman, MF
|
|
2009
|
12 |
7 |
p. A270-A271
nvt p.
|
artikel
|
| 135 |
PCN136 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS
|
Ramsey, SD
|
|
2009
|
12 |
7 |
p. A283-
1 p.
|
artikel
|
| 136 |
PCN62 COST ANALYSIS OF HORMONE RECEPTOR POSITIVE, ADVANCED BREAST CANCER TREATMENT WITH ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (BPHS)
|
Abdo Filho, E
|
|
2009
|
12 |
7 |
p. A268-
1 p.
|
artikel
|
| 137 |
PCN11 COST ANALYSIS OF THE TREATMENT OF ADVANCED METASTATIC STS IN THE IMSS: ESTIMATING MEDICAL COST WITH CENSORED DATA
|
Rely, K
|
|
2009
|
12 |
7 |
p. A494-
1 p.
|
artikel
|
| 138 |
PCN149 COST ANALYSIS OF 10-YEARS FOLLOW-UP OF CHEMOTHERAPY REGIMENS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2009
|
12 |
7 |
p. A285-
1 p.
|
artikel
|
| 139 |
PCN45 COST COMPARISON BETWEEN 90Y IBRITUMOMAB TIUXETAN CONSOLIDATION AND RITUXIMAB MAINTENANCE POST-CHEMOTHERAPY IN NAÏVE PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA IN SPAIN
|
Tomas, JF
|
|
2009
|
12 |
7 |
p. A264-
1 p.
|
artikel
|
| 140 |
PCN92 COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL+TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+
|
Tenorio, C
|
|
2009
|
12 |
7 |
p. A274-
1 p.
|
artikel
|
| 141 |
PCN84 COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS PACLITAXEL ONCE WEEKLY IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY IN SPAIN
|
Cortés, J
|
|
2009
|
12 |
7 |
p. A272-
1 p.
|
artikel
|
| 142 |
PCN102 COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2+VE BREAST CANCER IN ITALY UTILIZING FOLLOW UP DATA
|
Giuliani, G
|
|
2009
|
12 |
7 |
p. A276-
1 p.
|
artikel
|
| 143 |
PCN119 COST EFFECTIVENESS ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT THERAPY FOR EARLY STAGE BREAST CANCER BASED ON THE 100-MONTH ANALYSIS OF THE ATAC TRIAL FROM A GERMAN PERSPECTIVE
|
Kreif, N
|
|
2009
|
12 |
7 |
p. A279-A280
nvt p.
|
artikel
|
| 144 |
PCN81 COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA
|
Yoong, K
|
|
2009
|
12 |
7 |
p. A272-
1 p.
|
artikel
|
| 145 |
PCN85 COST-EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN RELAPSED MANTLE CELL LYMPHOMA PATIENTS IN CANADA
|
Yoong, K
|
|
2009
|
12 |
7 |
p. A273-
1 p.
|
artikel
|
| 146 |
PCN19 COST-EFFECTIVENESS ANALYSIS OF CLOFARABINE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO
|
Rely, K
|
|
2009
|
12 |
7 |
p. A496-
1 p.
|
artikel
|
| 147 |
PCN13 COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY)
|
Godoy, JI
|
|
2009
|
12 |
7 |
p. A495-
1 p.
|
artikel
|
| 148 |
PCN83 COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE + LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE
|
Magar, RS
|
|
2009
|
12 |
7 |
p. A272-
1 p.
|
artikel
|
| 149 |
PCN122 COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY
|
Iannazzo, S
|
|
2009
|
12 |
7 |
p. A280-
1 p.
|
artikel
|
| 150 |
PCN82 COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA
|
Obradovic, M
|
|
2009
|
12 |
7 |
p. A272-
1 p.
|
artikel
|
| 151 |
PCN99 COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN PATIENTS WITH SUPERFICIAL BASAL CELL CARCINOMA AND CONTRAINDICATION TO SURGICAL INTERVENTION/CRYOTHERAPY
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A275-A276
nvt p.
|
artikel
|
| 152 |
PCN24 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
7 |
p. A497-
1 p.
|
artikel
|
| 153 |
PCN114 COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY: RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION
|
Guidi, L
|
|
2009
|
12 |
7 |
p. A278-A279
nvt p.
|
artikel
|
| 154 |
PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN
|
Remák, E
|
|
2009
|
12 |
7 |
p. A270-
1 p.
|
artikel
|
| 155 |
PCN77 COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL
|
Silverio, NM
|
|
2009
|
12 |
7 |
p. A271-
1 p.
|
artikel
|
| 156 |
PCN39 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING TEMSIROLIMUS COMPARED TO INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA
|
Bonthapally, V
|
|
2009
|
12 |
7 |
p. A263-
1 p.
|
artikel
|
| 157 |
PCN26 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB + INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO
|
Salinas-Escudero, G
|
|
2009
|
12 |
7 |
p. A497-
1 p.
|
artikel
|
| 158 |
PCN20 COST-EFFECTIVENESS ASSESSMENT FOR COLOMBIA OF LETROZOLE VS. TAMOXIFEN IN ADJUVANT TREATMENT OF HORMONE RECEPTOR-POSITIVE, POST-MENOPAUSAL EARLY BREAST CANCER WOMEN
|
Gamboa, O
|
|
2009
|
12 |
7 |
p. A496-
1 p.
|
artikel
|
| 159 |
PCN78 COST-EFFECTIVENESS ASSESSMENT OF ZOLEDRONIC ACID (ZOL) RELATIVE TO PLACEBO (PBO) IN THE TREATMENT OF LUNG CANCER PATIENTS WITH SKELETAL METASTASES IN FIVE EUROPEAN COUNTRIES
|
Botteman, MF
|
|
2009
|
12 |
7 |
p. A271-
1 p.
|
artikel
|
| 160 |
PCN79 COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE+DOCETAXEL VS GEMCITABINE+DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE
|
Tenorio, C
|
|
2009
|
12 |
7 |
p. A271-
1 p.
|
artikel
|
| 161 |
PCN69 COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)—RESULTS FROM SPAIN, FRANCE AND ITALY
|
Hieke, K
|
|
2009
|
12 |
7 |
p. A269-
1 p.
|
artikel
|
| 162 |
PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY
|
Delea, TE
|
|
2009
|
12 |
7 |
p. A270-
1 p.
|
artikel
|
| 163 |
PCN100 COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
|
Rudakova, AV
|
|
2009
|
12 |
7 |
p. A276-
1 p.
|
artikel
|
| 164 |
PCN121 COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND
|
Sharp, L
|
|
2009
|
12 |
7 |
p. A280-
1 p.
|
artikel
|
| 165 |
PCN95 COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA
|
Kim, JH
|
|
2009
|
12 |
7 |
p. A275-
1 p.
|
artikel
|
| 166 |
PCN118 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION
|
Eggington, SG
|
|
2009
|
12 |
7 |
p. A279-
1 p.
|
artikel
|
| 167 |
PCN76 COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL
|
Earnshaw, SR
|
|
2009
|
12 |
7 |
p. A271-
1 p.
|
artikel
|
| 168 |
PCN104 COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
|
Chen, W
|
|
2009
|
12 |
7 |
p. A276-
1 p.
|
artikel
|
| 169 |
PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
|
Borget, I
|
|
2009
|
12 |
7 |
p. A275-
1 p.
|
artikel
|
| 170 |
PCN107 COST-EFFECTIVENESS OF HPV VACCINATION—AN OVERVIEW ON INTERNATIONAL STUDY RESULTS
|
Damm, O
|
|
2009
|
12 |
7 |
p. A277-
1 p.
|
artikel
|
| 171 |
PCN17 COST EFFECTIVENESS OF IMIQUIMOD IN SUPERFICIAL BASAL CELL CARCINOMA TREATMENT
|
Karve, S
|
|
2009
|
12 |
7 |
p. A495-A496
nvt p.
|
artikel
|
| 172 |
PCN22 COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
|
Rely, K
|
|
2009
|
12 |
7 |
p. A496-
1 p.
|
artikel
|
| 173 |
PCN98 COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY
|
Bonastre, J
|
|
2009
|
12 |
7 |
p. A275-
1 p.
|
artikel
|
| 174 |
PCN71 COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE
|
Roussel, M
|
|
2009
|
12 |
7 |
p. A270-
1 p.
|
artikel
|
| 175 |
PCN109 COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING
|
Pompen, M
|
|
2009
|
12 |
7 |
p. A277-
1 p.
|
artikel
|
| 176 |
PCN101 COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR BREAKTHROUGH PAIN IN CANCER PATIENTS—A SCOTTISH-BASED DECISION-ANALYSIS MODEL
|
Vissers, D
|
|
2009
|
12 |
7 |
p. A276-
1 p.
|
artikel
|
| 177 |
PCN75 COST-EFFECTIVENESS OF THALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA IN WALES
|
Joseph, I
|
|
2009
|
12 |
7 |
p. A271-
1 p.
|
artikel
|
| 178 |
PCN157 COST-EFFECTIVENESS OF UGT1A1 GENOTYPING IN IRINOTECAN CANCER THERAPY
|
Obradovic, M
|
|
2009
|
12 |
7 |
p. A287-
1 p.
|
artikel
|
| 179 |
PCN66 COST EVALUATION OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND QUADRIVALENT HPV VACCINE AGAINST CERVICAL CANCER WITHIN EUROPEAN COUNTRIES
|
Capri, S
|
|
2009
|
12 |
7 |
p. A269-
1 p.
|
artikel
|
| 180 |
PCN112 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE
|
Bastide, P
|
|
2009
|
12 |
7 |
p. A278-
1 p.
|
artikel
|
| 181 |
PCN111 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE
|
Bastide, P
|
|
2009
|
12 |
7 |
p. A278-
1 p.
|
artikel
|
| 182 |
PCN27 COST MINIMIZATION ANALYSIS OF TEGAFUR-URACIL ASSOCIATED TO LEUCOVORIN (UFT/LV) VERSUS CAPECITABINE ALONE FOR METASTATIC COLORECTAL CANCER UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, VD
|
|
2009
|
12 |
7 |
p. A497-A498
nvt p.
|
artikel
|
| 183 |
PCN110 COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX ± BEVACIZUMAB FOR TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN SAUDI ARABIAN HOSPITAL SETTING
|
Zazaa, AS
|
|
2009
|
12 |
7 |
p. A278-
1 p.
|
artikel
|
| 184 |
PCN48 COST OF CARE FOR COLORECTAL CANCER IN IRELAND: A HEALTH CARE PAYER PERSPECTIVE
|
Tilson, L
|
|
2009
|
12 |
7 |
p. A265-
1 p.
|
artikel
|
| 185 |
PCN40 COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN
|
Calderero, V
|
|
2009
|
12 |
7 |
p. A263-
1 p.
|
artikel
|
| 186 |
PCN56 COST OF RENAL CELL CARCINOMA TREATMENT IN PATIENTS TREATED WITH INTERFERON-ALPHA
|
Purmonen, T
|
|
2009
|
12 |
7 |
p. A266-A267
nvt p.
|
artikel
|
| 187 |
PCN53 COST PER DISEASE STAGE OF ADVANCED GASTRIC CANCER IN BRAZIL FROM THE PRIVATE PAYER PERSPECTIVE
|
Clark, O
|
|
2009
|
12 |
7 |
p. A266-
1 p.
|
artikel
|
| 188 |
PCN49 COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY: THE CO.MI.M. STUDY
|
Petrucci, MT
|
|
2009
|
12 |
7 |
p. A265-
1 p.
|
artikel
|
| 189 |
PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
|
Heigener, D
|
|
2009
|
12 |
7 |
p. A263-A264
nvt p.
|
artikel
|
| 190 |
PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS
|
Heigener, D
|
|
2009
|
12 |
7 |
p. A265-
1 p.
|
artikel
|
| 191 |
PCN52 COSTS OF ADVANCED GASTRIC CANCER (AGC) IN BRAZIL FROM THE PUBLIC PAYER PERSPECTIVE
|
Clark, O
|
|
2009
|
12 |
7 |
p. A266-
1 p.
|
artikel
|
| 192 |
PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
|
Bischoff, HG
|
|
2009
|
12 |
7 |
p. A265-
1 p.
|
artikel
|
| 193 |
PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
|
Asano, E
|
|
2009
|
12 |
7 |
p. A280-A281
nvt p.
|
artikel
|
| 194 |
PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN
|
Eggington, SG
|
|
2009
|
12 |
7 |
p. A279-
1 p.
|
artikel
|
| 195 |
PCN117 COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA
|
Wolowacz, SE
|
|
2009
|
12 |
7 |
p. A279-
1 p.
|
artikel
|
| 196 |
PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND
|
Rutkowski, J
|
|
2009
|
12 |
7 |
p. A280-
1 p.
|
artikel
|
| 197 |
PCN151 CROSS-REGIONAL FLOWS OF CANCER PATIENTS IN GREECE: URBANIZATION OF CANCER TREATMENT
|
Athanasakis, K
|
|
2009
|
12 |
7 |
p. A286-
1 p.
|
artikel
|
| 198 |
PCN9 DEVELOPMENT OF SERUM TESTS FOR COLORECTAL CANCER SCREENING
|
Schiff, L
|
|
2009
|
12 |
7 |
p. A257-
1 p.
|
artikel
|
| 199 |
PCN2 DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING CHEMOTHERAPY
|
Nalysnyk, L
|
|
2009
|
12 |
7 |
p. A256-
1 p.
|
artikel
|
| 200 |
PCN127 DYNAMIC CONTRAST-ENHANCED ULTRASOUND WITH QUANTIFICATION TO ASSESS TARGETED TREATMENT EFFICACY: RESULTS OF A MULTI-CENTRIC PROSPECTIVE COST STUDY
|
Bonastre, J
|
|
2009
|
12 |
7 |
p. A281-
1 p.
|
artikel
|
| 201 |
PCN12 ECONOMIC EVALUATION OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS OF FEC-D VS FEC, IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO
|
Erazo-Valle, A
|
|
2009
|
12 |
7 |
p. A494-A495
nvt p.
|
artikel
|
| 202 |
PCN94 ECONOMIC EVALUATION OF DOCETAXEL IN THE CONTEXT OF BREAST CANCER IN PORTUGAL
|
Pinto, CG
|
|
2009
|
12 |
7 |
p. A274-A275
nvt p.
|
artikel
|
| 203 |
PCN18 ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL
|
Teich, N
|
|
2009
|
12 |
7 |
p. A496-
1 p.
|
artikel
|
| 204 |
PCN15 ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO
|
Rely, K
|
|
2009
|
12 |
7 |
p. A495-
1 p.
|
artikel
|
| 205 |
PCN42 ECONOMIC EVALUATION OF THE USE OF HAEMOSTATIC SEALANT PATCH FOR PULMONARY LOBECTOMY PROCEDURE
|
Droghetti, A
|
|
2009
|
12 |
7 |
p. A264-
1 p.
|
artikel
|
| 206 |
PCN105 ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE FINNISH SETTING
|
Soini, EJ
|
|
2009
|
12 |
7 |
p. A277-
1 p.
|
artikel
|
| 207 |
PCN156 EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC CHANGE ON THE GERMAN ONCOLOGY MARKET
|
Ilgin, Y
|
|
2009
|
12 |
7 |
p. A287-
1 p.
|
artikel
|
| 208 |
PCN1 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS
|
Engel, T
|
|
2009
|
12 |
7 |
p. A492-
1 p.
|
artikel
|
| 209 |
PCN31 EL SENTIDO DE VIDA EN UN GRUPO DE MUJERES ACAPULQUEÑAS CON DIAGNÓSTICO DE CÁNCER
|
Legorreta, R
|
|
2009
|
12 |
7 |
p. A498-
1 p.
|
artikel
|
| 210 |
PCN72 EPIDEMIOLOGICAL AND COST-EFFECTIVENESS ANALYSIS OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND THE QUADRIVALENT HPV VACCINES IN FRANCE
|
Tehard, B
|
|
2009
|
12 |
7 |
p. A270-
1 p.
|
artikel
|
| 211 |
PCN4 ERYTHROPOIESIS STIMULATING AGENTS (ESA) FOR THE TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA IN PATIENTS WITH HEMOGLOBIN LEVELS (HB) <11G/DL-A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Paladini, L
|
|
2009
|
12 |
7 |
p. A493-
1 p.
|
artikel
|
| 212 |
PCN21 ESTUDIO DE COSTO EFECTIVIDAD DEL USO DE TRASTUZUMAB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER DE MAMA TEMPRANO HER2 POSITIVO EN EL INSTITUTO NACIONAL DE CANCEROLOGÍA DE COLOMBIA, DESDE EL PUNTO DE VISTA DEL PAGADOR
|
Díaz, JA
|
|
2009
|
12 |
7 |
p. A496-
1 p.
|
artikel
|
| 213 |
PCN2 ESTUDIO FASE II PARA EVALUAR LA EFICACIA Y SEGURIDAD DE 4′,4′-DIHIDROXIBENZOFENONA-2,4-DINITROFENIL-HIDRAZONA (A-007) GEL TÓPICO EN EL TRATAMIENTO DE LESIONES INTRAEPITELIALES ESCAMOSAS DE ALTO GRADO (LIEAG) DEL CUELLO UTERINO Y SU ASOCIACIÓN AL VIRUS DEL PAPILOMA HUMANO (VPH) DE ALTO RIESGO
|
De LaCruz, J
|
|
2009
|
12 |
7 |
p. A492-A493
nvt p.
|
artikel
|
| 214 |
PCN8 EVALUACIÓN DE LA CARGA DE ENFERMEDAD POR EL VIRUS DEL PAPILOMA HUMANO EN BOGOTÁ, COLOMBIA
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A494-
1 p.
|
artikel
|
| 215 |
PCN57 EVALUATION OF THE COMPLICATION RATE AND COST OF TREATMENT ACCORDING TO THE MASCC INDEX IN PATIENTS WITH FEBRILE NEUTROPENIA
|
Borget, I
|
|
2009
|
12 |
7 |
p. A267-
1 p.
|
artikel
|
| 216 |
PCN16 EVALUATION OF THE EFFICACY OF THE POPULATION-BASED CERVICAL CANCER SCREENING IN HUNGARY
|
Pakai, A
|
|
2009
|
12 |
7 |
p. A259-
1 p.
|
artikel
|
| 217 |
PCN142 EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES
|
Vargas, J
|
|
2009
|
12 |
7 |
p. A284-
1 p.
|
artikel
|
| 218 |
PCN36 EVIDENCE-BASED MEDICINE (EBM) AND THE PROFILE OF APPEALS FOLLOWING AUDITING IN CHEMOTHERAPY TREATMENTS
|
Alves, AF
|
|
2009
|
12 |
7 |
p. A262-A263
nvt p.
|
artikel
|
| 219 |
PCN37 EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA
|
Avxentyeva, M
|
|
2009
|
12 |
7 |
p. A263-
1 p.
|
artikel
|
| 220 |
PCN3 EXPERIENCIA CLÍNICA Y RESULTADOS CON INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF-R) EN PACIENTES LATINOS CON CÁNCER DE PULMON NO PEQUEÑAS CELULAS (CPNPC)
|
De La Cruz, J
|
|
2009
|
12 |
7 |
p. A493-
1 p.
|
artikel
|
| 221 |
PCN106 EXPLORING THE COST-EFFECTIVENESS OF A SMOKING-CESSATION PROGRAM ENHANCED WITH INDIVIDUAL GENETIC FEEDBACK ON LUNG CANCER RISK
|
Gordon, LG
|
|
2009
|
12 |
7 |
p. A277-
1 p.
|
artikel
|
| 222 |
PCN12 EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY: REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER
|
van Gils, CWM
|
|
2009
|
12 |
7 |
p. A258-
1 p.
|
artikel
|
| 223 |
PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC
|
Rosery, H
|
|
2009
|
12 |
7 |
p. A281-A282
nvt p.
|
artikel
|
| 224 |
PCN147 FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA
|
Miot, J
|
|
2009
|
12 |
7 |
p. A285-
1 p.
|
artikel
|
| 225 |
PCN139 FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
|
Cella, D
|
|
2009
|
12 |
7 |
p. A283-
1 p.
|
artikel
|
| 226 |
PCN25 HALF OF BREAST CANCER PATIENTS STARTING ON TAMOXIFEN COMPLETE FIVE YEARS OF ENDOCRINE TREATMENT
|
van Herk-Sukel, MPP
|
|
2009
|
12 |
7 |
p. A261-
1 p.
|
artikel
|
| 227 |
PCN3 HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS
|
van Herk-Sukel, MPP
|
|
2009
|
12 |
7 |
p. A256-
1 p.
|
artikel
|
| 228 |
PCN145 HEALTH ECONOMIC REVIEW OF NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT IN THE UNITED STATES
|
Munakata, J
|
|
2009
|
12 |
7 |
p. A284-A285
nvt p.
|
artikel
|
| 229 |
PCN93 HEALTH ECONOMICS OF HPV VACCINATION IN AUSTRIA—COST-EFFECTIVENESS OF VACCINATING 12 YEAR OLD GIRLS
|
Kundi, M
|
|
2009
|
12 |
7 |
p. A274-
1 p.
|
artikel
|
| 230 |
PCN130 HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL
|
Furlong, W
|
|
2009
|
12 |
7 |
p. A282-
1 p.
|
artikel
|
| 231 |
PCN61 HOSPITAL BURDEN RELATED TO UPPER AERODIGESTIVE TRACT CANCERS IN FRANCE
|
Cancalon, C
|
|
2009
|
12 |
7 |
p. A268-
1 p.
|
artikel
|
| 232 |
PCN50 HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE
|
Lacau St Guily, J
|
|
2009
|
12 |
7 |
p. A265-A266
nvt p.
|
artikel
|
| 233 |
PCN171 IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC)
|
Shabaruddin, FH
|
|
2009
|
12 |
7 |
p. A289-A290
nvt p.
|
artikel
|
| 234 |
PCN10 IMPACTO DE LA SUPERVIVENCIA DEL CÁNCER DE MAMA SOBRE LOS COSTOS MÉDICOS DIRECTOS
|
De la Cruz-Aguirre, K
|
|
2009
|
12 |
7 |
p. A494-
1 p.
|
artikel
|
| 235 |
PCN30 IMPACTO EMOCIONAL EN UN GRUPO DE MUJERES MEXICANAS CON DIAGNÓSTICO DE VPH Y NEOPLASIA INTRACERVICAL (NIC-II/III)
|
Legorreta, R
|
|
2009
|
12 |
7 |
p. A498-
1 p.
|
artikel
|
| 236 |
PCN140 IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP): RESULTS FROM THE VISTA TRIAL
|
Meunier, J
|
|
2009
|
12 |
7 |
p. A284-
1 p.
|
artikel
|
| 237 |
PCN32 IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM FOR PHARMACISTS
|
Kamal, S
|
|
2009
|
12 |
7 |
p. A262-
1 p.
|
artikel
|
| 238 |
PCN28 INCIDENCE AND PREVALENCE OF CUTANEOUS MELANOMA IN FRANCE: A POPULATION BASED STUDY FROM EIGHT CANCER REGISTRIES
|
Binder-Foucard, F
|
|
2009
|
12 |
7 |
p. A261-
1 p.
|
artikel
|
| 239 |
PCN11 INDIRECT COMPARISON TO ESTIMATE THE EFFICACY OF INTERVENTIONS IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA: A MIXED TREATMENT COMPARISON
|
Bonthapally, V
|
|
2009
|
12 |
7 |
p. A258-
1 p.
|
artikel
|
| 240 |
PCN138 INFORMATION NEEDS: A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT
|
Passalacqua, S
|
|
2009
|
12 |
7 |
p. A283-
1 p.
|
artikel
|
| 241 |
PCN65 INPATIENT COST AND REIMBURSEMENT FOR PATIENTS WITH PROGRESSIVE MALIGNANT THORACIC NEOPLASM IN GERMANY
|
Krych, M
|
|
2009
|
12 |
7 |
p. A268-
1 p.
|
artikel
|
| 242 |
PCN123 LONG-TERM COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN—AN UPDATED ANALYSIS BASED UPON THE 100 MONTH FOLLOW UP OF THE ANASTROZOLE OR TAMOXIFEN ALONE OR IN COMBINATION (ATAC) TRIAL
|
Paulsson, T
|
|
2009
|
12 |
7 |
p. A280-
1 p.
|
artikel
|
| 243 |
PCN91 LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER
|
Jackson, D
|
|
2009
|
12 |
7 |
p. A274-
1 p.
|
artikel
|
| 244 |
PCN126 LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL
|
Yang, S
|
|
2009
|
12 |
7 |
p. A281-
1 p.
|
artikel
|
| 245 |
PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS
|
Rosery, H
|
|
2009
|
12 |
7 |
p. A269-
1 p.
|
artikel
|
| 246 |
PCN158 LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES IN LUXEMBOURG
|
Carlson, JJ
|
|
2009
|
12 |
7 |
p. A287-
1 p.
|
artikel
|
| 247 |
PCN10 MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE
|
Blay, JY
|
|
2009
|
12 |
7 |
p. A257-A258
nvt p.
|
artikel
|
| 248 |
PCN90 MASS SCREENING FOR COLORECTAL CANCER: ARE ALTERNATIVES TO THE GUAIAC FECAL OCCULT BLOOD TEST COST-EFFECTIVE?
|
Chauvin, P
|
|
2009
|
12 |
7 |
p. A274-
1 p.
|
artikel
|
| 249 |
PCN7 METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
7 |
p. A493-A494
nvt p.
|
artikel
|
| 250 |
PCN146 MIND THE GAP: ASSESSING THE DIFFERENT DATA REQUIREMENTS BETWEEN REGULATORY APPROVAL AND HEALTH TECHNOLOGY ASSESSMENT
|
Ng-Haing, J
|
|
2009
|
12 |
7 |
p. A285-
1 p.
|
artikel
|
| 251 |
PCN160 MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC
|
Pavlik, T
|
|
2009
|
12 |
7 |
p. A287-A288
nvt p.
|
artikel
|
| 252 |
PCN152 NEW JAPANESE PREFECTURAL GOVERNMENT CANCER CONTROL PROGRAMS: A SYSTEMATIC REVIEW AND AN INTERNATIONAL COMPARISON
|
Imai, H
|
|
2009
|
12 |
7 |
p. A286-
1 p.
|
artikel
|
| 253 |
PCN21 NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER
|
Dhillon, N
|
|
2009
|
12 |
7 |
p. A260-
1 p.
|
artikel
|
| 254 |
PCN38 NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB
|
Valentim, J
|
|
2009
|
12 |
7 |
p. A263-
1 p.
|
artikel
|
| 255 |
PCN137 ONCOLOGY PATIENT-REPORTED CLAIMS: MAXIMISING THE CHANCE FOR SUCCESS
|
Rofail, D
|
|
2009
|
12 |
7 |
p. A283-
1 p.
|
artikel
|
| 256 |
PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES: THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
|
Gaultney, J
|
|
2009
|
12 |
7 |
p. A259-
1 p.
|
artikel
|
| 257 |
PCN155 “PATIENT ACCESS SCHEMES”—THE USE OF RISK-SHARING IN THE UK
|
Carroll, SM
|
|
2009
|
12 |
7 |
p. A286-A287
nvt p.
|
artikel
|
| 258 |
PCN29 PATTERNS OF COLORECTAL CANCER SCREENING AND OBESITY AMONG MEDICARE BENEFICIARIES
|
Kendall, KA
|
|
2009
|
12 |
7 |
p. A261-
1 p.
|
artikel
|
| 259 |
PCN144 PATTERNS OF EMPLOYMENT AFTER CANCER: RESULTS OF A LONGITUDINAL STUDY
|
de Moor, J
|
|
2009
|
12 |
7 |
p. A284-
1 p.
|
artikel
|
| 260 |
PCN153 PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA
|
Majek, O
|
|
2009
|
12 |
7 |
p. A286-
1 p.
|
artikel
|
| 261 |
PCN113 PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
|
Chen, HH
|
|
2009
|
12 |
7 |
p. A278-
1 p.
|
artikel
|
| 262 |
PCN103 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN
|
Bosch, F
|
|
2009
|
12 |
7 |
p. A276-
1 p.
|
artikel
|
| 263 |
PCN28 PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME
|
Salinas Escudero, G
|
|
2009
|
12 |
7 |
p. A498-
1 p.
|
artikel
|
| 264 |
PCN23 PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED WITH TEMOZOLOMIDE
|
Brignone, M
|
|
2009
|
12 |
7 |
p. A260-
1 p.
|
artikel
|
| 265 |
PCN108 PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO
|
Vargas, J
|
|
2009
|
12 |
7 |
p. A277-
1 p.
|
artikel
|
| 266 |
PCN133 POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA
|
Davies, J
|
|
2009
|
12 |
7 |
p. A282-
1 p.
|
artikel
|
| 267 |
PCN170 PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS
|
Degrassat-Théas, A
|
|
2009
|
12 |
7 |
p. A289-
1 p.
|
artikel
|
| 268 |
PCN34 QUALITY OF LIFE IN DIFFERENT STAGES OF COLORECTAL PATIENTS ATTENDED AT THE SOCIAL SECURITY MEXICAN INSTITUTE
|
Contreras-Hernandez, I
|
|
2009
|
12 |
7 |
p. A499-
1 p.
|
artikel
|
| 269 |
PCN32 QUALITY OF LIFE IN DIFFERENT STAGES OF MEXICAN BREAST CANCER PATIENTS
|
Contreras-Hernandez, I
|
|
2009
|
12 |
7 |
p. A498-
1 p.
|
artikel
|
| 270 |
PCN33 QUALITY OF LIFE OF PATIENTS WITH NON-HODGKIN LYMPHOMA AT THE SOCIAL SECURITY MEXICAN INSTITUTE
|
Contreras-Hernandez, I
|
|
2009
|
12 |
7 |
p. A499-
1 p.
|
artikel
|
| 271 |
PCN141 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY: THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA
|
Greil, R
|
|
2009
|
12 |
7 |
p. A284-
1 p.
|
artikel
|
| 272 |
PCN20 REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS— A COMPARATIVE ANALYSIS
|
Hammerman, A
|
|
2009
|
12 |
7 |
p. A260-
1 p.
|
artikel
|
| 273 |
PCN59 REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS
|
van Gils, CWM
|
|
2009
|
12 |
7 |
p. A267-
1 p.
|
artikel
|
| 274 |
PCN162 REIMBURSEMENT OF ACTIVE-IMMUNOTHERAPEUTICS (AI): AN ANALYSIS BASED ON A STUDY OF CURENT REIMBURSEMENT APPROACHES
|
de Cambra, S
|
|
2009
|
12 |
7 |
p. A288-
1 p.
|
artikel
|
| 275 |
PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY
|
Rosery, H
|
|
2009
|
12 |
7 |
p. A288-
1 p.
|
artikel
|
| 276 |
PCN26 RELATIVE IMPACT OF SCREENING AND THERAPEUTIC PROGRESS ON THE REDUCTION OF BREAST CANCER SPECIFIC MORTALITY IN FRANCE: A SIMULATION MODEL OVER THE PERIOD 1994–2005
|
Bouee, S
|
|
2009
|
12 |
7 |
p. A261-
1 p.
|
artikel
|
| 277 |
PCN5 RENAL CELL CARCINOMA PATIENTS ARE TWICE AS LIKELY TO DEVELOP THROMBOEMBOLIC EVENTS COMPARED TO CANCER-FREE CONTROLS
|
van Herk-Sukel, MPP
|
|
2009
|
12 |
7 |
p. A256-A257
nvt p.
|
artikel
|
| 278 |
PCN58 RESOURCES USED IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY REQUIRING BLOOD TRANSFUSIONS. EPICOST STUDY, PRELIMINARY RESULTS (ONVIDA GROUP)
|
Camps, C
|
|
2009
|
12 |
7 |
p. A267-
1 p.
|
artikel
|
| 279 |
PCN169 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER
|
Saggia, MG
|
|
2009
|
12 |
7 |
p. A289-
1 p.
|
artikel
|
| 280 |
PCN167 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF COLORECTAL CANCER
|
Saggia, MG
|
|
2009
|
12 |
7 |
p. A289-
1 p.
|
artikel
|
| 281 |
PCN63 REVIEW OF THE ECONOMIC IMPACT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
|
Sasane, M
|
|
2009
|
12 |
7 |
p. A268-
1 p.
|
artikel
|
| 282 |
PCN25 REVISIÓN SISTEMÁTICA Y EVALUACIÓN ECONÓMICA DE LA ABLACIÓN POR RADIOFRECUENCIA EN TUMORES HEPÁTICOS
|
Callejo, D
|
|
2009
|
12 |
7 |
p. A497-
1 p.
|
artikel
|
| 283 |
PCN29 REVISÃO DE CONTAS EM ONCOLOGIA E MEDICINA BASEADA EM EVIDÊNCIAS (MBE): IMPACTO FINANCEIRO E BUSCA PELA QUALIDADE
|
Alves, AF
|
|
2009
|
12 |
7 |
p. A498-
1 p.
|
artikel
|
| 284 |
PCN163 RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER HOSPITALIZATIONS IN WEST VIRGINIA, USA
|
Shah, N
|
|
2009
|
12 |
7 |
p. A288-
1 p.
|
artikel
|
| 285 |
PCN165 SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA
|
Santos, EA
|
|
2009
|
12 |
7 |
p. A288-A289
nvt p.
|
artikel
|
| 286 |
PCN17 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A259-
1 p.
|
artikel
|
| 287 |
PCN35 SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER
|
Goulart, BHL
|
|
2009
|
12 |
7 |
p. A499-
1 p.
|
artikel
|
| 288 |
PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS
|
Nuijten, MJ
|
|
2009
|
12 |
7 |
p. A272-
1 p.
|
artikel
|
| 289 |
PCN30 THE BURDEN OF MULTIPLE MYELOMA: ASSESSMENT ON OCCURRENCE, OUTCOMES AND COST USING A RETROSPECTIVE LONGITUDINAL STUDY BASED ON ADMINISTRATIVE CLAIMS DATABASE
|
de Portu, S
|
|
2009
|
12 |
7 |
p. A262-
1 p.
|
artikel
|
| 290 |
PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO
|
Juarez-Garcia, A
|
|
2009
|
12 |
7 |
p. A495-
1 p.
|
artikel
|
| 291 |
PCN16 THE COST AND HEALTH CONSEQUENCES OF DIFFERENT BREAST CANCER SCREENING STRATEGIES IN COLOMBIA
|
Gamboa, O
|
|
2009
|
12 |
7 |
p. A495-
1 p.
|
artikel
|
| 292 |
PCN86 THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA—A NORDIC COMPARISON
|
Liwing, J
|
|
2009
|
12 |
7 |
p. A273-
1 p.
|
artikel
|
| 293 |
PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
|
Chouaid, C
|
|
2009
|
12 |
7 |
p. A264-
1 p.
|
artikel
|
| 294 |
PCN51 THE COSTS OF BREAST CANCER PRIOR TO AND FOLLOWING DIAGNOSIS
|
Broeckx, S
|
|
2009
|
12 |
7 |
p. A266-
1 p.
|
artikel
|
| 295 |
PCN55 THE ECONOMIC EVALUATION OF SUNITINIB AND SORAFENIB IN MRCC PATIENTS IN THE CZECH REPUBLIC
|
Demlova, R
|
|
2009
|
12 |
7 |
p. A266-
1 p.
|
artikel
|
| 296 |
PCN150 THE RELATIONSHIP BETWEEN DRUG UTILIZATION AND OUT OF POCKET EXPENSES FOR ORAL ANTINEOPLASTICS COMPARED TO A MARKET BASKET OF COMMONLY USED DRUGS
|
Sepulveda, B
|
|
2009
|
12 |
7 |
p. A285-A286
nvt p.
|
artikel
|
| 297 |
PCN166 TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION
|
Clark, O
|
|
2009
|
12 |
7 |
p. A289-
1 p.
|
artikel
|
| 298 |
PCN60 TREATMENT COSTS ASSOCIATED WITH METASTATIC BREAST CANCER
|
Park, HJ
|
|
2009
|
12 |
7 |
p. A267-
1 p.
|
artikel
|
| 299 |
PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
|
de Castro Carpeño, J
|
|
2009
|
12 |
7 |
p. A264-
1 p.
|
artikel
|
| 300 |
PCN172 TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: A RETROSPECTIVE LONGITUDINAL STUDY
|
Colman, S
|
|
2009
|
12 |
7 |
p. A290-
1 p.
|
artikel
|
| 301 |
PCN38 TREATMENT PATTERNS OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE TO ANTHRACYCLINE AND TAXANE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Serrano, SV
|
|
2009
|
12 |
7 |
p. A500-
1 p.
|
artikel
|
| 302 |
PCN159 TREND OF METASTASECTOMY AND CHEMO- AND BIOLOGIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
|
Wang, F
|
|
2009
|
12 |
7 |
p. A287-
1 p.
|
artikel
|
| 303 |
PCN27 TRENDS IN COLORECTAL CANCER SCREENING (CRC) PATTERNS AMONG COMMUNITY DWELLING MEDICARE BENEFICIARIES
|
Maneno, M
|
|
2009
|
12 |
7 |
p. A261-
1 p.
|
artikel
|
| 304 |
PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
|
Engel, T
|
|
2009
|
12 |
7 |
p. A288-
1 p.
|
artikel
|
| 305 |
PCN68 US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
|
Chin, C
|
|
2009
|
12 |
7 |
p. A269-
1 p.
|
artikel
|
| 306 |
PCN135 USING THE FACT-LEUKEMIA SUBSCALE TO EVALUATE QUALITY OF LIFE IN LEUKEMIA PATIENTS WORLDWIDE
|
Arnold, BJ
|
|
2009
|
12 |
7 |
p. A282-A283
nvt p.
|
artikel
|
| 307 |
PCN132 UTILITY LIBRARY TO CAPTURE UTILITIES IN THE AREA OF ONCOLOGY
|
Stafford, MR
|
|
2009
|
12 |
7 |
p. A282-
1 p.
|
artikel
|
| 308 |
PCN134 VALIDATION OF A KOREAN TRANSLATION OF CANCER THERAPY SATISFACTION QUESTIONNAIRE (CTSQ): A PILOT STUDY
|
An, SM
|
|
2009
|
12 |
7 |
p. A282-
1 p.
|
artikel
|
| 309 |
PCN143 WILLINGNESS TO PAY FOR A LIFE-YEAR GAINED FROM THE PERSPECTIVE OF THE GENERAL POPULATION
|
Obradovic, M
|
|
2009
|
12 |
7 |
p. A284-
1 p.
|
artikel
|
| 310 |
PCV169 ACETYLSALICYLIC ACID(ASA) MONOTHERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: AN ASSESSMENT OF THE MEDICAL BENEFIT USING THE IQWIG METHODOLOGICAL APPROACH
|
Maxion-Bergemann, S
|
|
2009
|
12 |
7 |
p. A345-
1 p.
|
artikel
|
| 311 |
PCV167 A CLUSTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE AN AMBULATORY PRIMARY CARE MANAGEMENT PROGRAM FOR PATIENTS WITH DYSLIPIDEMIA: TEAM STUDY
|
Lalonde, L
|
|
2009
|
12 |
7 |
p. A344-
1 p.
|
artikel
|
| 312 |
PCV14 A COMPARISON OF BLOOD PRESSURE OUTCOMES ASSOCIATED WITH THE USE OF ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) IN PATIENTS SEEN PREDOMINANTLY IN PRIMARY CARE PRACTICES
|
Biskupiak, J
|
|
2009
|
12 |
7 |
p. A314-
1 p.
|
artikel
|
| 313 |
PCV67 A COST-OF-ILLNESS ANALYSIS OF ATRIAL FIBRILLATION IN SWEDEN
|
Ericson, L
|
|
2009
|
12 |
7 |
p. A325-
1 p.
|
artikel
|
| 314 |
PCV32 A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE
|
Laforest, L
|
|
2009
|
12 |
7 |
p. A317-
1 p.
|
artikel
|
| 315 |
PCV170 A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG HUNGARIAN PATIENTS IN PRIMARY CARE
|
Kiss, Z
|
|
2009
|
12 |
7 |
p. A345-
1 p.
|
artikel
|
| 316 |
PCV40 ACUTE MYOCARDIAL AND CEREBRAL INFARCTION REGARDING TO SEASONAL, WEEKLY AND DAILY VARIATION IN CASE OF HUNGARY
|
Kriszbacher, I
|
|
2009
|
12 |
7 |
p. A319-
1 p.
|
artikel
|
| 317 |
PCV166 ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE: A NET COST ANALYSIS & REIMBURSEMENT IMPLICATIONS
|
Pilz, G
|
|
2009
|
12 |
7 |
p. A344-
1 p.
|
artikel
|
| 318 |
PCV33 ADHERENCE AND PERSISTENCE WITH STATIN THERAPY: PHARMACOUTILIZATION ANALYSIS FROM ADMINISTRATIVE DATABASES OF 5 ITALIAN LOCAL HEALTH UNITS (LHU)
|
Santoni, L
|
|
2009
|
12 |
7 |
p. A318-
1 p.
|
artikel
|
| 319 |
PCV158 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM: USAGE IN CROATIA DURING A SEVEN-YEAR PERIOD
|
Vitezic, D
|
|
2009
|
12 |
7 |
p. A343-
1 p.
|
artikel
|
| 320 |
PCV48 A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTICOAGULATION STRATEGIES IN PERCUTANEOUS CORONARY INTERVENTION
|
Olchanski, N
|
|
2009
|
12 |
7 |
p. A321-
1 p.
|
artikel
|
| 321 |
PCV10 A MARGINAL STRUCTURAL MODEL TO COMPARE THE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN RECEPTOR BLOCKERS IN VETERANS WITH CHRONIC HEART FAILURE
|
Johnson, M
|
|
2009
|
12 |
7 |
p. A313-
1 p.
|
artikel
|
| 322 |
PCV21 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS
|
Petrella, RJ
|
|
2009
|
12 |
7 |
p. A315-
1 p.
|
artikel
|
| 323 |
PCV84 AN ASSESSMENT OF THE COST OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW TRACT DYSFUNCTION
|
Raikou, M
|
|
2009
|
12 |
7 |
p. A328-
1 p.
|
artikel
|
| 324 |
PCV122 ANGIOGRAPHY FOR DIAGNOSING PAOD: COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA
|
Bergmann, K
|
|
2009
|
12 |
7 |
p. A335-A336
nvt p.
|
artikel
|
| 325 |
PCV24 ANÁLISIS DEL CONSUMO DE AGENTES HIPOLIPEMIANTES EN COLOMBIA DEL 2002 AL 2006
|
Alfonso, R
|
|
2009
|
12 |
7 |
p. A504-
1 p.
|
artikel
|
| 326 |
PCV111 A PATIENT'S VIEW OF THE COST-EFFECTIVENESS OF USING LOWDOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK
|
Amirsadri-Naeini, M
|
|
2009
|
12 |
7 |
p. A333-A334
nvt p.
|
artikel
|
| 327 |
PCV152 ASSESSING THE IMPACT OF A COMMUNITY PHARMACY BASED MTM PROGRAM ON OUTCOMES FOR EMPLOYEES WITH HYPERTENSION
|
Pinto, SL
|
|
2009
|
12 |
7 |
p. A342-
1 p.
|
artikel
|
| 328 |
PCV142 ASSESSING THE QUALITY OF QUALITY OF LIFE MEASURES IN HEART FAILURE: A COMPARISON OF AVAILABLE INSTRUMENTS
|
Herdman, M
|
|
2009
|
12 |
7 |
p. A340-
1 p.
|
artikel
|
| 329 |
PCV149 ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2
|
Turska, W
|
|
2009
|
12 |
7 |
p. A341-
1 p.
|
artikel
|
| 330 |
PCV7 ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES
|
Balu, S
|
|
2009
|
12 |
7 |
p. A312-
1 p.
|
artikel
|
| 331 |
PCV24 A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CLINICAL TRIALS REVIEWING ANTI-ARRHYTHMIC DRUGS FOR THE TREATMENT OF ATRIAL FIBRILLATION
|
Sullivan, SD
|
|
2009
|
12 |
7 |
p. A316-
1 p.
|
artikel
|
| 332 |
PCV9 AVALIAÇÃO DO PERFIL EPIDEMIOLÓGICO E DE PRESCRIÇÃO PARA PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS
|
Wadt, M
|
|
2009
|
12 |
7 |
p. A501-
1 p.
|
artikel
|
| 333 |
PCV28 BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POPULATION ANALYSIS OF NET CLINICAL BENEFIT
|
Schmitt, C
|
|
2009
|
12 |
7 |
p. A317-
1 p.
|
artikel
|
| 334 |
PCV55 BUDGET IMPACT ANALYSIS OF DIAGNOSTIC OF UNEXPLAINED AND/OR RECURRENT SYNCOPE WITH APPLICATION OF IMPLANTABLE LOOP RECORDER
|
Gwiosda, B
|
|
2009
|
12 |
7 |
p. A322-
1 p.
|
artikel
|
| 335 |
PCV60 BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE
|
Chevreul, K
|
|
2009
|
12 |
7 |
p. A323-
1 p.
|
artikel
|
| 336 |
PCV50 BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS
|
Olchanski, N
|
|
2009
|
12 |
7 |
p. A321-
1 p.
|
artikel
|
| 337 |
PCV79 BURDEN OF ILLNESS STUDY IN PATIENTS WITH RESISTANT HYPERTENSION IN UK
|
Wasiak, R
|
|
2009
|
12 |
7 |
p. A327-
1 p.
|
artikel
|
| 338 |
PCV23 CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON RIESGO CARDIOVASCULAR
|
Alfonzo, N
|
|
2009
|
12 |
7 |
p. A504-
1 p.
|
artikel
|
| 339 |
PCV9 CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATION'S PERSPECTIVE IN THE UNITED STATES
|
Balu, S
|
|
2009
|
12 |
7 |
p. A313-
1 p.
|
artikel
|
| 340 |
PCV165 CHANGES IN THE COST-EFFICACY OF STATINS IN SPAIN AFTER THE INTRODUCTION OF GENERICS AND REFERENCE PRICES
|
Plans-Rubió, P
|
|
2009
|
12 |
7 |
p. A344-
1 p.
|
artikel
|
| 341 |
PCV68 CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) COST OF ILLNESS IN THE PRIVATELY-INSURED POPULATION IN THE UNITED STATES
|
Kirson, NY
|
|
2009
|
12 |
7 |
p. A325-
1 p.
|
artikel
|
| 342 |
PCV22 CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES
|
Mrozek, M
|
|
2009
|
12 |
7 |
p. A315-
1 p.
|
artikel
|
| 343 |
PCV15 COMBINED OPTIMAL LIPID VALUE GOAL ATTAINMENT AFTER TREATMENT INITIATION WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS EZETIMIBE PLUS SIMVASTATIN COMBINATION THERAPY IN A MANAGED CARE PATIENT POPULATION WITH PRIOR CARDIOVASCULAR DISEASE IN THE UNITED STATES
|
Balu, S
|
|
2009
|
12 |
7 |
p. A314-
1 p.
|
artikel
|
| 344 |
PCV168 COMMUNITY PHARMACY DISPENSING OF PRESCRIPTION MEDICINE SAMPLE PACKS—CHANGING THE BUSINESS OF MEDICINE INITIATION?
|
Kyle, GJ
|
|
2009
|
12 |
7 |
p. A344-A345
nvt p.
|
artikel
|
| 345 |
PCV16 COMPARATIVE EFFICACY OF LOSARTAN AND IRBESARTAN IN HYPERTENSIVE PATIENTS AT SARABURI HOSPITAL, THAILAND 2007
|
Auamnoy, T
|
|
2009
|
12 |
7 |
p. A314-
1 p.
|
artikel
|
| 346 |
PCV138 COMPARATIVE RESEARCH BETWEEN ORAL AND SUBCUTANEOUS THROMBOPROPHYLAXIS: THE STOPWATCH PROJECT
|
Quante, M
|
|
2009
|
12 |
7 |
p. A339-
1 p.
|
artikel
|
| 347 |
PCV130 COMPLIANCE (ADHERENCE) TO ANTIHYPERTENSIVE THERAPY IN AUSTRALIA
|
Ortiz, M
|
|
2009
|
12 |
7 |
p. A337-
1 p.
|
artikel
|
| 348 |
PCV42 CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS ACCORDING TO METEOROLOGICAL AND ASTRONOMICAL FACTORS
|
Paljunite, A
|
|
2009
|
12 |
7 |
p. A319-
1 p.
|
artikel
|
| 349 |
PCV36 CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS UNDER THE EFFECTS OF CERTAIN HARMFUL HABITS AND OPERATIVE DATA
|
Paljunite, A
|
|
2009
|
12 |
7 |
p. A318-
1 p.
|
artikel
|
| 350 |
PCV73 COST–ANALYSIS OF STROKE PATIENTS WITH THE INTEGRATED WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA
|
Ku, MJ
|
|
2009
|
12 |
7 |
p. A326-
1 p.
|
artikel
|
| 351 |
PCV4 COST AND OUTCOME ANALYSIS COMPARING PTCA & CABG IN LOW AND HIGH RISK PATIENTS
|
Singh, S
|
|
2009
|
12 |
7 |
p. A500-
1 p.
|
artikel
|
| 352 |
PCV66 COST BURDEN OF ATHENA ENDPOINTS IN ATHENA-LIKE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES
|
Patel, PP
|
|
2009
|
12 |
7 |
p. A324-
1 p.
|
artikel
|
| 353 |
PCV85 COST CONSEQUENCES OF REDUCED CVD RISK THROUGH IMPROVED SBP CONTROL: A COMPARATIVE ANALYSIS OF VALSARTAN VERSUS LOSARTAN
|
Baker, TM
|
|
2009
|
12 |
7 |
p. A328-
1 p.
|
artikel
|
| 354 |
PCV13 COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE COMPARED TO CLINICAL JUDGMENT IN PATIENTS PRESENTING TO ACUTE CARE SETTINGS WITH DYSPNEA IN UNIFIED HEALTH SYSTEM
|
Araujo, D
|
|
2009
|
12 |
7 |
p. A502-
1 p.
|
artikel
|
| 355 |
PCV12 COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Fernandes, RA
|
|
2009
|
12 |
7 |
p. A502-
1 p.
|
artikel
|
| 356 |
PCV15 COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Fernandes, RA
|
|
2009
|
12 |
7 |
p. A502-A503
nvt p.
|
artikel
|
| 357 |
PCV91 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN AS ADJUNCTIVE THERAPY WITH FIBRINOLYSIS IN SPANISH PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI): RESULTS FROM EXTRACT-TIMI 25
|
Betegón, L
|
|
2009
|
12 |
7 |
p. A329-
1 p.
|
artikel
|
| 358 |
PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
|
Weitz, J
|
|
2009
|
12 |
7 |
p. A333-
1 p.
|
artikel
|
| 359 |
PCV93 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED WITH DOUBLING THE STATIN DOSE: ANALYSIS OF THE INFORCE STUDY IN THE UK
|
Reckless, JP
|
|
2009
|
12 |
7 |
p. A330-
1 p.
|
artikel
|
| 360 |
PCV96 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING
|
Félix, J
|
|
2009
|
12 |
7 |
p. A330-
1 p.
|
artikel
|
| 361 |
PCV17 COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN 10 MG VS. ATORVASTATIN 20 MG FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
|
Anaya, P
|
|
2009
|
12 |
7 |
p. A503-
1 p.
|
artikel
|
| 362 |
PCV16 COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
7 |
p. A503-
1 p.
|
artikel
|
| 363 |
PCV59 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN
|
Espallardo, O
|
|
2009
|
12 |
7 |
p. A323-
1 p.
|
artikel
|
| 364 |
PCV92 COST-EFFECTIVENESS OF AN EXERCISE TRAINING PROGRAM IN HEART FAILURE
|
Kuhr, EM
|
|
2009
|
12 |
7 |
p. A329-A330
nvt p.
|
artikel
|
| 365 |
PCV119 COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS
|
Thurston, SJ
|
|
2009
|
12 |
7 |
p. A335-
1 p.
|
artikel
|
| 366 |
PCV116 COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION—A HORIZONS TRIAL ANALYSIS USING UK VALUATIONS
|
Schwenkglenks, M
|
|
2009
|
12 |
7 |
p. A334-A335
nvt p.
|
artikel
|
| 367 |
PCV95 COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES IN SOUTH KOREA
|
Shin, S
|
|
2009
|
12 |
7 |
p. A330-
1 p.
|
artikel
|
| 368 |
PCV103 COST-EFFECTIVENESS OF EXTENDED VERSUS NON-EXTENDED PROPHYLAXIS WITH ENOXAPARIN IN HIGH-RISK SURGICAL PATIENTS IN AUSTRALIA
|
Tilden, D
|
|
2009
|
12 |
7 |
p. A332-
1 p.
|
artikel
|
| 369 |
PCV113 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN MAJOR ORTHOPEDIC SURGERY IN POLAND
|
Kawalec, P
|
|
2009
|
12 |
7 |
p. A334-
1 p.
|
artikel
|
| 370 |
PCV105 COST-EFFECTIVENESS OF GENEOTYPE-GUIDED DOSING OF SHORTTERM USE OF WARFARIN AMONG DVT/PE PATIENTS
|
Teschemaker, AR
|
|
2009
|
12 |
7 |
p. A332-
1 p.
|
artikel
|
| 371 |
PCV97 COST-EFFECTIVENESS OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE ANGINA IN A DUTCH SETTING
|
Almeida, J
|
|
2009
|
12 |
7 |
p. A330-A331
nvt p.
|
artikel
|
| 372 |
PCV108 COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE
|
Debroucker, F
|
|
2009
|
12 |
7 |
p. A333-
1 p.
|
artikel
|
| 373 |
PCV98 COST-EFFECTIVENESS OF ORGANISED INPATIENT CARE FOR STROKE
|
Launois, R
|
|
2009
|
12 |
7 |
p. A331-
1 p.
|
artikel
|
| 374 |
PCV14 COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA
|
Castro, D
|
|
2009
|
12 |
7 |
p. A502-
1 p.
|
artikel
|
| 375 |
PCV87 COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI: RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE
|
Mahoney, EM
|
|
2009
|
12 |
7 |
p. A328-A329
nvt p.
|
artikel
|
| 376 |
PCV112 COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND
|
McCullagh, L
|
|
2009
|
12 |
7 |
p. A334-
1 p.
|
artikel
|
| 377 |
PCV11 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA
|
Pereira, R
|
|
2009
|
12 |
7 |
p. A502-
1 p.
|
artikel
|
| 378 |
PCV109 COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA
|
Bae, EY
|
|
2009
|
12 |
7 |
p. A333-
1 p.
|
artikel
|
| 379 |
PCV86 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE
|
Fagnani, F
|
|
2009
|
12 |
7 |
p. A328-
1 p.
|
artikel
|
| 380 |
PCV102 COST-EFFECTIVENESS OF VARIOUS 'SCREEN-AND-TREAT' SCENARIOS DIRECTED AT ELEVATED ALBUMINURIA TO PREVENT CARDIOVASCULAR AND RENAL DISEASE IN THE GENERAL POPULATION
|
Boersma, C
|
|
2009
|
12 |
7 |
p. A331-A332
nvt p.
|
artikel
|
| 381 |
PCV18 COSTO-EFECTIVIDAD DE ETEXILATO DE DABIGATRAN EN LA PROFILAXIS DE LA ENFERMEDAD TROMBOEMBOLICA VENOSA (ETV) ASOCIADA CON CIRUGIA DE CADERA EN EL PACIENTE ADULTO EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)
|
Ledezma-Gómez, H
|
|
2009
|
12 |
7 |
p. A503-
1 p.
|
artikel
|
| 382 |
PCV18 COST OF ACHIEVING LDL REDUCTION AMONG PATIENTS TREATED WITH EZETIMIBE CO-ADMINISTRATION COMPARED TO STATIN MONOTHERAPY IN THE UK
|
Punekar, YS
|
|
2009
|
12 |
7 |
p. A314-A315
nvt p.
|
artikel
|
| 383 |
PCV123 COST OF ARTERIAL HYPERTENSION ACCORDING TO LEVELS OF MORBIDITY IN PRIMARY CARE SETTING
|
Sicras-Mainar, A
|
|
2009
|
12 |
7 |
p. A336-
1 p.
|
artikel
|
| 384 |
PCV63 COST OF CARDIOVASCULAR DISEASE IN KOREA: INCIDENCE-BASED APPROACH
|
Lee, YS
|
|
2009
|
12 |
7 |
p. A324-
1 p.
|
artikel
|
| 385 |
PCV124 COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
|
Ondrackova, B
|
|
2009
|
12 |
7 |
p. A336-
1 p.
|
artikel
|
| 386 |
PCV61 COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS: RESULTS OF HF-ACTION TRIAL
|
Reed, SD
|
|
2009
|
12 |
7 |
p. A323-
1 p.
|
artikel
|
| 387 |
PCV8 COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM AFTER ELECTIVE TOTAL HIP REPLACEMENT
|
Lukac, M
|
|
2009
|
12 |
7 |
p. A501-
1 p.
|
artikel
|
| 388 |
PCV57 COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE
|
Bielik, J
|
|
2009
|
12 |
7 |
p. A322-A323
nvt p.
|
artikel
|
| 389 |
PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND—A DISCRETE EVENT SIMULATION MODELLING
|
Soini, EJ
|
|
2009
|
12 |
7 |
p. A335-
1 p.
|
artikel
|
| 390 |
PCV27 COUNTRY-SPECIFIC DIFFERENCES IN 12-MONTH PATTERNS OF ANTIPLATELET USE IN ACS PATIENTS UNDERGOING PCI IN 2007–08: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)
|
Zeymer, U
|
|
2009
|
12 |
7 |
p. A316-
1 p.
|
artikel
|
| 391 |
PCV171 CRITICAL APPRAISAL OF THE JAPANESE GUIDELINE FOR THE MANAGEMENT OF STROKE
|
Origasa, H
|
|
2009
|
12 |
7 |
p. A345-
1 p.
|
artikel
|
| 392 |
PCV114 DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS
|
Boersma, C
|
|
2009
|
12 |
7 |
p. A334-
1 p.
|
artikel
|
| 393 |
PCV45 DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS
|
Smolen, HJ
|
|
2009
|
12 |
7 |
p. A320-
1 p.
|
artikel
|
| 394 |
PCV6 DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENT RISK AMONG PRIMARY AND SECONDARY RISK DYSLIPIDEMIA MANAGED CARE PATIENTS IN THE UNITED STATES
|
Balu, S
|
|
2009
|
12 |
7 |
p. A312-
1 p.
|
artikel
|
| 395 |
PCV132 DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA
|
Ortiz, M
|
|
2009
|
12 |
7 |
p. A338-
1 p.
|
artikel
|
| 396 |
PCV76 DIRECT COSTS OF DIAGNOSTIC AND TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN GERMANY
|
Benkert, D
|
|
2009
|
12 |
7 |
p. A326-
1 p.
|
artikel
|
| 397 |
PCV120 DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES
|
Âkerborg, Ö
|
|
2009
|
12 |
7 |
p. A335-
1 p.
|
artikel
|
| 398 |
PCV52 ECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING RECURRENT STROKE
|
Jackson, D
|
|
2009
|
12 |
7 |
p. A321-A322
nvt p.
|
artikel
|
| 399 |
PCV107 ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH SIMVASTATIN FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA
|
Van Nooten, F
|
|
2009
|
12 |
7 |
p. A333-
1 p.
|
artikel
|
| 400 |
PCV118 ECONOMIC EVALUATION OF INHALED ILOPROST IN PRIMARY PULMONARY HYPERTENSION IN THE UK
|
Ashley, D
|
|
2009
|
12 |
7 |
p. A335-
1 p.
|
artikel
|
| 401 |
PCV81 ECONOMIC IMPLICATIONS OF OBESITY AMONG PEOPLE WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIA
|
Ademi, Z
|
|
2009
|
12 |
7 |
p. A327-
1 p.
|
artikel
|
| 402 |
PCV10 ECONOMIC VALUE OF RESTING HEART RATE AS AN INDEPENDENT CARDIOVASCULAR RISK FACTOR IN STABLE ANGINA PATIENTS
|
Félix, J
|
|
2009
|
12 |
7 |
p. A501-A502
nvt p.
|
artikel
|
| 403 |
PCV13 EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND SIMVASTATIN IN THE REDUCTION OF CARDIOVASCULAR EVENTS: AN INDIRECT COMPARISON META-ANALYSIS
|
Ribeiro, RA
|
|
2009
|
12 |
7 |
p. A313-A314
nvt p.
|
artikel
|
| 404 |
PCV19 EFFECT OF CALCIUM CHANNEL BLOCKERS ON CARDIOVASCULAR DISEASE PREVENTION
|
Park, HJ
|
|
2009
|
12 |
7 |
p. A315-
1 p.
|
artikel
|
| 405 |
PCV127 EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE
|
Cyr, PL
|
|
2009
|
12 |
7 |
p. A337-
1 p.
|
artikel
|
| 406 |
PCV22 EFFECTS OF TADALAFIL ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
|
Pepke-Zaba, J
|
|
2009
|
12 |
7 |
p. A504-
1 p.
|
artikel
|
| 407 |
PCV121 ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC STROKE IN THE NETHERLANDS. A COST-UTILITY ANALYSIS
|
Bouvy, J
|
|
2009
|
12 |
7 |
p. A335-
1 p.
|
artikel
|
| 408 |
PCV72 ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA ACCORDING TO THE AGE OF ONSET: USING NATIONAL HEALTH INSURANCE CLAIMS DATABASE
|
Kang, HY
|
|
2009
|
12 |
7 |
p. A326-
1 p.
|
artikel
|
| 409 |
PCV41 ESTIMATION OF PERSONS ELIGIBLE FOR ICD/CRT THERAPY IN WESTERN EUROPE UNDER THE CURRENT ESC GUIDELINES: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Fattore, G
|
|
2009
|
12 |
7 |
p. A319-
1 p.
|
artikel
|
| 410 |
PCV125 EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE
|
Cyr, PL
|
|
2009
|
12 |
7 |
p. A336-
1 p.
|
artikel
|
| 411 |
PCV25 EVALUATION OF THREE METHODS: OF SCHEDULING APPOINTMENT USING SIMULATION EXPERIMENTS
|
Sobolev, B
|
|
2009
|
12 |
7 |
p. A504-
1 p.
|
artikel
|
| 412 |
PCV54 EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN
|
Jackson, D
|
|
2009
|
12 |
7 |
p. A322-
1 p.
|
artikel
|
| 413 |
PCV147 EXPERIENCE WITH UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TREATED WITH LOW-DOSE ACETYLSALICYLIC ACID
|
Sörstadius, E
|
|
2009
|
12 |
7 |
p. A341-
1 p.
|
artikel
|
| 414 |
PCV143 EXPLORING PATIENTS' SATISFACTION WITH ANTICOAGULANT TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO THE PERCEPTION OF ANTICOAGULANT TREATMENT QUESTIONNAIRE (PACT-Q)
|
Regnault, A
|
|
2009
|
12 |
7 |
p. A340-
1 p.
|
artikel
|
| 415 |
PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE
|
Hadker, N
|
|
2009
|
12 |
7 |
p. A321-
1 p.
|
artikel
|
| 416 |
PCV53 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A UK HEALTH CARE PAYER PERSPECTIVE
|
Hadker, N
|
|
2009
|
12 |
7 |
p. A322-
1 p.
|
artikel
|
| 417 |
PCV163 GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS: AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION
|
Zhao, Z
|
|
2009
|
12 |
7 |
p. A344-
1 p.
|
artikel
|
| 418 |
PCV146 HAS THE TYPE OF ATRIAL FIBRILLATION DIFFERENT IMPACT ON HRQOL?
|
Arribas, F
|
|
2009
|
12 |
7 |
p. A340-A341
nvt p.
|
artikel
|
| 419 |
PCV77 HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS
|
Zhao, Z
|
|
2009
|
12 |
7 |
p. A326-A327
nvt p.
|
artikel
|
| 420 |
PCV161 HEALTH CARE RESOURCES UTILIZATION IN ACUTE CORONARY SYNDROME PATIENTS ONE YEAR AFTER PCI : FRENCH RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)
|
Ferrieres, J
|
|
2009
|
12 |
7 |
p. A343-
1 p.
|
artikel
|
| 421 |
PCV144 HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN
|
Wagner, S
|
|
2009
|
12 |
7 |
p. A340-
1 p.
|
artikel
|
| 422 |
PCV148 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA
|
Müller-Nordhorn, J
|
|
2009
|
12 |
7 |
p. A341-
1 p.
|
artikel
|
| 423 |
PCV136 HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS
|
Doyle, S
|
|
2009
|
12 |
7 |
p. A338-
1 p.
|
artikel
|
| 424 |
PCV135 HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY : RESULTS FROM THE NATIONAL RISK FACTOR SURVEY
|
Augustovski, FA
|
|
2009
|
12 |
7 |
p. A338-
1 p.
|
artikel
|
| 425 |
PCV44 HEART FAILURE IN OLDER PEOPLE: A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION
|
Brown, SH
|
|
2009
|
12 |
7 |
p. A320-
1 p.
|
artikel
|
| 426 |
PCV3 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND RISK FOR MAJOR CARDIOVASCULAR EVENTS IN MEN AND WOMEN
|
Webb, SF
|
|
2009
|
12 |
7 |
p. A500-
1 p.
|
artikel
|
| 427 |
PCV38 HOSPITALIZATION AND MORTALITY IN ADVANCED-AGE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES
|
Patel, PP
|
|
2009
|
12 |
7 |
p. A319-
1 p.
|
artikel
|
| 428 |
PCV17 HOW DOES THE DUAL COMBINATION OF ARBS+HCTZ COMPARE TO OTHER DUAL COMBINATIONS IN THE TREATMENT OF HYPERTENSION?
|
Petrella, RJ
|
|
2009
|
12 |
7 |
p. A314-
1 p.
|
artikel
|
| 429 |
PCV7 IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA (IC), SOB A PERSPECTIVA DO SISTEMA UNICO DE SAUDE (SUS), NO BRASIL
|
Nasciben, VD
|
|
2009
|
12 |
7 |
p. A501-
1 p.
|
artikel
|
| 430 |
PCV6 IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA, SOB A PERSPECTIVA DO PAGADOR PRIVADO NO BRASIL
|
Nasciben, VD
|
|
2009
|
12 |
7 |
p. A501-
1 p.
|
artikel
|
| 431 |
PCV155 IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE: THE CASE OF MEDICARE PART D
|
Donohue, JM
|
|
2009
|
12 |
7 |
p. A342-
1 p.
|
artikel
|
| 432 |
PCV145 IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS
|
Reynolds, MR
|
|
2009
|
12 |
7 |
p. A340-
1 p.
|
artikel
|
| 433 |
PCV56 IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME
|
Mauskopf, J
|
|
2009
|
12 |
7 |
p. A322-
1 p.
|
artikel
|
| 434 |
PCV2 INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
|
Yu, N
|
|
2009
|
12 |
7 |
p. A311-
1 p.
|
artikel
|
| 435 |
PCV74 INCREMENTAL COSTS OF HYPERTENSION, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND THEIR COMBINATIONS
|
Tang, CH
|
|
2009
|
12 |
7 |
p. A326-
1 p.
|
artikel
|
| 436 |
PCV133 INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH CHRONIC HEART DISEASES
|
Origasa, H
|
|
2009
|
12 |
7 |
p. A338-
1 p.
|
artikel
|
| 437 |
PCV101 IS PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE GERMAN HEALTH CARE SYSTEM? A MODEL-BASED ANALYSIS
|
Davies, A
|
|
2009
|
12 |
7 |
p. A331-
1 p.
|
artikel
|
| 438 |
PCV128 LOADING WITH WARFARIN PROLONGS LENGTH OF HOSPITAL STAY IN PATIENTS WITH ATRIAL FIBRILLATION
|
Tan, ES
|
|
2009
|
12 |
7 |
p. A337-
1 p.
|
artikel
|
| 439 |
PCV31 LONGITUDINAL ASSESSMENT OF LIPID ABNORMALITIES IN A SAMPLE OF ITALIAN PATIENTS: PREVALENCE AND ATTAINMENT OF GOAL/NORMAL LEVELS
|
Ambegaonkar, BM
|
|
2009
|
12 |
7 |
p. A317-
1 p.
|
artikel
|
| 440 |
PCV80 LONGITUDINAL COST IMPACT OF ATRIAL FIBRILLATION IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES
|
Reinhold, T
|
|
2009
|
12 |
7 |
p. A327-
1 p.
|
artikel
|
| 441 |
PCV70 MANAGEMENT OF ACUTE ISCHEMIC STROKE (IS) AND ASSOCIATED COSTS OVER A 12-MONTH PERIOD IN FRANCE
|
Saragoussi, D
|
|
2009
|
12 |
7 |
p. A325-
1 p.
|
artikel
|
| 442 |
PCV153 MARYLAND MEN'S CARDIOVASCULAR PROMOTION—MVP
|
Shaya, FT
|
|
2009
|
12 |
7 |
p. A342-
1 p.
|
artikel
|
| 443 |
PCV157 MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT DIABETES MELLITUS
|
Zhu, B
|
|
2009
|
12 |
7 |
p. A343-
1 p.
|
artikel
|
| 444 |
PCV20 METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND NON-DRUG TREATMENT
|
Lopes, N
|
|
2009
|
12 |
7 |
p. A503-
1 p.
|
artikel
|
| 445 |
PCV129 METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE WITH COMMON TREATMENTS
|
Meszaros, A
|
|
2009
|
12 |
7 |
p. A337-
1 p.
|
artikel
|
| 446 |
PCV1 MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT—ACE INHIBITOR INDUCED COUGH
|
Vegter, S
|
|
2009
|
12 |
7 |
p. A311-
1 p.
|
artikel
|
| 447 |
PCV131 NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK: THE IMPACT OF GASTROINTESTINAL SYMPTOMS
|
Sörstadius, E
|
|
2009
|
12 |
7 |
p. A337-A338
nvt p.
|
artikel
|
| 448 |
PCV78 ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE INITIAL HOSPITALIZATION
|
Zhao, Z
|
|
2009
|
12 |
7 |
p. A327-
1 p.
|
artikel
|
| 449 |
PCV29 OUTCOMES ASSESSMENT IN LOW & HIGH RISK P.T.C.A. PATIENTS
|
Singh, S
|
|
2009
|
12 |
7 |
p. A317-
1 p.
|
artikel
|
| 450 |
PCV90 PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY RESUSCITATION: AN ANALYSIS OF OUTCOME, QUALITY OF LIFE AND COST-EFFECTIVENESS
|
Oeyen, S
|
|
2009
|
12 |
7 |
p. A329-
1 p.
|
artikel
|
| 451 |
PCV75 PATIENTS WITH PULMONARY EMBOLISM AFTER ORTHOPAEDIC SURGERY HAVE SIGNIFICANTLY INCREASED COSTS FOR INPATIENT STAY
|
Lukac, M
|
|
2009
|
12 |
7 |
p. A326-
1 p.
|
artikel
|
| 452 |
PCV46 PERFLUTREN PROTEIN-TYPE A MICROSPHERES INJECTABLE SUSPENSION, USP DOES NOT INCREASE MORTALITY IN CRITICALLY ILL PATIENTS: RESULTS FROM A RETROSPECTIVE PROPENSITY-MATCHED CASE-CONTROL STUDY
|
Main, M
|
|
2009
|
12 |
7 |
p. A320-
1 p.
|
artikel
|
| 453 |
PCV5 PERIODONTAL DISEASE, STATIN USE, AND CARDIOVASCULAR EVENTS
|
Misra, A
|
|
2009
|
12 |
7 |
p. A312-
1 p.
|
artikel
|
| 454 |
PCV99 PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY
|
Rudakova, AV
|
|
2009
|
12 |
7 |
p. A331-
1 p.
|
artikel
|
| 455 |
PCV30 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008: CZECH REPUBLIC BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
|
Coufal, Z
|
|
2009
|
12 |
7 |
p. A317-
1 p.
|
artikel
|
| 456 |
PCV26 PRACTICE PATTERNS AND QUALITY OF LIFE IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE NORDIC COUNTRIES: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
|
James, S
|
|
2009
|
12 |
7 |
p. A316-
1 p.
|
artikel
|
| 457 |
PCV35 PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES
|
Zhu, B
|
|
2009
|
12 |
7 |
p. A318-
1 p.
|
artikel
|
| 458 |
PCV89 PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE? A MODEL-BASED ANALYSIS
|
Davies, A
|
|
2009
|
12 |
7 |
p. A329-
1 p.
|
artikel
|
| 459 |
PCV1 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE COADMINISTRATION OF FENOFIBRIC ACID AND LOW- OR MODERATEDOSE STATINS IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA
|
Webb, SF
|
|
2009
|
12 |
7 |
p. A500-
1 p.
|
artikel
|
| 460 |
PCV106 PREDICTED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE OPTIMAL LIPID VALUES WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH A STATIN IN SPECIAL PATIENT POPULATIONS WITH MIXED DYSLIPIDEMIA
|
Webb, SF
|
|
2009
|
12 |
7 |
p. A332-
1 p.
|
artikel
|
| 461 |
PCV2 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA
|
Webb, SF
|
|
2009
|
12 |
7 |
p. A500-
1 p.
|
artikel
|
| 462 |
PCV134 PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY: A RETROSPECTIVE
|
Cammarota, S
|
|
2009
|
12 |
7 |
p. A338-
1 p.
|
artikel
|
| 463 |
PCV139 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF ATRIAL FIBRILLATION PATIENTS RECEIVING WARFARIN
|
Robinson, P
|
|
2009
|
12 |
7 |
p. A339-
1 p.
|
artikel
|
| 464 |
PCV140 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF WARFARIN-NAÏVE ATRIAL FIBRILLATION PATIENTS
|
Cottrell, S
|
|
2009
|
12 |
7 |
p. A339-
1 p.
|
artikel
|
| 465 |
PCV137 PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: THE PREFER STUDY
|
Scalone, L
|
|
2009
|
12 |
7 |
p. A338-A339
nvt p.
|
artikel
|
| 466 |
PCV164 PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION
|
Hutton, J
|
|
2009
|
12 |
7 |
p. A344-
1 p.
|
artikel
|
| 467 |
PCV71 PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME IN SPAIN: AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL
|
Alegría, E
|
|
2009
|
12 |
7 |
p. A325-
1 p.
|
artikel
|
| 468 |
PCV37 PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS AT MODERATE CARDIOVASCULAR RISK—GREEK RESULTS OF THE PANDORA STUDY
|
Carvounis, C
|
|
2009
|
12 |
7 |
p. A318-
1 p.
|
artikel
|
| 469 |
PCV8 PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR DIABETES MELLITUS. THE PANDORA SURVEY—BELGIUM RESULTS
|
Wautrecht, JC
|
|
2009
|
12 |
7 |
p. A312-A313
nvt p.
|
artikel
|
| 470 |
PCV5 PROPHYLAXIS OF HEART TRANSPLANTATION REJECTION: FINANCIAL IMPACT ANALYSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM AND A REVIEW OF ECONOMIC EVALUATIONS STUDIES OF EVEROLIMUS, MMF (MYCOPHENOLATE MOFETIL) AND AZATHIOPRINE
|
Suzuki, C
|
|
2009
|
12 |
7 |
p. A500-A501
nvt p.
|
artikel
|
| 471 |
PCV162 PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM—THE SIMVASTATIN CASE
|
VanHaeren, E
|
|
2009
|
12 |
7 |
p. A343-
1 p.
|
artikel
|
| 472 |
PCV62 PULMONARY ARTERIAL HYPERTENSION (PAH) COST OF ILLNESS IN THE U.S. PRIVATELY-INSURED POPULATION
|
Kirson, NY
|
|
2009
|
12 |
7 |
p. A323-A324
nvt p.
|
artikel
|
| 473 |
PCV34 QUANTIFICATION METHODS OF ITALIAN PREVALENT POPULATION SUFFERING FROM ATRIAL FIBRILLATION USING PUBLISHED EPIDEMIOLOGICAL DATA
|
Raviele, A
|
|
2009
|
12 |
7 |
p. A318-
1 p.
|
artikel
|
| 474 |
PCV160 REAL-WORLD PRACTICE PATTERNS OF ACUTE CORONARY SYNDROME (ACS) PATIENTS WITH AND WITHOUT DIABETES MELLITUS (DM)
|
Zhao, Z
|
|
2009
|
12 |
7 |
p. A343-
1 p.
|
artikel
|
| 475 |
PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA
|
Mahoney, EM
|
|
2009
|
12 |
7 |
p. A336-
1 p.
|
artikel
|
| 476 |
PCV83 RELATIONSHIP BETWEEN THE COST AND HOSPITAL QUALITY
|
Baser, O
|
|
2009
|
12 |
7 |
p. A328-
1 p.
|
artikel
|
| 477 |
PCV39 RETROSPECTIVE CLAIM DATABASE ANALYSIS OF THE IMPACT OF THE ASCOT-TYPE PROFILE ON ALL-CAUSES MORTALITY AND CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITHOUT KNOWN CORONARY HEART DISEASE IN A MEDITERRANEAN POPULATION IN SPAIN
|
Sicras, A
|
|
2009
|
12 |
7 |
p. A319-
1 p.
|
artikel
|
| 478 |
PCV151 REVIEW OF STUDIES EVALUATING THE IMPACT OF POLICY-DRIVEN STATIN SWITCH PROGRAMS ON PATIENTS
|
Folia, C
|
|
2009
|
12 |
7 |
p. A341-A342
nvt p.
|
artikel
|
| 479 |
PCV19 REVISÃO SISTEMÁTICA DE ESTUDOS DE CUSTO-EFETIVIDADE DA ROSUVASTATINA VS. ATORVASTATINA
|
Rodrigues, FDA
|
|
2009
|
12 |
7 |
p. A503-
1 p.
|
artikel
|
| 480 |
PCV21 SELF-REPORTED GENERAL HEALTH WAS THE MOST INFLUENTIAL VARIABLE OF EQ-5D SOCIAL PREFERENCES SCORES IN A GENERAL POPULATION SURVEY IN ARGENTINA, AND ITS INFLUENCE DIFFERED ACCORDING TO GENDER, AGE AND INCOME STATUS
|
Augustovski, FA
|
|
2009
|
12 |
7 |
p. A504-
1 p.
|
artikel
|
| 481 |
PCV64 SHORT AND LONG-TERM ECONOMIC BURDEN OF ISCHEMIC STROKE/TIA PATIENTS
|
Berenson, K
|
|
2009
|
12 |
7 |
p. A324-
1 p.
|
artikel
|
| 482 |
PCV4 SIGNAL DETECTION OF BRADYCARDIA ASSOCIATED WITH ATENOLOL HYDROCHLORIDE
|
Kumar, A
|
|
2009
|
12 |
7 |
p. A312-
1 p.
|
artikel
|
| 483 |
PCV104 THE COST-EFFECTIVENESS ANALYSIS IN SCREENING OF DEEP VEIN THROMBOSIS IN A CLINICAL LABORATORY
|
Bogavac-Stanojevic, N
|
|
2009
|
12 |
7 |
p. A332-
1 p.
|
artikel
|
| 484 |
PCV88 THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND
|
Redmond, S
|
|
2009
|
12 |
7 |
p. A329-
1 p.
|
artikel
|
| 485 |
PCV94 THE COST-EFFECTIVENESS OF TITRATION TO GOAL WITH BRAND ROSUVASTATIN COMPARED TO GENERIC SIMVASTATIN IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: PRIMARY AND SECONDARY PREVENTION IN THE BELGIAN HEALTH CARE SETTING
|
Van den Steen, D
|
|
2009
|
12 |
7 |
p. 330-
1 p.
|
artikel
|
| 486 |
PCV69 THE COST-OF-ILLNESS OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW
|
Wolowacz, SE
|
|
2009
|
12 |
7 |
p. A325-
1 p.
|
artikel
|
| 487 |
PCV58 THE DIAGNOSTIC BENEFIT OF STRESS TEST PRIOR TO CARDIAC MULTI-SLICE COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: CLINIC AND ECONOMIC OUTCOMES FROM THE EMILIA-ROMAGNA MSCT REGISTRY
|
Berti, E
|
|
2009
|
12 |
7 |
p. A323-
1 p.
|
artikel
|
| 488 |
PCV25 THE EFFECT OF ANTI-ARRHYTHMIC DRUG THERAPY ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Mitchell, S
|
|
2009
|
12 |
7 |
p. A316-
1 p.
|
artikel
|
| 489 |
PCV20 THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF LOW DOSE ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE IN PREVENTING SERIOUS VASCULAR EVENTS: A NETWORK META-ANALYSIS
|
Dewilde, S
|
|
2009
|
12 |
7 |
p. A315-
1 p.
|
artikel
|
| 490 |
PCV82 THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE
|
Huq, MM
|
|
2009
|
12 |
7 |
p. A327-A328
nvt p.
|
artikel
|
| 491 |
PCV154 THE INFLUENCE OF INSURANCE COMPANIES' REGULATIONS ON DRUG UTILIZATION; THE EXAMPLE OF SIMVASTATIN AND PREFERENCE POLICY
|
Pechlivanoglou, P
|
|
2009
|
12 |
7 |
p. A342-
1 p.
|
artikel
|
| 492 |
PCV51 THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY
|
Jackson, D
|
|
2009
|
12 |
7 |
p. A321-
1 p.
|
artikel
|
| 493 |
PCV47 THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ALL-CAUSE MORTALITY
|
Simons, WR
|
|
2009
|
12 |
7 |
p. A320-A321
nvt p.
|
artikel
|
| 494 |
PCV100 THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE MORTALITY
|
Simons, WR
|
|
2009
|
12 |
7 |
p. A331-
1 p.
|
artikel
|
| 495 |
PCV115 TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION
|
DeMaria, J
|
|
2009
|
12 |
7 |
p. A334-
1 p.
|
artikel
|
| 496 |
PCV172 TREATMENT PATTERNS AMONG PATIENTS WITH HYPERTENSION: RESULTS OF A US SURVEY
|
Sun, SX
|
|
2009
|
12 |
7 |
p. A345-
1 p.
|
artikel
|
| 497 |
PCV65 TWO-YEAR CLINICAL AND ECONOMIC IMPACT OF PERIPHERAL ARTERIAL DISEASE ON PATIENTS FROM SPAIN WITH ESTABLISHED CORONARY ARTERY OR CEREBROVASCULAR DISEASE: RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
|
Ramirez de Arellano, A
|
|
2009
|
12 |
7 |
p. A324-
1 p.
|
artikel
|
| 498 |
PCV11 UNDERSTANDING THE IMPACT OF STATIN TITRATION; A MODELLING APPROACH
|
Gray, AM
|
|
2009
|
12 |
7 |
p. A313-
1 p.
|
artikel
|
| 499 |
PCV141 UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TAKING LOW-DOSE ACETYLSALICYLIC ACID: AN OBSERVATIONAL STUDY
|
Sörstadius, E
|
|
2009
|
12 |
7 |
p. A339-
1 p.
|
artikel
|
| 500 |
PCV3 USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE HEARTH FAILURE
|
Lachaine, J
|
|
2009
|
12 |
7 |
p. A311-A312
nvt p.
|
artikel
|
| 501 |
PCV43 USING ELECTRONIC MEDICAL RECORDS (EMRS) TO ASSESS ANTICOAGULATION STATUS ACCORDING TO STROKE RISK IN PATIENTS WITH ATRIAL FIBRILLATION IN AMBULATORY CARE SETTINGS
|
Cload, P
|
|
2009
|
12 |
7 |
p. A320-
1 p.
|
artikel
|
| 502 |
PCV23 WHAT IS THE EFFECTIVENESS OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES WHEN USED AS MONOTHERAPY IN THE REAL-WORLD?
|
Petrella, RJ
|
|
2009
|
12 |
7 |
p. A315-A316
nvt p.
|
artikel
|
| 503 |
PCV12 WHAT IS THE IMPACT OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES ON CV-EVENTS IN HYPERTENSIVE PATIENTS?
|
Petrella, RJ
|
|
2009
|
12 |
7 |
p. A313-
1 p.
|
artikel
|
| 504 |
PCV150 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN
|
Wagner, S
|
|
2009
|
12 |
7 |
p. A341-
1 p.
|
artikel
|
| 505 |
PDB1 A COMPARISON OF CLINICAL EFFICACY OF INSULIN GLARGINE ADDED TO ORAL ANTIDIABETIC DRUGS VS PREMIXED INSULINS ALONE IN THE TREATEMENT OF TYPE-2 DIABETES MELLITUS
|
Rogoz, A
|
|
2009
|
12 |
7 |
p. A401-
1 p.
|
artikel
|
| 506 |
PDB20 A COST CONSEQUENCE MODEL TO ASSESS THE ECONOMIC IMPACT IN GERMANY OF PATIENTS ACHIEVING KDOQITM TARGETS WITH THE USE OF A COMBINATION OF CINACALCET + TRADITIONAL THERAPY (TT) COMPARED WITH TT ALONE
|
Ho, J
|
|
2009
|
12 |
7 |
p. A405-
1 p.
|
artikel
|
| 507 |
PDB33 A COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE-I DIABETES PATIENTS IN ITALY
|
Giardina, S
|
|
2009
|
12 |
7 |
p. A407-
1 p.
|
artikel
|
| 508 |
PDB12 ADHERENCE TO GLIMEPIRIDE FOR TYPE 2 DIABETICS IN COLOMBIA
|
Fragozo, A
|
|
2009
|
12 |
7 |
p. A507-
1 p.
|
artikel
|
| 509 |
PDB6 ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
|
Wade, R
|
|
2009
|
12 |
7 |
p. A402-
1 p.
|
artikel
|
| 510 |
PDB73 ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES
|
Adalsteinsson, E
|
|
2009
|
12 |
7 |
p. A415-
1 p.
|
artikel
|
| 511 |
PDB8 ANTIDIABETIC DRUG UTILIZATION IN A UNIVERSITY HEALTH CARE SETTING
|
Mousnad, M
|
|
2009
|
12 |
7 |
p. A402-
1 p.
|
artikel
|
| 512 |
PDB25 A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY
|
Eandi, M
|
|
2009
|
12 |
7 |
p. A406-
1 p.
|
artikel
|
| 513 |
PDB75 APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS
|
Andreykiv, M
|
|
2009
|
12 |
7 |
p. A415-A416
nvt p.
|
artikel
|
| 514 |
PDB68 A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
|
Pawaskar, MD
|
|
2009
|
12 |
7 |
p. A414-
1 p.
|
artikel
|
| 515 |
PDB64 A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN
|
Kalsekar, A
|
|
2009
|
12 |
7 |
p. A413-
1 p.
|
artikel
|
| 516 |
PDB54 ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS
|
Stephens, JM
|
|
2009
|
12 |
7 |
p. A411-
1 p.
|
artikel
|
| 517 |
PDB48 ASSESSING THE MINIMUM CLINICALLY IMPORTANT DIFFERENCE OF THE WORRY SCALE OF THE HYPOGLYCAEMIA FEAR SURVEY IN PATIENTS WITH TYPE 2 DIABETES
|
Stargardt, T
|
|
2009
|
12 |
7 |
p. A410-
1 p.
|
artikel
|
| 518 |
PDB45 ASSESSING UTILITIES AND DISUTILITIES FOR TYPE 2 DIABETES TREATMENT-RELATED ATTRIBUTES IN AN ASIAN POPULATION
|
Bruhn, D
|
|
2009
|
12 |
7 |
p. A410-
1 p.
|
artikel
|
| 519 |
PDB77 BASELINE CHARACTERISTICS OF PATIENTS BEGINNING BASAL, BASAL PLUS SHORT-ACTING, SHORT-ACTING OR PREMIX INSULIN: DATA FROM THE CREDIT STUDY
|
Home, P
|
|
2009
|
12 |
7 |
p. A416-
1 p.
|
artikel
|
| 520 |
PDB53 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM): EFFECTS ON WORK PRODUCTIVITY
|
Purayidathil, FW
|
|
2009
|
12 |
7 |
p. A411-
1 p.
|
artikel
|
| 521 |
PDB11 COMPARATIVE STUDY OF ANNUAL TREATMENT COST OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN MEXICO
|
Reyes-Lopez, A
|
|
2009
|
12 |
7 |
p. A507-
1 p.
|
artikel
|
| 522 |
PDB57 COMPARING THE IMPACT OF DEPRESSION, DIABETES, AND ANXIETY ON PATIENT PRODUCTIVITY AND QUALITY OF LIFE: RESULTS FROM A NATIONALLY REPRESENTATIVE PANEL DATA
|
Bansal, M
|
|
2009
|
12 |
7 |
p. A412-
1 p.
|
artikel
|
| 523 |
PDB24 COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
|
Suchankova, E
|
|
2009
|
12 |
7 |
p. A405-A406
nvt p.
|
artikel
|
| 524 |
PDB31 COST-EFFECTIVENESS ANALYSIS OF VOGLIBOSE FOR PREVENTION OF TYPE-2 DIABETES MELLITUS IN JAPANESE INDIVIDUALS WITH IMPAIRED GLUCOSE TOLERANCE
|
Ikeda, S
|
|
2009
|
12 |
7 |
p. A407-
1 p.
|
artikel
|
| 525 |
PDB27 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
|
Bruhn, D
|
|
2009
|
12 |
7 |
p. A406-
1 p.
|
artikel
|
| 526 |
PDB32 COST-EFFECTIVENESS OF NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE (CHD), DIABETES MELLITUS TYPE 2 (DMT2) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY
|
Aidelsburger, P
|
|
2009
|
12 |
7 |
p. A407-
1 p.
|
artikel
|
| 527 |
PDB37 COST-MINIMIZATION ANALYSIS COMPARING BASAL ANALOGUE INSULINS IN HUNGARY
|
Kosa, J
|
|
2009
|
12 |
7 |
p. A408-
1 p.
|
artikel
|
| 528 |
PDB10 COST-MINIMIZATION ANALYSIS COMPARING INSULIN GLARGINE TO INSULIN DETEMIR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS IN BRAZIL
|
Bahia, L
|
|
2009
|
12 |
7 |
p. A506-
1 p.
|
artikel
|
| 529 |
PDB15 COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN
|
Marinel.lo, J
|
|
2009
|
12 |
7 |
p. A404-
1 p.
|
artikel
|
| 530 |
PDB18 COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
|
Pawaskar, MD
|
|
2009
|
12 |
7 |
p. A404-
1 p.
|
artikel
|
| 531 |
PDB4 COST OF TYPE 2 DIABETES COMPLICATIONS IN MEXICO
|
Meléndez, G
|
|
2009
|
12 |
7 |
p. A505-
1 p.
|
artikel
|
| 532 |
PDB36 COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL-BOLUS TREATMENT CONCEPT IN GERMANY
|
Neilson, A
|
|
2009
|
12 |
7 |
p. A408-
1 p.
|
artikel
|
| 533 |
PDB38 COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY
|
Neilson, A
|
|
2009
|
12 |
7 |
p. A408-
1 p.
|
artikel
|
| 534 |
PDB2 COSTS OF DISEASE COMPLICATIONS RELATED TO DM2 IN MEXICO: A SYSTEMATIC REVIEW
|
Uc-Coyoc, R
|
|
2009
|
12 |
7 |
p. A505-
1 p.
|
artikel
|
| 535 |
PDB1 COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA: A PROBABILISTIC MODEL
|
Pichon-Riviere, A
|
|
2009
|
12 |
7 |
p. A505-
1 p.
|
artikel
|
| 536 |
PDB40 COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND
|
Szmurlo, D
|
|
2009
|
12 |
7 |
p. A409-
1 p.
|
artikel
|
| 537 |
PDB41 COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE
|
Dziewiatka, M
|
|
2009
|
12 |
7 |
p. A409-
1 p.
|
artikel
|
| 538 |
PDB30 CSII COMPARED TO MDI: A HEALTH ECONOMIC ANALYSIS IN THE GERMAN HEALTH CARE SETTING
|
Neeser, K
|
|
2009
|
12 |
7 |
p. A407-
1 p.
|
artikel
|
| 539 |
PDB11 DATABASE ANALYSIS ON PREVALENCE AND RISK FACTORS OF DIABETIC FOOT SYNDROME (DFS) IN GERMANY
|
Lauterbach, S
|
|
2009
|
12 |
7 |
p. A403-
1 p.
|
artikel
|
| 540 |
PDB61 DIABETES REGIMEN UTILIZATION IN A LARGE MANAGED CARE SETTING; A COMPARISON WITH ADA/EASD CONSENSUS STATEMENT GUIDELINES
|
Palmer, L
|
|
2009
|
12 |
7 |
p. A413-
1 p.
|
artikel
|
| 541 |
PDB78 DIFFERENCES IN THE CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES STARTING INSULIN IN THE NORTH, SOUTH AND EAST OF EUROPE: DATA FROM THE CREDIT STUDY
|
Marre, M
|
|
2009
|
12 |
7 |
p. A416-
1 p.
|
artikel
|
| 542 |
PDB10 DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS
|
Reichelt, A
|
|
2009
|
12 |
7 |
p. A403-
1 p.
|
artikel
|
| 543 |
PDB79 DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COMPARED WITH THE OVERALL POPULATION IN THE CREDIT STUDY?
|
Vespasiani, G
|
|
2009
|
12 |
7 |
p. A416-
1 p.
|
artikel
|
| 544 |
PDB39 ECONOMIC ANALYSIS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE I DIABETES MELLITUS IN MEXICO
|
Reyes-Lopez, A
|
|
2009
|
12 |
7 |
p. A408-A409
nvt p.
|
artikel
|
| 545 |
PDB9 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO: MONOTHERAPY VS SEQUENTIAL THERAPY
|
Salinas Escudero, G
|
|
2009
|
12 |
7 |
p. A506-
1 p.
|
artikel
|
| 546 |
PDB62 ECONOMIC IMPACT OF COMPLIANCE AND PERSISTENCE TO TREATMENT WITH ANTIDIABETES MEDICATION IN T2DM—A SYSTEMATIC REVIEW
|
Breitscheidel, L
|
|
2009
|
12 |
7 |
p. A413-
1 p.
|
artikel
|
| 547 |
PDB13 ENCUESTA SOBRE LAS PRACTICAS DE UTILIZACION Y TITULACION DE INSULINA EN LATINOAMERICA
|
Aschner, P
|
|
2009
|
12 |
7 |
p. A507-
1 p.
|
artikel
|
| 548 |
PDB5 ESTIMACIÓN DEL COSTO ASOCIADO A LA PÉRDIDA DE PRODUCTIVIDAD POR MORTALIDAD ATRIBUIBLE A LA DIABETES EN ARGENTINA
|
Elgart, J
|
|
2009
|
12 |
7 |
p. A505-
1 p.
|
artikel
|
| 549 |
PDB76 ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS
|
Kaas, C
|
|
2009
|
12 |
7 |
p. A416-
1 p.
|
artikel
|
| 550 |
PDB74 ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES—A REVIEW OF THE LITERATURE
|
Jensen, RCØ
|
|
2009
|
12 |
7 |
p. A415-
1 p.
|
artikel
|
| 551 |
PDB6 EVALUACIÓN DE LOS COSTOS ASOCIADOS A LA ELECCIÓN DE LA INSULINA: EL DILEMA DE LOS PAGADORES
|
Bustamante, H
|
|
2009
|
12 |
7 |
p. A506-
1 p.
|
artikel
|
| 552 |
PDB60 EVALUATION OF THE PATIENT'S PERSPECTIVE OF MEDICAL CARE IN TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS
|
Stark, R
|
|
2009
|
12 |
7 |
p. A412-A413
nvt p.
|
artikel
|
| 553 |
PDB44 EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS
|
Pinto, SL
|
|
2009
|
12 |
7 |
p. A409-A410
nvt p.
|
artikel
|
| 554 |
PDB3 FORECASTING THE NUMBER OF DIABETIC PATIENS IN THE UNITED STATES IN 2050
|
Baser, O
|
|
2009
|
12 |
7 |
p. A401-
1 p.
|
artikel
|
| 555 |
PDB71 GLYCAEMIC AND CHOLESTEROL CONTROL OF TYPE 2 DIABETIC PATIENTS ATTENDING SPECIALIST OUTPATIENT CLINICS IN SINGAPORE
|
Lim, BK
|
|
2009
|
12 |
7 |
p. A415-
1 p.
|
artikel
|
| 556 |
PDB12 GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS
|
Wieczorek, A
|
|
2009
|
12 |
7 |
p. A403-
1 p.
|
artikel
|
| 557 |
PDB16 GLYCEMIC CONTROL IN THE INPATIENT SETTING: INSULIN ASPART COMPARED TO HUMAN BOLUS INSULIN
|
Ko, K
|
|
2009
|
12 |
7 |
p. A404-
1 p.
|
artikel
|
| 558 |
PDB67 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2009
|
12 |
7 |
p. A414-
1 p.
|
artikel
|
| 559 |
PDB47 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES OVER THE 24 MONTHS FOLLOWING INITIATION OF INSULIN
|
Meadows, K
|
|
2009
|
12 |
7 |
p. A410-
1 p.
|
artikel
|
| 560 |
PDB7 HOSPITALIZACIONES POR INSUFICIENCIA CARDÍACA EN PERSONAS CON DIABETES: LOS COSTOS DE SU PREVENCIÓN VS. LOS DE SU TRATAMIENTO
|
Caporale, JE
|
|
2009
|
12 |
7 |
p. A506-
1 p.
|
artikel
|
| 561 |
PDB9 IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE
|
Huse, D
|
|
2009
|
12 |
7 |
p. A402-A403
nvt p.
|
artikel
|
| 562 |
PDB42 INSULIN ADMINISTRATION WITH FLEXPEN® IS ASSOCIATED WITH INCREASED ADHERENCE AND NO ADDED COSTS TO PAYERS IN A US MANAGED CARE SETTING
|
Henk, HJ
|
|
2009
|
12 |
7 |
p. A409-
1 p.
|
artikel
|
| 563 |
PDB55 LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, FOR INTERNATIONAL USE
|
Celerier, S
|
|
2009
|
12 |
7 |
p. A411-A412
nvt p.
|
artikel
|
| 564 |
PDB4 LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS
|
Ligthelm, R
|
|
2009
|
12 |
7 |
p. A402-
1 p.
|
artikel
|
| 565 |
PDB34 LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN
|
Kotowa, W
|
|
2009
|
12 |
7 |
p. A407-A408
nvt p.
|
artikel
|
| 566 |
PDB35 LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE-2 DIABETES PATIENTS ON BASAL-BOLUS THERAPY UNDER REAL WORLD CONDITIONS IN GERMANY
|
Bierwirth, R
|
|
2009
|
12 |
7 |
p. A408-
1 p.
|
artikel
|
| 567 |
PDB80 MEASURING GLYCOSYLATED HAEMOGLOBIN LEVELS IN PATIENTS WITH DIABETES: IMPACT OF LOWER QOF TARGETS ON ACHIEVEMENT OF CLINICAL INDICATORS AND QOF POINTS
|
Kingslake, SL
|
|
2009
|
12 |
7 |
p. A416-A417
nvt p.
|
artikel
|
| 568 |
PDB43 MEDICATION ADHERENCE IN LOW INCOME ELDERLY TYPE 2 DIABETES PATIENTS: A RETROSPECTIVE COHORT STUDY
|
Patel, I
|
|
2009
|
12 |
7 |
p. A409-
1 p.
|
artikel
|
| 569 |
PDB13 MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY
|
Wu, CS
|
|
2009
|
12 |
7 |
p. A403-
1 p.
|
artikel
|
| 570 |
PDB70 ORAL MEDICATIONS VS INSULIN FOR DIABETES: EPIDEMIOLOGICAL & HEALTH POLICY IMPLICATIONS IN GREECE
|
Hatzikou, M
|
|
2009
|
12 |
7 |
p. A414-A415
nvt p.
|
artikel
|
| 571 |
PDB52 PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-COM STUDY
|
Moock, J
|
|
2009
|
12 |
7 |
p. A411-
1 p.
|
artikel
|
| 572 |
PDB66 PAYING FOR COSTLY PHARMACEUTICALS—REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES
|
Orlewska, E
|
|
2009
|
12 |
7 |
p. A414-
1 p.
|
artikel
|
| 573 |
PDB29 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE
|
Citarella, A
|
|
2009
|
12 |
7 |
p. A406-A407
nvt p.
|
artikel
|
| 574 |
PDB23 PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL
|
Benoit, K
|
|
2009
|
12 |
7 |
p. A405-
1 p.
|
artikel
|
| 575 |
PDB72 QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA
|
Jo, MW
|
|
2009
|
12 |
7 |
p. A415-
1 p.
|
artikel
|
| 576 |
PDB65 REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN TYPE 2 DIABETES IN THE NETHERLANDS
|
Thomsen, TL
|
|
2009
|
12 |
7 |
p. A413-A414
nvt p.
|
artikel
|
| 577 |
PDB2 REAL WORLD CLINICAL EFFECTIVENESS OF SITAGLIPTIN THERAPY FOR MANAGEMENT OF TYPE 2 DIABETES: A RETROSPECTIVE DATABASE ANALYSIS
|
Wade, R
|
|
2009
|
12 |
7 |
p. A401-
1 p.
|
artikel
|
| 578 |
PDB3 RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO ACROMEGALY TREATMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
7 |
p. A505-
1 p.
|
artikel
|
| 579 |
PDB8 SELF-MONITORING OF BLOOD GLUCOSE FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETIC MEDICATION: COSTEFFECTIVENESS IN MEXICO
|
Tunis, S
|
|
2009
|
12 |
7 |
p. A506-
1 p.
|
artikel
|
| 580 |
PDB22 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETES DRUGS (OADS): COST-EFFECTIVENESS IN FRANCE, GERMANY, AND SPAIN
|
Tunis, S
|
|
2009
|
12 |
7 |
p. A405-
1 p.
|
artikel
|
| 581 |
PDB69 SIGNIFICANT REDUCTIONS IN POLYPHARMACY AND HEALTH CARE UTILIZATION WITH INSULIN PUMP THERAPY (CSII) IN PATIENTS WITH TYPE 2 DIABETES
|
Lynch, P
|
|
2009
|
12 |
7 |
p. A414-
1 p.
|
artikel
|
| 582 |
PDB5 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A402-
1 p.
|
artikel
|
| 583 |
PDB14 THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A403-A404
nvt p.
|
artikel
|
| 584 |
PDB7 THE CLINICAL EFFECTIVENESS OF SOMATROPIN (GENOTROPIN®) IN CHILDREN WITH SHORT STATURE: A SYSTEMATIC REVIEW
|
Heatley, RM
|
|
2009
|
12 |
7 |
p. A402-
1 p.
|
artikel
|
| 585 |
PDB28 THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A406-
1 p.
|
artikel
|
| 586 |
PDB50 THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN WORKING ADULTS
|
Brod, M
|
|
2009
|
12 |
7 |
p. A411-
1 p.
|
artikel
|
| 587 |
PDB56 THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS)
|
Swinnen, SG
|
|
2009
|
12 |
7 |
p. A412-
1 p.
|
artikel
|
| 588 |
PDB26 THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION
|
Kolbin, AS
|
|
2009
|
12 |
7 |
p. A406-
1 p.
|
artikel
|
| 589 |
PDB81 THE ROAD TO INSULIN—A PATH OF TREATMENT ANALYSIS OF REAL-WORLD PHARMACY DATA FROM THE USA
|
Christensen, TE
|
|
2009
|
12 |
7 |
p. A417-
1 p.
|
artikel
|
| 590 |
PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
|
Jain, R
|
|
2009
|
12 |
7 |
p. A413-
1 p.
|
artikel
|
| 591 |
PDB58 THE “WHO, HOW AND THEN WHAT…” OF INSULIN INITIATION IN UK PRIMARY CARE
|
Smith, HT
|
|
2009
|
12 |
7 |
p. A412-
1 p.
|
artikel
|
| 592 |
PDB19 TIME TO OPIOID USE AND HEALTH CARE COSTS AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS
|
Zhao, Y
|
|
2009
|
12 |
7 |
p. A404-A405
nvt p.
|
artikel
|
| 593 |
PDB17 TREATMENT COSTS ATTRIBUTABLE TO BEING OVERWEIGHT OR OBESE IN U.S. DIABETIC PATIENTS: QUANTILE REGRESSION APPROACH
|
Suh, DC
|
|
2009
|
12 |
7 |
p. A404-
1 p.
|
artikel
|
| 594 |
PDB49 UNDERSTANDING AND ASSESSING THE IMPACT OF GROWTH HORMONE DEFICIENCY IN ADULTS
|
Brod, M
|
|
2009
|
12 |
7 |
p. A410-
1 p.
|
artikel
|
| 595 |
PDB51 USING FACTOR ANALYSIS TO CONFIRM THE VALIDITY OF DIABETES HEALTH PROFILE-I, DIABETES AND LIFE STYLE FOR TURKISH DIABETIC PATIENTS
|
Malhan, S
|
|
2009
|
12 |
7 |
p. A411-
1 p.
|
artikel
|
| 596 |
PDB59 USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM PROGRAM ON OUTCOMES
|
Pinto, SL
|
|
2009
|
12 |
7 |
p. A412-
1 p.
|
artikel
|
| 597 |
PDB46 UTILITIES FOR INFUSION THERAPY IN TYPE I DIABETES
|
Lloyd, A
|
|
2009
|
12 |
7 |
p. A410-
1 p.
|
artikel
|
| 598 |
PDB14 UTILIZACIÓN DE RECURSOS Y GASTOS EN SALUD DE PERSONAS CON DIABETES EN ARGENTINA. UN ANÁLISIS DESCRIPTIVO DE LA ENCUESTA NACIONAL DE UTILIZACIÓN Y GASTOS EN SERVICIOS DE SALUD
|
Gonzalez, L
|
|
2009
|
12 |
7 |
p. A507-
1 p.
|
artikel
|
| 599 |
PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS
|
Goeree, RA
|
|
2009
|
12 |
7 |
p. A405-
1 p.
|
artikel
|
| 600 |
PG11 A RECORD-LINKAGE STUDY OF ADVERSE UPPER GASTRO-INTESTINAL EVENTS WITH NSAIDS IN A UK POPULATION UTILISING DIFFERENT EPIDEMIOLOGICAL DESIGNS TO MINIMISE CONFOUNDING
|
Donnan, PT
|
|
2009
|
12 |
7 |
p. A345-A346
nvt p.
|
artikel
|
| 601 |
PG122 CIRCULAR STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE: HTA REPORT—LOMBARDIA REGION, ITALY
|
Berto, P
|
|
2009
|
12 |
7 |
p. A349-
1 p.
|
artikel
|
| 602 |
PG117 CONSUMPTION OF HEALTH CARE RESOURCES ASSOCIATED WITH CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: AN OBSERVATIONAL EUROPEAN STUDY
|
Lanas, A
|
|
2009
|
12 |
7 |
p. A348-
1 p.
|
artikel
|
| 603 |
PG18 COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY
|
Borrill, J
|
|
2009
|
12 |
7 |
p. A347-
1 p.
|
artikel
|
| 604 |
PG19 COST-EFFECTIVENESS OF INTRAVENOUS IRON IN INFLAMMATORY BOWEL DISEASE PATIENTS INTOLERANT TO ORAL IRON
|
Borg, S
|
|
2009
|
12 |
7 |
p. A347-
1 p.
|
artikel
|
| 605 |
PG110 ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT: PRELIMINARY RESULTS
|
Martín-Escudero, V
|
|
2009
|
12 |
7 |
p. A347-
1 p.
|
artikel
|
| 606 |
PG118 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON GENERIC HEALTH RELATED QUALITY OF LIFE USING THE EQ-5D INDEX SCORES IN PATIENTS WITH CHRONIC NON-MALIGNANT PAIN AND OPIOID-INDUCED CONSTIPATION
|
Iyer, S
|
|
2009
|
12 |
7 |
p. A348-A349
nvt p.
|
artikel
|
| 607 |
PG120 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE—BLIND CLINICAL TRIAL
|
Iyer, S
|
|
2009
|
12 |
7 |
p. A349-
1 p.
|
artikel
|
| 608 |
PG16 EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
|
Bastide, P
|
|
2009
|
12 |
7 |
p. A346-A347
nvt p.
|
artikel
|
| 609 |
PGI1 A STRONG NONLINEAR RELATIONSHIP BETWEEN ADHERENCE WITH DRUG THERAPY AND CONTINUOUS RISK FACTORS IN PPI USERS
|
Pedan, A
|
|
2009
|
12 |
7 |
p. A507-
1 p.
|
artikel
|
| 610 |
PGI2 CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLÍNICAS—UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE (HC-FMUSP)
|
Nabeshima, MA
|
|
2009
|
12 |
7 |
p. A508-
1 p.
|
artikel
|
| 611 |
PGI3 COST-EFFECTIVENESS OF PEG-IFN ALPHA 2A OR 2B PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C IN MEXICO
|
Salinas Escudero, G
|
|
2009
|
12 |
7 |
p. A508-
1 p.
|
artikel
|
| 612 |
PGI4 ESTUDO FARMAECONÔMICO DA INTERVENÇÃO FARMACÊUTICA NA UTILIZAÇÃO DO OMEPRAZOL EM UTI
|
Silva, EA
|
|
2009
|
12 |
7 |
p. A508-
1 p.
|
artikel
|
| 613 |
PG13 INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE TREATMENT OF PEPTIC ULCER BLEEDING (PUB)
|
Edwards, SJ
|
|
2009
|
12 |
7 |
p. A346-
1 p.
|
artikel
|
| 614 |
PGI5 WHAT ARE THE COSTS FOR NON-COMPLIANCE WITH GUIDELINES FOR TREATMENT OF CHRONIC HEPATITIS C?
|
Lukac, M
|
|
2009
|
12 |
7 |
p. A508-
1 p.
|
artikel
|
| 615 |
PG17 MANAGEMENT OF OPIOID INDUCED CONSTIPATION (OIC) IN PAIN PATIENTS: A COST OF ILLNESS STUDY IN BELGIUM AND THE NETHERLANDS
|
Caekelbergh, K
|
|
2009
|
12 |
7 |
p. A347-
1 p.
|
artikel
|
| 616 |
PG119 PATIENT RELEVANT ASPECTS OF DIAGNOSTIC QUESTIONNAIRES AND THEIR SUBSCALES IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD)
|
Burkowitz, J
|
|
2009
|
12 |
7 |
p. A349-
1 p.
|
artikel
|
| 617 |
PG15 PREDICTORS FOR RESPONSE TO PRUCALOPRIDE IN PATIENTS WITH CHRONIC CONSTIPATION
|
Dubois, D
|
|
2009
|
12 |
7 |
p. A346-
1 p.
|
artikel
|
| 618 |
PG116 RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OPIOIDINDUCED CONSTIPATION (OIC) IN CANCER PATIENTS IN SWEDEN
|
Ovanfors, A
|
|
2009
|
12 |
7 |
p. A348-
1 p.
|
artikel
|
| 619 |
PG112 RESOURCE UTILIZATION AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C (CHC) IN THAILAND: A HEAVY BUT MANAGEABLE ECONOMIC BURDEN
|
Thongsawat, S
|
|
2009
|
12 |
7 |
p. A348-
1 p.
|
artikel
|
| 620 |
PG123 STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE—COMPARISON OF HTA REPORTS, FOR TWO ITALIAN REGIONS
|
Berto, P
|
|
2009
|
12 |
7 |
p. A350-
1 p.
|
artikel
|
| 621 |
PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE
|
Assasi, N
|
|
2009
|
12 |
7 |
p. A346-
1 p.
|
artikel
|
| 622 |
PG111 THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND
|
Shore, E
|
|
2009
|
12 |
7 |
p. A347-A348
nvt p.
|
artikel
|
| 623 |
PG121 TREATMENT OF CHRONIC HEPATITIS C WHICH DO NOT FOLLOW CLINICAL GUIDELINES IS INCREASING DIRECT MEDICAL COSTS
|
Lukac, M
|
|
2009
|
12 |
7 |
p. A349-
1 p.
|
artikel
|
| 624 |
PG115 TREATMENT OF MODERATE TO SEVERE PAIN WITH OXYCODONE/ NALOXONE TO REDUCE OPIOID-INDUCED CONSTIPATION: A COST-UTILITY ANALYSIS IN BELGIUM AND THE NETHERLANDS
|
Gerlier, L
|
|
2009
|
12 |
7 |
p. A348-
1 p.
|
artikel
|
| 625 |
PG12 WORK PRODUCTIVITY IN PRIMARY CARE PATIENTS CONSULTING WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS: ESTIMATES FROM THE DANISH RESPONSE STUDY
|
Malmberg, I
|
|
2009
|
12 |
7 |
p. A346-
1 p.
|
artikel
|
| 626 |
PHC1 COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS: OF INGUINAL HERNIA REPAIR IN BRAZIL
|
Plisko, R
|
|
2009
|
12 |
7 |
p. A508-
1 p.
|
artikel
|
| 627 |
PHC2 COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS: OF INGUINAL HERNIA REPAIR IN MEXICO
|
Plisko, R
|
|
2009
|
12 |
7 |
p. A509-
1 p.
|
artikel
|
| 628 |
PHP71 A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)
|
Kolasa, K
|
|
2009
|
12 |
7 |
p. A250-
1 p.
|
artikel
|
| 629 |
PHP6 ACUT CARE HOSPITAL BED OCCUPANCY RATE IN HUNGARY BETWEEN 2000 AND 2008
|
Gresz, M
|
|
2009
|
12 |
7 |
p. A238-
1 p.
|
artikel
|
| 630 |
PHP86 ADHERENCE OF PHARMACOECONOMIC STUDIES SUBMITTED FOR THE REIMBURSEMENT AND PRICING SYSTEM IN 2008 TO THE CZECH PHARMACOECONOMIC GUIDELINES
|
Petrikova, A
|
|
2009
|
12 |
7 |
p. A253-
1 p.
|
artikel
|
| 631 |
PHP6 AGRAVOS POR MEDICAMENTOS: FREQUÊNCIA E CUSTO DIRETO PARA O SISTEMA DE SAÚDE
|
Chrispim, PPM
|
|
2009
|
12 |
7 |
p. A510-
1 p.
|
artikel
|
| 632 |
PHP96 ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN®) IN TOTAL PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN PATIENTS: A PHARMACOECONOMIC SIMULATION MODEL
|
Eandi, M
|
|
2009
|
12 |
7 |
p. A255-
1 p.
|
artikel
|
| 633 |
PHP52 AN EVALUATION OF THE POLICY AND THE PROCEDURES OF SUCCESSFUL PHARMACEUTICAL EXPORTERS AND THE COMPARISON IRANIAN COUNTERPART POLICY
|
Seyedifar/Meysam, MS
|
|
2009
|
12 |
7 |
p. A246-A247
nvt p.
|
artikel
|
| 634 |
PHP48 A NEW TEST OF THE CARERQOL INSTRUMENT: MEASURING ‘CARE-RELATED QUALITY OF LIFE’ OF INFORMAL CAREGIVERS FOR USE IN ECONOMIC EVALUATIONS
|
Hoefman, RJ
|
|
2009
|
12 |
7 |
p. A246-
1 p.
|
artikel
|
| 635 |
PHP9 ANÁLISE DOS GASTOS E DA DISTRIBUIÇÃO DE MEDICAMENTOS NA ATENÇÃO BÁSICA DE SAÚDE DO MUNICÍPIO DE FORTALEZA, CEARÁ, BRASIL
|
Pereira, MB
|
|
2009
|
12 |
7 |
p. A510-
1 p.
|
artikel
|
| 636 |
PHP24 ANTIPSYCHOTICS CONSUMPTION IN THE REPUBLIC OF CROATIA IN 2005, 2006 AND 2007
|
Draganic, P
|
|
2009
|
12 |
7 |
p. A241-
1 p.
|
artikel
|
| 637 |
PHP14 A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET
|
Simoens, S
|
|
2009
|
12 |
7 |
p. A240-
1 p.
|
artikel
|
| 638 |
PHP31 A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES
|
Clarke, J
|
|
2009
|
12 |
7 |
p. A243-
1 p.
|
artikel
|
| 639 |
PHP73 APPLYING KEY PRINCIPLES FOR IMPROVED HEALTH TECHNOLOGY ASSESSMENT: AN ANALYSIS OF 14 HTA ORGANIZATIONS
|
Neumann, PJ
|
|
2009
|
12 |
7 |
p. A250-
1 p.
|
artikel
|
| 640 |
PHP19 APPLYING “VALUE BASED” PRICING TO REGENERATIVE MEDICINE BASED PHARMACEUTICALS
|
Watch, J
|
|
2009
|
12 |
7 |
p. A240-A241
nvt p.
|
artikel
|
| 641 |
PHP53 APPROPRIATE CLASSIFICATION OF HOSPITAL INFUSION SERVICES: MEDICARE REIMBURSEMENT CONSIDERATIONS
|
Pierce, CA
|
|
2009
|
12 |
7 |
p. A247-
1 p.
|
artikel
|
| 642 |
PHP89 ARE INCREMENTAL BENEFITS FROM MEDICAL CARE DECREASING? AN ANALYSIS OF QALY GAINS OVER TIME
|
Greenberg, D
|
|
2009
|
12 |
7 |
p. A253-A254
nvt p.
|
artikel
|
| 643 |
PHP72 A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND
|
Tilson, L
|
|
2009
|
12 |
7 |
p. A250-
1 p.
|
artikel
|
| 644 |
PHP79 A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE
|
Lenderking, WR
|
|
2009
|
12 |
7 |
p. A251-
1 p.
|
artikel
|
| 645 |
PHP82 ASSESSMENT OF LIFESPAN AND HEALTH STATUS EXPECTATIONS IN HUNGARY; RESULTS OF A WEB-SURVEY
|
Péntek, M
|
|
2009
|
12 |
7 |
p. A252-
1 p.
|
artikel
|
| 646 |
PHP51 ASSESSMENT OF PRESCRIPTION DRUG KNOWLEDGE AND THE IMPACT OF COUNSELING ON IT IN PATIENTS VISITING A PUBLIC TEACHING HOSPITAL IN NORTH INDIA
|
Kachhadiya, R
|
|
2009
|
12 |
7 |
p. A246-
1 p.
|
artikel
|
| 647 |
PHP94 ASSESSMENT OF SHORT AND LONG TERM INGUINAL HERNIA RECURRENCE CASES AFTER HEAVY WEIGHT MESH DEVICE UTILIZATION UNDER PUBLIC HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL. WILL THE NEW TECHNOLOGIES IMPROVE THE SURGICAL OUTCOMES?
|
Baran, R
|
|
2009
|
12 |
7 |
p. A254-
1 p.
|
artikel
|
| 648 |
PHP27 ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES (INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA
|
Kim, JY
|
|
2009
|
12 |
7 |
p. A242-
1 p.
|
artikel
|
| 649 |
PHP99 A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS OF ACUPUNCTURE
|
Kim, SY
|
|
2009
|
12 |
7 |
p. A255-
1 p.
|
artikel
|
| 650 |
PHP22 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION AND PHARMACOECONOMICS STUDIES IN KOREA
|
Oh, EH
|
|
2009
|
12 |
7 |
p. A512-
1 p.
|
artikel
|
| 651 |
PHP13 ATENÇÃO FARMACÊUTICA E FARMACOECONOMIA: UMA REVISÃO DE LITERATURA
|
Martins, BPR
|
|
2009
|
12 |
7 |
p. A510-A511
nvt p.
|
artikel
|
| 652 |
PHP27 AVALIAÇÃO DA EFETIVIDADE DA REDE MUNICIPAL PÚBLICA DE APOIO DIAGNÓSTICO EM PATOLOGIA CLÍNICA: O CASO DE BELO HORIZONTE (MG)
|
Sancho, LG
|
|
2009
|
12 |
7 |
p. A511-A512
nvt p.
|
artikel
|
| 653 |
PHP7 BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS
|
Varga, S
|
|
2009
|
12 |
7 |
p. A238-
1 p.
|
artikel
|
| 654 |
PHP15 BIOSIMILARS: HGH TO TNFS, HOW WILL PAYERS RESPOND?
|
Long, M
|
|
2009
|
12 |
7 |
p. A240-
1 p.
|
artikel
|
| 655 |
PHP13 CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY
|
Nagy, Z
|
|
2009
|
12 |
7 |
p. A239-A240
nvt p.
|
artikel
|
| 656 |
PHP17 CAN ELECTRONIC NOTIFICATIONS ABOUT SUBSTITUTES CHANGE PHYSICIANS' DRUG PRESCRIPTION HABITS? DEFINITELY YES!
|
Zuker, A
|
|
2009
|
12 |
7 |
p. A240-
1 p.
|
artikel
|
| 657 |
PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW
|
Gaebel, K
|
|
2009
|
12 |
7 |
p. A252-
1 p.
|
artikel
|
| 658 |
PHP18 COMPARATIVE ANALYSIS OF THE IMPACT OF POSITIVE DRUG LIST SYSTEM BETWEEN NEW DRUGS VS INCREMENTALLY MODIFIED DRUGS IN SOUTH KOREA
|
Ha, DM
|
|
2009
|
12 |
7 |
p. A240-
1 p.
|
artikel
|
| 659 |
PHP35 COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION
|
Gavrankapetanovic, I
|
|
2009
|
12 |
7 |
p. A243-A244
nvt p.
|
artikel
|
| 660 |
PHP92 COMPARISON OF THE TIME TO PREPARE CONTRAST MEDIA INJECTION IN CT SCAN EXAM WITH PREFILLED SYRINGES AND BOTTLES IN 7 EUROPEAN COUNTRIES
|
Lafuma, A
|
|
2009
|
12 |
7 |
p. A254-
1 p.
|
artikel
|
| 661 |
PHP63 CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH TECHNOLOGIES IN SPAIN
|
Paz, S
|
|
2009
|
12 |
7 |
p. A248-
1 p.
|
artikel
|
| 662 |
PHP87 COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS
|
De Smedt, D
|
|
2009
|
12 |
7 |
p. A253-
1 p.
|
artikel
|
| 663 |
PHP66 COST-EFFECTIVENESS RESEARCH ON PREVENTIVE MEASURES: A SURVEY OF THE PUBLICATIONS IN 2008
|
van Gils, P
|
|
2009
|
12 |
7 |
p. A249-
1 p.
|
artikel
|
| 664 |
PHP20 COST-EFFECTIVE PHARMACEUTICAL CARE IN THE NETHERLANDS? A REVIEW OF THE PHARMACOECONOMICS AND ITS ROLE IN THE ASSESSMENT AND REIMBURSEMENT OF NEW DRUGS
|
Hoomans, T
|
|
2009
|
12 |
7 |
p. A241-
1 p.
|
artikel
|
| 665 |
PHP39 COST MEASURE IN PRIMARY CARE: RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL
|
Sicras-Mainar, A
|
|
2009
|
12 |
7 |
p. A244-
1 p.
|
artikel
|
| 666 |
PHP98 COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS
|
Stokes, ME
|
|
2009
|
12 |
7 |
p. A255-
1 p.
|
artikel
|
| 667 |
PHP17 DECENTRALIZATION AND ORGANIZATIONAL REFORM IN IRANIAN PUBLIC HOSPITALS AFFILIATED WITH MINISTRY OF HEALTH
|
Jafarisirizi, M
|
|
2009
|
12 |
7 |
p. A511-
1 p.
|
artikel
|
| 668 |
PHP76 DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS INDICATOR (FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN THE RESULTS (FINANCING BIAS (FB)) OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES (EEHT)
|
Canon, O
|
|
2009
|
12 |
7 |
p. A251-
1 p.
|
artikel
|
| 669 |
PHP2 DISTORÇÕES CAUSADAS PELAS AÇÕES JUDICIAIS À SAÚDE PÚBLICA NO MUNICÍPIO DE GOIÂNIA
|
Provin, MP
|
|
2009
|
12 |
7 |
p. A509-
1 p.
|
artikel
|
| 670 |
PHP11 DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS?
|
Grandfils, N
|
|
2009
|
12 |
7 |
p. A239-
1 p.
|
artikel
|
| 671 |
PHP69 DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF DRUGS AND MEDICAL SERVICES IN AUSTRALIA
|
Gallego, G
|
|
2009
|
12 |
7 |
p. A249-A250
nvt p.
|
artikel
|
| 672 |
PHP47 EARLY ASSESSMENT OF HIGHLY INNOVATIVE MEDICAL TECHNOLOGY: CLINICAL AND ECONOMICAL GAINS OF POINT-OF-CARE APPLICATIONS FOR MEASURING POTASSIUM CONCENTRATIONS
|
Wetering, G
|
|
2009
|
12 |
7 |
p. A246-
1 p.
|
artikel
|
| 673 |
PHP3 EFFECTS OF THE IMPLEMENTATION OF AN ANNUAL CO-PAYMENT LIMIT FOR PRESCRIPTION DRUGS IN AUSTRIA
|
Ortner, T
|
|
2009
|
12 |
7 |
p. A237-A238
nvt p.
|
artikel
|
| 674 |
PHP74 ELECTROMAGNETIC INTERFERENCES BETWEEN WIRELESS COMMUNICATION TECHNOLOGY AND CRITICAL CARE MEDICAL EQUIPMENT: A HEALTH TECHNOLOGY ASSESSMENT
|
Bouza, C
|
|
2009
|
12 |
7 |
p. A250-A251
nvt p.
|
artikel
|
| 675 |
PHP83 EVALUATING PHARMACEUTICAL MARKETING TOOLS IMPLEMENTED BY THE COMPANIES, OBSERVED AND EXPERIENCED BY PHYSICIANS IN PAKISTAN
|
Masood, I
|
|
2009
|
12 |
7 |
p. A252-
1 p.
|
artikel
|
| 676 |
PHP15 EVALUATION OF SEVERITY SCORING INDICES IN ACUTE ORGANOPHOSPHORUS POISONED PATIENTS IN A TERTIARY CARE HOSPITAL
|
Thunga, G
|
|
2009
|
12 |
7 |
p. A511-
1 p.
|
artikel
|
| 677 |
PHP24 EXPERIÊNCIA BRASILEIRA NO TREINAMENTO DE GESTORES E TÉCNICOS NA ELABORAÇÃO DE MINI-ATS: FERRAMENTA CONTRA A JUDICIALIZAÇÃO EM SAÚDE
|
Laranjeira, FO
|
|
2009
|
12 |
7 |
p. A512-
1 p.
|
artikel
|
| 678 |
PHP68 FIRST IMPRESSIONS FROM A SHORT TRAINING COURSE IN RATIONAL USE OF DRUGS FOR THE PHARMACOLOGISTS IN THE PHARMACY SCHOOLS IN TURKEY
|
Toklu, HZ
|
|
2009
|
12 |
7 |
p. A249-
1 p.
|
artikel
|
| 679 |
PHP62 FREE BUT VALUABLE: THE ECONOMIC SIGNIFICANCE OF SERVICES PROVIDED BY PORTUGUESE PHARMACIES
|
Gouveia, M
|
|
2009
|
12 |
7 |
p. A248-
1 p.
|
artikel
|
| 680 |
PHP8 GASTOS COM MEDICAMENTOS E CARATERÍSTICAS DOS SERVIÇOS FARMACÊUTICOS NA ATENÇÃO PRIMÁRIA DE SAÚDE DE FORTALEZA EM 2007
|
Chaves, E
|
|
2009
|
12 |
7 |
p. A510-
1 p.
|
artikel
|
| 681 |
PHP23 GENERAL PRACTITIONERS' PRESCRIPTIONS INDICATORS TRENDS, A TIME-SERIES REVIEW DURING 1998–2003 IN IRAN
|
Soleymani, F
|
|
2009
|
12 |
7 |
p. A241-
1 p.
|
artikel
|
| 682 |
PHP10 GERENCIAMENTO DE DOENÇAS CRÔNICAS: UM NOVO PARADIGMA PARA OS PLANOS DE SAÚDE?
|
de Oliveira, KRD
|
|
2009
|
12 |
7 |
p. A510-
1 p.
|
artikel
|
| 683 |
PHP57 GLOBAL PRICING AND REIMBURSEMENT (P & R) TRENDS: FURTHER DEVELOPMENTS IN SUPPLY AND DEMAND SIDE CONTROLS FOR MEDICINES
|
Mallinson, M
|
|
2009
|
12 |
7 |
p. A247-
1 p.
|
artikel
|
| 684 |
PHP36 HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS
|
Mullins, CD
|
|
2009
|
12 |
7 |
p. A244-
1 p.
|
artikel
|
| 685 |
PHP9 HELSPOR'S ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE: COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA
|
Kousoulakou, H
|
|
2009
|
12 |
7 |
p. A239-
1 p.
|
artikel
|
| 686 |
PHP38 HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY
|
Androutsou, L
|
|
2009
|
12 |
7 |
p. A244-
1 p.
|
artikel
|
| 687 |
PHP88 HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH NATIONAL FIGURES?
|
Blak, BT
|
|
2009
|
12 |
7 |
p. A253-
1 p.
|
artikel
|
| 688 |
PHP70 HTA INSITE: ANALYSIS OF AN ON-LINE DATABASE OF ALL NICE SUBMISSIONS AND DECISIONS
|
Niziol, C
|
|
2009
|
12 |
7 |
p. A250-
1 p.
|
artikel
|
| 689 |
PHP25 IMPACT OF REDUCED COPAYMENTS ON MEDICATION ADHERENCE: DX-RX PAIRINGTM PROGRAM OUTCOMES
|
Kim, YA
|
|
2009
|
12 |
7 |
p. A242-
1 p.
|
artikel
|
| 690 |
PHP91 IMPLANTABLE LOOP RECORDERS IN UNEXPLAINED TRANSIENT LOSS OF CONSCIOUSNESS (T-LOC) DIAGNOSTICS: A COST-SAVING OPPORTUNITY FOR THE UK NATIONAL HEALTH SERVICE (NHS)
|
Petkar, S
|
|
2009
|
12 |
7 |
p. A254-
1 p.
|
artikel
|
| 691 |
PHP26 IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF THE AFFORDABILITY OF MEDICINES
|
Niëns, LM
|
|
2009
|
12 |
7 |
p. A242-
1 p.
|
artikel
|
| 692 |
PHP43 INTERNATIONAL PAYER RESARCH: COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK
|
de Cambra, S
|
|
2009
|
12 |
7 |
p. A245-
1 p.
|
artikel
|
| 693 |
PHP5 JUDICIALIZAÇÃO DO ACESSO AO TRATAMENTO DE DOENÇAS RARAS: DOENÇA DE FABRY NO ESTADO DO RIO GRANDE DO SUL
|
Balbinotto, G
|
|
2009
|
12 |
7 |
p. A509-A510
nvt p.
|
artikel
|
| 694 |
PHP41 LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM: ASSESSING THE ADVERSE EFFECTS
|
Arickx, F
|
|
2009
|
12 |
7 |
p. A245-
1 p.
|
artikel
|
| 695 |
PHP95 MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES
|
Noe, L
|
|
2009
|
12 |
7 |
p. A255-
1 p.
|
artikel
|
| 696 |
PHP58 MEDICARE DRUG PAYMENT AND PHARMACY HANDLING COSTS: HOW FAR HAVE WE COME?
|
Pierce, CA
|
|
2009
|
12 |
7 |
p. A247-
1 p.
|
artikel
|
| 697 |
PHP4 MUDANÇAS INSTITUCIONAIS NO PERÍODO RECENTE E SEUS IMPACTOS NA INDUSTRIA FARMACÊUTICA BRASILEIRA: HA UM SISTEMA DE INOVAÇÃO A CAMINHO?
|
Urias, E
|
|
2009
|
12 |
7 |
p. A509-
1 p.
|
artikel
|
| 698 |
PHP77 NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE
|
Collar, JM
|
|
2009
|
12 |
7 |
p. A251-
1 p.
|
artikel
|
| 699 |
PHP49 PALLIATIVE CARE AND ITS REIMBURSEMENT FOR OUTPATIENT SERVICES IN GERMANY—A SURVEY AMONG OFFICE-BASED PHYSICIANS
|
Prenzler, A
|
|
2009
|
12 |
7 |
p. A246-
1 p.
|
artikel
|
| 700 |
PHP16 PARALLEL TRADE OF PHARMACEUTICALS IN POLAND
|
Baran-Lewandowska, I
|
|
2009
|
12 |
7 |
p. A240-
1 p.
|
artikel
|
| 701 |
PHP90 PATIENT-HEALTH CARE PROVIDER COMMUNICATION: IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE
|
Layton, MR
|
|
2009
|
12 |
7 |
p. A254-
1 p.
|
artikel
|
| 702 |
PHP33 PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) IMPLEMENTED IN SAUDI ARABIA
|
Al-Shawairkh, AS
|
|
2009
|
12 |
7 |
p. A243-
1 p.
|
artikel
|
| 703 |
PHP28 PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT
|
Pilat-Nalecz, K
|
|
2009
|
12 |
7 |
p. A242-
1 p.
|
artikel
|
| 704 |
PHP42 PHARMACEUTICAL EXPENDITURE AND POTENTIAL AVENUES FOR COST CONTAINMENT IN IRELAND
|
Heaney, RM
|
|
2009
|
12 |
7 |
p. A245-
1 p.
|
artikel
|
| 705 |
PHP12 PHARMACOECONOMIC CONTRIBUTION OF LATIN AMERICA TO ISPOR CONFERENCES
|
Machado, M
|
|
2009
|
12 |
7 |
p. A510-
1 p.
|
artikel
|
| 706 |
PHP100 PHARMACY STUDY OF NATURAL HEALTH PRODUCT ADVERSE REACTIONS (SONAR): ACTIVE SURVEILLANCE INCREASES AR REPORTING AND REVEALS TWO NEW INTERACTIONS
|
Cvijovic, K
|
|
2009
|
12 |
7 |
p. A255-A256
nvt p.
|
artikel
|
| 707 |
PHP61 POSITIVE DRUG LIST IN BULGARIA—5 YEARS LATER
|
Ivanova, AD
|
|
2009
|
12 |
7 |
p. A248-
1 p.
|
artikel
|
| 708 |
PHP93 POTENTIAL COST-SAVINGS USING IMPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS: THE CASE FOR THE NETHERLANDS
|
Van Genugten, M
|
|
2009
|
12 |
7 |
p. A254-
1 p.
|
artikel
|
| 709 |
PHP2 PREDICTING PERSISTENT FREQUENT USE OF THE PRIMARY HEALTH CARE SERVICES IN A FINNISH SETTING: A BAYESIAN APPROACH
|
Koskela, T
|
|
2009
|
12 |
7 |
p. A237-
1 p.
|
artikel
|
| 710 |
PHP60 PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES
|
Shepelev, J
|
|
2009
|
12 |
7 |
p. A248-
1 p.
|
artikel
|
| 711 |
PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
|
Mansour, E
|
|
2009
|
12 |
7 |
p. A242-A243
nvt p.
|
artikel
|
| 712 |
PHP14 PROJETO SPIDER: AVALIÇÃO DO IMPACTO DOS CENTROS DE INFORMAÇÕES TOXICOLÓGICAS NO BRASIL
|
Silva, MT
|
|
2009
|
12 |
7 |
p. A511-
1 p.
|
artikel
|
| 713 |
PHP23 PROPUESTA PARA EL ESTABLECIMIENTO DE UN MODELO DE LA EVALUACIÓN DE TECNOLOGÍAS DE LA SALUD EN COLOMBIA: ESTRUCTURA, PROCESO Y METODOLOGÍA
|
Einarson, TR
|
|
2009
|
12 |
7 |
p. A512-
1 p.
|
artikel
|
| 714 |
PHP65 PUBLICATION OF COST-EFFECTIVENESS ANALYSES AND SUBSEQUENT CITATIONS IN THE MEDICAL AND HEALTH ECONOMICS LITERATURE
|
Greenberg, D
|
|
2009
|
12 |
7 |
p. A249-
1 p.
|
artikel
|
| 715 |
PHP64 QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN: A REVIEW OF THE 2003–2009 LITERATURE
|
Lizan Tudela, LV
|
|
2009
|
12 |
7 |
p. A248-A249
nvt p.
|
artikel
|
| 716 |
PHP10 QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY— A METHODOLOGICAL APPROACH
|
Kalo, Z
|
|
2009
|
12 |
7 |
p. A239-
1 p.
|
artikel
|
| 717 |
PHP26 RATIONAL MYTHS AND RISK TRANSFER IN A PUBLIC HEALTH ORGANIZATION. THE CASE OF PUBLIC HOSPITALS IN BUENOS AIRES CITY, ARGENTINA 2000–2004
|
Crojethovic, M
|
|
2009
|
12 |
7 |
p. A512-
1 p.
|
artikel
|
| 718 |
PHP55 RECOMMENDATIONS FOR ORPHAN DRUGS IN TWO EU MEMBER STATES—A FOCUS ON THE UNDERLYING PHARMACOECONOMIC EVALUATIONS
|
Vegter, S
|
|
2009
|
12 |
7 |
p. A247-
1 p.
|
artikel
|
| 719 |
PHP85 RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA
|
Arbuckle, R
|
|
2009
|
12 |
7 |
p. A253-
1 p.
|
artikel
|
| 720 |
PHP84 REGIONAL DIFFERENCES IN ACUTE CARE HOSPITAL BED CAPACITIES FOLLOWING THE 2006–2008 HEALTH CARE REFORM IN HUNGARY
|
Vas, G
|
|
2009
|
12 |
7 |
p. A252-
1 p.
|
artikel
|
| 721 |
PHP5 RISK OF DEATH AND HOSPITAL LENGTH OF STAY ASSOCIATED WITH CLINICAL EVENTS POTENTIALLY CAUSED BY NEUROMUSCULAR BLOCKADE REVERSAL AGENTS
|
Félix, J
|
|
2009
|
12 |
7 |
p. A238-
1 p.
|
artikel
|
| 722 |
PHP75 SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES
|
Benguria-Arrate, G
|
|
2009
|
12 |
7 |
p. A251-
1 p.
|
artikel
|
| 723 |
PHP12 SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET
|
Stino, M
|
|
2009
|
12 |
7 |
p. A239-
1 p.
|
artikel
|
| 724 |
PHP37 SOCIAL HEALTH INSURANCE, PREVENTIVE CARE AND HEALTH CARE EXPENDITURE
|
Chen, Q
|
|
2009
|
12 |
7 |
p. A244-
1 p.
|
artikel
|
| 725 |
PHP8 SURVEY ON THE MANAGEMENT OF ORAL ANTICOAGULATION THERAPY (OAT) IN ITALY
|
Iannazzo, S
|
|
2009
|
12 |
7 |
p. A238-A239
nvt p.
|
artikel
|
| 726 |
PHP1 THE COMMERCIALIZATION OF HEALTH CARE ALLOCATION: CONSUMERS' TOTAL AND DISTRIBUTIONAL HEALTH OUTCOME PERCEPTIONS AND ATTITUDE TOWARDS FLEXIBLE CARE ACCESS PRICING STRATEGIES BY HOSPITALS
|
Benning, T
|
|
2009
|
12 |
7 |
p. A237-
1 p.
|
artikel
|
| 727 |
PHP40 THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND
|
Heikkonen, TT
|
|
2009
|
12 |
7 |
p. A244-A245
nvt p.
|
artikel
|
| 728 |
PHP97 THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE
|
Zalis'ka, O
|
|
2009
|
12 |
7 |
p. A255-
1 p.
|
artikel
|
| 729 |
PHP67 THE PROBLEM-BASED LEARNING AS A NEW PRACTICAL METHOD OF SKILL DEVELOPMENT IN THE HEALTH SCIENCES HIGHER EDUCATION
|
Szögedi-Müller, I
|
|
2009
|
12 |
7 |
p. A249-
1 p.
|
artikel
|
| 730 |
PHP45 THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES—WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES
|
White, J
|
|
2009
|
12 |
7 |
p. A245-
1 p.
|
artikel
|
| 731 |
PHP78 THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)
|
Kolasa, K
|
|
2009
|
12 |
7 |
p. A251-
1 p.
|
artikel
|
| 732 |
PHP21 THE ROLE OF MONETARY AND NON-MONETARY INCENTIVES ON THE CHOICE OF PRACTICE ESTABLISHMENT: A STATED PREFERENCE STUDY OF YOUNG PHYSICIANS IN GERMANY
|
Günther, OH
|
|
2009
|
12 |
7 |
p. A241-
1 p.
|
artikel
|
| 733 |
PHP56 THE ROLE OF PHARMACOECONOMICS IN DRUG REIMBURSEMENT DECISION-MAKING IN THE NETHERLANDS
|
Franken, M
|
|
2009
|
12 |
7 |
p. A247-
1 p.
|
artikel
|
| 734 |
PHP32 THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK
|
Lucas, F
|
|
2009
|
12 |
7 |
p. A243-
1 p.
|
artikel
|
| 735 |
PHP22 TOO MANY AGENCIES FOR DRUG EVALUATION IN SPAIN?
|
Collar, JM
|
|
2009
|
12 |
7 |
p. A241-
1 p.
|
artikel
|
| 736 |
PHP1 TRANSPARENCY IN LATIN AMERICAN HTA: HOW DO WE MEASURE SUCCESS?
|
Shankland, B
|
|
2009
|
12 |
7 |
p. A509-
1 p.
|
artikel
|
| 737 |
PHP59 TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS
|
Aggarwal, S
|
|
2009
|
12 |
7 |
p. A248-
1 p.
|
artikel
|
| 738 |
PHP29 UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
|
Harris, A
|
|
2009
|
12 |
7 |
p. A242-
1 p.
|
artikel
|
| 739 |
PHP4 USE OF FREE MEDICINE SAMPLES, DOCTOR PATIENT COMMUNICATION AND COST-RELATED NON-ADHERENCE AMONG OLDER ADULTS
|
Donohue, JM
|
|
2009
|
12 |
7 |
p. A238-
1 p.
|
artikel
|
| 740 |
PHP81 USE OF SELF-REPORTED HEALTH STATUS TO PREDICT EMPLOYEE MEDICAL EXPENDITURES
|
Huse, D
|
|
2009
|
12 |
7 |
p. A252-
1 p.
|
artikel
|
| 741 |
PHP34 USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE UNITED KINGDOWM AND AUSTRALIA
|
Taylor, M
|
|
2009
|
12 |
7 |
p. A243-
1 p.
|
artikel
|
| 742 |
PHP19 WHAT DOES BRANDED PHARMA BRING TO LATIN AMERICA AND OTHER EMERGING MARKETS?
|
Sparrowhawk, K
|
|
2009
|
12 |
7 |
p. A511-
1 p.
|
artikel
|
| 743 |
PHP46 WTP FOR A QALY: THE INDIVIDUAL PERSPECTIVE
|
Bobinac, A
|
|
2009
|
12 |
7 |
p. A245-A246
nvt p.
|
artikel
|
| 744 |
PIH8 A BUDGET IMPACT ANALYSIS OF DIENOGEST IN TREATING ENDOMETRIOSIS ASSOCIATED PELVIC PAIN IN GERMANY
|
Knight, C
|
|
2009
|
12 |
7 |
p. A291-
1 p.
|
artikel
|
| 745 |
PIH2 ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI'S) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS)
|
Chen, H
|
|
2009
|
12 |
7 |
p. A290-
1 p.
|
artikel
|
| 746 |
PIH15 AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA
|
Jung, S
|
|
2009
|
12 |
7 |
p. A293-
1 p.
|
artikel
|
| 747 |
PIH12 ANÁLISE DA APRESENTAÇÃO GRÁFICA DA BULA DE MEDICAMENTO NA PERSPECTIVA DAS ESTRATÉGIAS LEITURA DE PACIENTES EM CONTEXTO DE USO
|
Fujita, P
|
|
2009
|
12 |
7 |
p. A514-A515
nvt p.
|
artikel
|
| 748 |
PIH3 ANÁLISE DO IMPACTO ORÇAMENTARIO DO CATETER COM BALÃO DE SILICONE PARA ABLAÇÃO TERMICA ENDOMETRIAL (THERMACHOICE®) VERSUS HISTERECTOMIA NO TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, NA PERSPECTIVA DO PAGADOR PRIVADO, NO BRASIL
|
Machado, F
|
|
2009
|
12 |
7 |
p. A513-
1 p.
|
artikel
|
| 749 |
PIH37 ASSESSMENT OF THE QUALITY OF LIFE IN WOMEN WITH VENOUS DISEASE
|
Taieb, C
|
|
2009
|
12 |
7 |
p. A297-
1 p.
|
artikel
|
| 750 |
PIH8 AUTOPERCEPCIÓN DEL ESTADO SALUD DE LA POBLACIÓN ADULTA DE LA REGIÓN METROPOLITANA EN CHILE: UNA APLICACIÓN DE EQ-5D Y DE LA ESCALA VISUAL ANALOGA
|
Valenzuela, P
|
|
2009
|
12 |
7 |
p. A514-
1 p.
|
artikel
|
| 751 |
PIH5 AVALIAÇÃO DO USO DE RECURSOS E DOS CUSTOS DAS COMPLICAÇÕES DA ABLAÇÃO ENDOMETRIAL PARA O TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, NA PERSPECTIVA DO PAGADOR PÚBLICO. UM COMPARATIVO ENTRE DUAS TECNICAS: ABLAÇÃO TERMICA DE SEGUNDA GERAÇÃO E HISTERECTOMIA
|
Baran, R
|
|
2009
|
12 |
7 |
p. A513-
1 p.
|
artikel
|
| 752 |
PIH4 AVALIAÇÃO DO USO DE RECURSOS E DOS CUSTOS DAS COMPLICAÇÕES DA ABLAÇÃO ENDOMETRIAL PARA O TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, SOB A PERSPECTIVA DO PAGADOR PRIVADO NO BRASIL. UM COMPARATIVO ENTRE DUAS TÉCNICAS: ABLAÇÃO TÉRMICA DE SEGUNDA GERAÇÃO E HISTERECTOMIA
|
Nasciben, VD
|
|
2009
|
12 |
7 |
p. A513-
1 p.
|
artikel
|
| 753 |
PIH6 CHANGES OF HEART RATE VARIABILITY AFTER SHORT-TERM MEDITATION TRAINING IN COLLEGE STUDENT
|
Chung, JH
|
|
2009
|
12 |
7 |
p. A291-
1 p.
|
artikel
|
| 754 |
PIH24 CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY: TIME AND SUPPLIES WITH PRINEO* VS. STANDARD OF CARE FOR BREAST RECONSTRUCTION SURGERY
|
De Cock, E
|
|
2009
|
12 |
7 |
p. A294-
1 p.
|
artikel
|
| 755 |
PIH19 COST-EFFECTIVENESS ANALYSIS OF THE NEW FERTILITY TREATMENT (RFSH+RLH)
|
Palumbo, A
|
|
2009
|
12 |
7 |
p. A293-
1 p.
|
artikel
|
| 756 |
PIH21 COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)
|
Rozenbaum, M
|
|
2009
|
12 |
7 |
p. A294-
1 p.
|
artikel
|
| 757 |
PIH13 :COST-EFFECTIVENESS OF REDUCING MULTIPLE BIRTHS: IN-VITRO FERTILIZATION STRATEGIES IN CANADA
|
Zowall, H
|
|
2009
|
12 |
7 |
p. A292-
1 p.
|
artikel
|
| 758 |
PIH7 COST OF PNEUMONIA HOSPITALIZATION IN ELDERLY PEOPLE FROM TWO LARGE BRAZILIAN HOSPITALS
|
Toniolo, J
|
|
2009
|
12 |
7 |
p. A514-
1 p.
|
artikel
|
| 759 |
PIH36 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN POSTMENOPAUSAL WOMEN ENROLLED IN POSSIBLE EU®
|
Freemantle, N
|
|
2009
|
12 |
7 |
p. A296-A297
nvt p.
|
artikel
|
| 760 |
PIH33 DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA
|
Petric, M
|
|
2009
|
12 |
7 |
p. A296-
1 p.
|
artikel
|
| 761 |
PIH3 DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE: 4-YEAR RESULTS FROM THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY
|
Haillot, O
|
|
2009
|
12 |
7 |
p. A290-
1 p.
|
artikel
|
| 762 |
PIH43 EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS
|
Boomkamp, IS
|
|
2009
|
12 |
7 |
p. A298-
1 p.
|
artikel
|
| 763 |
PIH12 ECONOMIC BURDEN OF POSTMENOPAUSAL OSTEOPOROSIS IN GERMANY: A SYSTEMATIC REVIEW
|
Steinle, T
|
|
2009
|
12 |
7 |
p. A292-
1 p.
|
artikel
|
| 764 |
PIH23 ECONOMIC EVALUATION OF ATOSIBAN COMPARED TO BETAMIMETICS FOR THE TREATMENT OF PRETERM LABOUR IN AUSTRIA
|
Wex, J
|
|
2009
|
12 |
7 |
p. A294-
1 p.
|
artikel
|
| 765 |
PIH17 ECONOMIC EVALUATION OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: THE POPULAR HEALTH CARE SYSTEM PERSPECTIVE
|
Reyes, A
|
|
2009
|
12 |
7 |
p. A293-
1 p.
|
artikel
|
| 766 |
PIH16 ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTION
|
Navarro Espigares, JL
|
|
2009
|
12 |
7 |
p. A293-
1 p.
|
artikel
|
| 767 |
PIH10 ESTIMATING THE BURDEN OF WOMEN SUFFERING FROM PMS/PMDD: ANALYSIS OF A CROSS-SECTIONAL DATASET
|
Lowin, J
|
|
2009
|
12 |
7 |
p. A292-
1 p.
|
artikel
|
| 768 |
PIH5 EXAMINATION OF GAIT DURING THE TRIMESTERS OF PREGNANCY
|
Hock, M
|
|
2009
|
12 |
7 |
p. A291-
1 p.
|
artikel
|
| 769 |
PIH22 HEALTH ECONOMIC EVALUATION OF A NEW VACCINE FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS A GERMAN ANALYSIS
|
Wasem, J
|
|
2009
|
12 |
7 |
p. A294-
1 p.
|
artikel
|
| 770 |
PIH27 HEALTH RELATED QUALITY OF LIFE AND UTILITY SCORES IN MENOPAUSAL WOMEN
|
Iskedjian, M
|
|
2009
|
12 |
7 |
p. A295-
1 p.
|
artikel
|
| 771 |
PIH1 MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES ATENDIDOS EN ATENCIÓN PRIMARIA DE SALUD
|
Garcia, J
|
|
2009
|
12 |
7 |
p. A512-A513
nvt p.
|
artikel
|
| 772 |
PIH7 MORTALITY ACCORDING TO THE DAY OF ADMISSION IN INTENSIVE CARE UNITS AND MATERNITY WARDS IN HUNGARY
|
Gresz, M
|
|
2009
|
12 |
7 |
p. A291-
1 p.
|
artikel
|
| 773 |
PIH1 PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS
|
Kovács, E
|
|
2009
|
12 |
7 |
p. A290-
1 p.
|
artikel
|
| 774 |
PIH18 PHARMACOECONOMIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: INSURANCE COMPANIES PERSPECTIVE
|
Reyes, A
|
|
2009
|
12 |
7 |
p. A293-
1 p.
|
artikel
|
| 775 |
PIH41 PRESCRIPTION PATTERNS AND EXPENDITURE OF LONG-TERM BENZODIAZEPINE TREATMENT IN ELDERLY OUTPATIENTS IN TAIWAN
|
Cheng, JS
|
|
2009
|
12 |
7 |
p. A297-
1 p.
|
artikel
|
| 776 |
PIH9 PREVALENCE AND BURDEN OF ILLNESS OF MENOPAUSE: A CANADIAN OBSERVATIONAL STUDY
|
Iskedjian, M
|
|
2009
|
12 |
7 |
p. A291-A292
nvt p.
|
artikel
|
| 777 |
PIH11 REDUÇÃO DE GASTOS COM A IMPLANTAÇÃO DE PROTOCOLO DE DILUIÇÃO PARA PREPARO DE MEDICAMENTOS INTRAVENOSOS EM HOSPITAL UNIVERSITÁRIO DE MÉDIA COMPLEXIDADE DE S˜O PAULO
|
Bossi Jr, F
|
|
2009
|
12 |
7 |
p. A514-
1 p.
|
artikel
|
| 778 |
PIH38 RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND MULTIMORBIDITY AMONG OLDER PERSONS IN GERMANY—RESULTS OF THE PRISCUS-COHORT
|
Hodek, JM
|
|
2009
|
12 |
7 |
p. A297-
1 p.
|
artikel
|
| 779 |
PIH6 RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO PNEUMOCOCCAL DISEASE-RELATED HOSPITALIZATIONS ON BRAZILIAN PUBLIC HEALTH CARE SYSTEM
|
Pepe, C
|
|
2009
|
12 |
7 |
p. A514-
1 p.
|
artikel
|
| 780 |
PIH42 RESULTS OF AN OBSERVATIONAL STUDY IN 574 COMMUNITY PHARMACIES IN SPAIN CHARACTERIZING PATIENT PROFILES OF MEN ASKING FOR ERECTILE DYSFUNCTION MEDICATION
|
Martí, B
|
|
2009
|
12 |
7 |
p. A298-
1 p.
|
artikel
|
| 781 |
PIH4 ROLE OF LIFESTYLE-RELATED FACTORS IN PELVIC FLOOR MUSCLE STRENGTH CHANGES DURING PREGNANCY
|
Hock, M
|
|
2009
|
12 |
7 |
p. A290-A291
nvt p.
|
artikel
|
| 782 |
PIH11 SOCIO-ECONOMIC ASPECTS OF THE PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION IN GERMANY: A BURDEN OF DISEASE STUDY
|
Walter, E
|
|
2009
|
12 |
7 |
p. A292-
1 p.
|
artikel
|
| 783 |
PIH30 SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CONCEPTS AND MEASUREMENT
|
Rofail, D
|
|
2009
|
12 |
7 |
p. A295-A296
nvt p.
|
artikel
|
| 784 |
PIH35 THE APPLICATIONS OF GEOGRAPHIC INFORMATION SYSTEM TO QUALITY OF LIFE STUDIES: USING TAIWAN AS AN EXAMPLE
|
Yang, JJ
|
|
2009
|
12 |
7 |
p. A296-
1 p.
|
artikel
|
| 785 |
PIH14 THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND
|
Jensen, JAG
|
|
2009
|
12 |
7 |
p. A292-
1 p.
|
artikel
|
| 786 |
PIH13 THE IMPACT OF FAMILY PHYSICIAN PROGRAM ON HEALTH INDICATORS IN IRAN (2003–2007)
|
Barati, O
|
|
2009
|
12 |
7 |
p. A515-
1 p.
|
artikel
|
| 787 |
PIH25 TIME AND SUPPLIES FOR WOUND MANAGEMENT DURING AND AFTER BREAST REDUCTION SURGERY IN GERMANY AND THE NETHERLANDS: PRINEO* VS STANDARD OF CARE
|
De Cock, E
|
|
2009
|
12 |
7 |
p. A294-A295
nvt p.
|
artikel
|
| 788 |
PIH26 TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS
|
Neidecker, MV
|
|
2009
|
12 |
7 |
p. A295-
1 p.
|
artikel
|
| 789 |
PIH2 USO DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN PACIENTES ANCIANOS HOSPITALIZADOS EN MEDICINA INTERNA DE UN HOSPITAL UNIVERSITARIO
|
Escobar, L
|
|
2009
|
12 |
7 |
p. A513-
1 p.
|
artikel
|
| 790 |
PIH29 VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE
|
Burgess, SM
|
|
2009
|
12 |
7 |
p. A295-
1 p.
|
artikel
|
| 791 |
PIH28 VALIDATION OF THE SF—36 IN PATIENTS WITH ENDOMETRIOSIS
|
Stull, D
|
|
2009
|
12 |
7 |
p. A295-
1 p.
|
artikel
|
| 792 |
PIH39 VALIDITY AND RELIABILITY OF QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE FOR TURKISH WOMEN
|
Malhan, S
|
|
2009
|
12 |
7 |
p. A297-
1 p.
|
artikel
|
| 793 |
PIH44 VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG PHYSICIANS AFTER THE RELEASE OF WHI REPORT
|
Chen, WC
|
|
2009
|
12 |
7 |
p. A298-
1 p.
|
artikel
|
| 794 |
PIH40 WILLINGNESS TO PAY PER QUALITY-ADJUSTED LIFE YEAR OF CHRONIC PROSTATITIS PATIENTS IN CHINA
|
Zhao, FL
|
|
2009
|
12 |
7 |
p. A297-
1 p.
|
artikel
|
| 795 |
PIH32 WOMEN'S PREFERENCES FOR OVARIAN STIMULATING HORMONES IN THE TREATMENT OF INFERTILITY
|
Espallardo, O
|
|
2009
|
12 |
7 |
p. A296-
1 p.
|
artikel
|
| 796 |
PIN10 A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN
|
Darba, J
|
|
2009
|
12 |
7 |
p. A419-
1 p.
|
artikel
|
| 797 |
PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCVI3) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
|
Patel, R
|
|
2009
|
12 |
7 |
p. A428-
1 p.
|
artikel
|
| 798 |
PIN44 A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
|
Sidhu, MK
|
|
2009
|
12 |
7 |
p. A425-
1 p.
|
artikel
|
| 799 |
PIN13 ANÁLISIS COSTO EFECTIVIDAD DE PRUEBAS RÁPIDAS PARA EL DIAGNÓSTICO DEL VIH COMO HERRAMIENTA DE PREVENCIÓN Y CONTROL DE LA EPIDEMIA
|
Caso, A
|
|
2009
|
12 |
7 |
p. A517-
1 p.
|
artikel
|
| 800 |
PIN22 ANNUAL COSTS OF CHRONIC HEPATITIS B DISEASE STATES IN PORTUGAL
|
Raluy, M
|
|
2009
|
12 |
7 |
p. A421-
1 p.
|
artikel
|
| 801 |
PIN69 A PATIENT SATISFACTION QUESTIONNAIRE FOR ASSESSING PHARMACEUTICAL CARE SERVICES IN NIGERIAN HIV CLINICS
|
Njilele, NA
|
|
2009
|
12 |
7 |
p. A430-
1 p.
|
artikel
|
| 802 |
PIN49 A PHARMACOECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION IN ITALY
|
Iannazzo, S
|
|
2009
|
12 |
7 |
p. A426-
1 p.
|
artikel
|
| 803 |
PIN64 A PROBABILISTIC COST-EFFECTIVENESS MODEL FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN
|
Darba, J
|
|
2009
|
12 |
7 |
p. A429-
1 p.
|
artikel
|
| 804 |
PIN7 BUDGETARY IMPACT OF ADDING DORIPENEM TO A HOSPITAL FORMULARY IN GERMANY
|
Kongnakorn, T
|
|
2009
|
12 |
7 |
p. A418-
1 p.
|
artikel
|
| 805 |
PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA
|
Ismaila, AS
|
|
2009
|
12 |
7 |
p. A418-
1 p.
|
artikel
|
| 806 |
PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA
|
Dimitrova, MJ
|
|
2009
|
12 |
7 |
p. A419-
1 p.
|
artikel
|
| 807 |
PIN12 BUDGET IMPACT ANALYSIS OF THREE CANDINS IN THE TREATMENT OF INVASIVE CANDIDIASIS IN ADULT NON- NEUTROPENIC PATIENTS IN SPAIN
|
Garcia, M
|
|
2009
|
12 |
7 |
p. A419-
1 p.
|
artikel
|
| 808 |
PIN13 BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES IN THE TREATMENT OF INPATIENT CAP
|
Pitrelli, A
|
|
2009
|
12 |
7 |
p. A419-
1 p.
|
artikel
|
| 809 |
PIN14 BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS: AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW RECOMMENDATIONS IN FRANCE
|
Bernard, M
|
|
2009
|
12 |
7 |
p. A419-A420
nvt p.
|
artikel
|
| 810 |
PIN21 BURDEN AND COST OF SNAKEBITE ENVENOMING: ANTIVENOM OUT OF REACH?
|
Aggarwal, A
|
|
2009
|
12 |
7 |
p. A421-
1 p.
|
artikel
|
| 811 |
PIN20 BURDEN OF PEDIATRIC INFLUENZA IN EUROPE: A GAP ANALYSIS
|
Rycroft, C
|
|
2009
|
12 |
7 |
p. A421-
1 p.
|
artikel
|
| 812 |
PIN5 CARGA FINANCIERA POR HEPATITIS A EN MÉXICO
|
Rivas-Oropeza, I
|
|
2009
|
12 |
7 |
p. A516-
1 p.
|
artikel
|
| 813 |
PIN21 CHANGE IN QUALITY OF LIFE AFTER BEING DIAGNOSED WITH HIV
|
Tsevat, J
|
|
2009
|
12 |
7 |
p. A519-
1 p.
|
artikel
|
| 814 |
PIN35 CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7- AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE
|
Papanicolaou, S
|
|
2009
|
12 |
7 |
p. A423-A424
nvt p.
|
artikel
|
| 815 |
PIN26 CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING ESCHERICHIACOLI IN HONG KONG
|
Mok, SS
|
|
2009
|
12 |
7 |
p. A422-
1 p.
|
artikel
|
| 816 |
PIN48 COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R AND OTHER RITONAVIR-BOOSTED PROTEASE INHIBITORS FOR FIRST-LINE TREATMENT OF HIV-I INFECTION IN GERMANY
|
Brogan, A
|
|
2009
|
12 |
7 |
p. A426-
1 p.
|
artikel
|
| 817 |
PIN11 COST EFFECTIVENESS ANALYSIS OF ELDERLY POLYSACCHARIDE PNEUMOCOCCAL VACCINATION IN SAO PAULO STATE
|
Toniolo, J
|
|
2009
|
12 |
7 |
p. A517-
1 p.
|
artikel
|
| 818 |
PIN46 COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS PODOPHYLLOTOXIN IN TREATMENT OF GENITAL/PERIANAL WARTS IN POLAND
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A426-
1 p.
|
artikel
|
| 819 |
PIN38 COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE
|
Kang, HY
|
|
2009
|
12 |
7 |
p. A424-
1 p.
|
artikel
|
| 820 |
PIN31 COST-EFFECTIVENESS ANALYSIS OF TELBIVUDINE VS LAMIVUDINE IN TREATING THE PATIENTS WITH HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B IN CHINA
|
Chen, W
|
|
2009
|
12 |
7 |
p. A423-
1 p.
|
artikel
|
| 821 |
PIN45 COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS
|
Westra, TA
|
|
2009
|
12 |
7 |
p. A425-A426
nvt p.
|
artikel
|
| 822 |
PIN56 COST-EFFECTIVENESS OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT NAIVE HIV PATIENTS IN SPAIN
|
Thuresson, PO
|
|
2009
|
12 |
7 |
p. A428-
1 p.
|
artikel
|
| 823 |
PIN40 COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO
|
Soto-Molina, H
|
|
2009
|
12 |
7 |
p. A424-A425
nvt p.
|
artikel
|
| 824 |
PIN10 COST EFFECTIVENESS OF ENTECAVIR VERSUS LAMIVUDINE IN SUPPRESSING VIRAL REPLICATION TO UNDETECTABLE GOAL IN CHRONIC HEPATITIS B (CHB) PATIENTS IN BRAZIL
|
Nita, M
|
|
2009
|
12 |
7 |
p. A517-
1 p.
|
artikel
|
| 825 |
PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-I-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS
|
Moeremans, K
|
|
2009
|
12 |
7 |
p. A428-
1 p.
|
artikel
|
| 826 |
PIN16 COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO
|
Carlos, F
|
|
2009
|
12 |
7 |
p. A420-
1 p.
|
artikel
|
| 827 |
PIN27 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN AND TEICOPLANIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS IN CZECH REPUBLIC
|
Suchankova, E
|
|
2009
|
12 |
7 |
p. A422-
1 p.
|
artikel
|
| 828 |
PIN39 COST-EFFECTIVENESS OF MASS VARICELLA VACCINATION IN FRANCE: ECONOMIC CONSEQUENCES OF AN INTENSIVE VACCINATION PROGRAM
|
Littlewood, KJ
|
|
2009
|
12 |
7 |
p. A424-
1 p.
|
artikel
|
| 829 |
PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
|
Jensen, DM
|
|
2009
|
12 |
7 |
p. A427-
1 p.
|
artikel
|
| 830 |
PIN60 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA
|
Sheng, F
|
|
2009
|
12 |
7 |
p. A428-A429
nvt p.
|
artikel
|
| 831 |
PIN37 COST EFFECTIVENESS OF PEGYLATED-INTERFERON ALPHA 2B + RIBAVIRIN FOR CHRONIC HEPATIITIS C (CHC) IN PATIENTS WHO HAVE PREVIOUSLY FAILED TREATMENT WITH INTERFERON- BASED THERAPY IN AUSTRALIA
|
Norris, S
|
|
2009
|
12 |
7 |
p. A424-
1 p.
|
artikel
|
| 832 |
PIN42 COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENTTO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
|
Claes, C
|
|
2009
|
12 |
7 |
p. A425-
1 p.
|
artikel
|
| 833 |
PIN62 COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS
|
Helsper, CW
|
|
2009
|
12 |
7 |
p. A429-
1 p.
|
artikel
|
| 834 |
PIN55 COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN
|
Suarez, D
|
|
2009
|
12 |
7 |
p. A427-A428
nvt p.
|
artikel
|
| 835 |
PIN32 COST EFFECTIVENESS OF UNIVERSAL ROTAVIRUS VACCINATION IN IRELAND: A PRELIMINARY ANALYSIS
|
Redmond, S
|
|
2009
|
12 |
7 |
p. A423-
1 p.
|
artikel
|
| 836 |
PIN43 COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
|
Whillans, F
|
|
2009
|
12 |
7 |
p. A425-
1 p.
|
artikel
|
| 837 |
PIN51 COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO
|
Soria-Cedillo, IF
|
|
2009
|
12 |
7 |
p. A427-
1 p.
|
artikel
|
| 838 |
PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL
|
Valentim, J
|
|
2009
|
12 |
7 |
p. A427-
1 p.
|
artikel
|
| 839 |
PIN7 COSTO-BENEFICIO DEL USO DE TIGECICLINA VS. TRIPLE ESQUEMA ANTIMICROBIANO CEFOTAXIMA/AMIKACINA/METRONIDAZOL EN PACIENTES CON INFECCIONES INTRAABDOMINALES Y DE PIEL Y TEJIDOS BLANDOS EN MÉXICO
|
Gorbea, MDC
|
|
2009
|
12 |
7 |
p. A516-
1 p.
|
artikel
|
| 840 |
PIN29 COST OF DIABETIC FOOT INFECTIONS DUE TO MRSA: AN ECONOMIC ANALYSIS OF DATA FROM PATIENTS TREATED WITH LINEZOLID IN SPAIN
|
Zaragoza, R
|
|
2009
|
12 |
7 |
p. A422-
1 p.
|
artikel
|
| 841 |
PIN6 COSTS OF NOSOCOMIAL PNEUMONIA IN A THIRD LEVEL HOSPITAL OF MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)
|
Ortega-Alvarado, S
|
|
2009
|
12 |
7 |
p. A516-
1 p.
|
artikel
|
| 842 |
PIN63 COST-UTILITY ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN GERMANY
|
Knoll, S
|
|
2009
|
12 |
7 |
p. A429-
1 p.
|
artikel
|
| 843 |
PIN61 COST-UTILITY ANALYSIS OF ROTAVIRUS VACCINE (ROTARIX®) IN JAPAN
|
Igarashi, A
|
|
2009
|
12 |
7 |
p. A429-
1 p.
|
artikel
|
| 844 |
PIN73 CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND
|
Das, R
|
|
2009
|
12 |
7 |
p. A431-
1 p.
|
artikel
|
| 845 |
PIN24 DIFFERENT APPROACHES FOR ESTIMATING INDIRECT COST IN THE ECONOMIC ASSESSMENT OF PNEUMOCOCCAL VACCINES IN GERMANY
|
Jochum, D
|
|
2009
|
12 |
7 |
p. A421-A422
nvt p.
|
artikel
|
| 846 |
PIN78 DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER—A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME
|
Elbirt, D
|
|
2009
|
12 |
7 |
p. A432-
1 p.
|
artikel
|
| 847 |
PIN28 ECONOMIC ANALYSIS ABOUT VALGANCICLOVIR PROPHYLAXIS AGAINST INFECTION FROM CITOMEGALOVIRUS IN PATIENTS WITH RENAL TRANSPLANTATION
|
García-Tellez, I
|
|
2009
|
12 |
7 |
p. A422-
1 p.
|
artikel
|
| 848 |
PIN34 ECONOMIC ASSESSMENT OF MASS VACCINATION WITH PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN POLAND
|
Kawalec, P
|
|
2009
|
12 |
7 |
p. A423-
1 p.
|
artikel
|
| 849 |
PIN19 ECONOMIC EVALUATION OF RUBELLA AND CONTROL STRATEGIES DURING AN OUTBREAK IN FORTALEZA (CEARÁ), BRAZIL, 2007
|
Mota, DM
|
|
2009
|
12 |
7 |
p. A518-
1 p.
|
artikel
|
| 850 |
PIN75 ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON THE MALARIA CONTROL PROGRAM IN BRAZIL
|
Quinn, BP
|
|
2009
|
12 |
7 |
p. A431-
1 p.
|
artikel
|
| 851 |
PIN14 EVALUACIÓN DE COSTO EFECTIVIDAD COMPARATIVO DE QUATRO ESQUEMAS DE TRATAMIENTO DE INFECCIÓN URINARIA BAJA EN MUJERESJÓVENES, IMPACTO ECONÓMICO EN UN ENTORNO DE SALUD MUNICIPAL DE CARACAS, VENEZUELA
|
Castro Mendez, JS
|
|
2009
|
12 |
7 |
p. A517-
1 p.
|
artikel
|
| 852 |
PIN12 EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE NEUMOCOCO EN COLOMBIA
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A517-
1 p.
|
artikel
|
| 853 |
PIN17 EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE BOGOTÁ, D.C
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A518-
1 p.
|
artikel
|
| 854 |
PIN8 EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE COLOMBIA
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A516-
1 p.
|
artikel
|
| 855 |
PIN15 EVALUACIÓN ECONÓMICA DEL IMPACTO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN BOGOTÁ D.C
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A518-
1 p.
|
artikel
|
| 856 |
PIN16 EVALUACIÓN ECONÓMICA DEL IMPACTO DE LA INTRODUCCIÓN DE LA VACUNA DE NEUMOCOCO EN BOGOTÁ, D.C
|
de La Hoz, F
|
|
2009
|
12 |
7 |
p. A518-
1 p.
|
artikel
|
| 857 |
PIN1 FRENCH OBSERVATIONAL COHORT OF HIV-I INFECTED PATIENTS TREATED WITH ENFUVIRTIDE: LONG-TERM EFFICACY AND SAFETY (ZOOM)
|
Meynard, JL
|
|
2009
|
12 |
7 |
p. A417-
1 p.
|
artikel
|
| 858 |
PIN1 GENDER DIFFERENCES IN METABOLIC PROFILE AND CARDIOVASCULAR RISK AMONG BRAZILIAN HIV-INFECTED PATIENTS ON HAART: RAPID II STUDY
|
Ferreira, P
|
|
2009
|
12 |
7 |
p. A515-
1 p.
|
artikel
|
| 859 |
PIN2 HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE
|
Zhang, HF
|
|
2009
|
12 |
7 |
p. A417-
1 p.
|
artikel
|
| 860 |
PIN3 HEPATOCELLULAR CARCINOMA (HCC) RISK ESTIMATION BASED ON CHRONIC HEPATITIS B (CHB) VIRAL LOAD LEVELS IN BRAZILIAN PATIENTS
|
Cheinquer, H
|
|
2009
|
12 |
7 |
p. A515-
1 p.
|
artikel
|
| 861 |
PIN18 IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE INFLUENZA EN COLOMBIA
|
Porras, A
|
|
2009
|
12 |
7 |
p. A518-
1 p.
|
artikel
|
| 862 |
PIN4 IMPACT OF CHRONIC HEPATITIS B IN THE BRAZILIAN HEALTH SYSTEM ACCORDING WITH DATA FROM DATASUS (ADMINISTRATIVE DATABASE) FROM MINISTRY OF HEALTH
|
Nita, M
|
|
2009
|
12 |
7 |
p. A515-A516
nvt p.
|
artikel
|
| 863 |
PIN65 IMPACT OF ETRAVIRINE (ETR) ON HOSPITALISATIONS AND HOSPITAL-RELATED COSTS CALCULATED BY GERMAN-DRGS: 48-WEEK FINDINGS FROM POOLED DUET TRIALS
|
Stoll, M
|
|
2009
|
12 |
7 |
p. A429-A430
nvt p.
|
artikel
|
| 864 |
PIN2 INTEGRATION OF PHARMACO-ECONOMIC OUTCOME BASED RESEARCH WITH LOCAL CONTEXT: A MODEL FOR RATIONAL HEALTH CARE DECISION-MAKING IN DEVELOPING COUNTRIES
|
Mathew, JL
|
|
2009
|
12 |
7 |
p. A515-
1 p.
|
artikel
|
| 865 |
PIN74 LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN
|
Plans-Rubió, P
|
|
2009
|
12 |
7 |
p. A431-
1 p.
|
artikel
|
| 866 |
PIN20 LONG-TERM CONSEQUENCES OF AN INTENSE RUBELLA VACCINATION PROGRAM IN FORTALEZA, BRAZIL: A COST-EFFECTIVENESS ANALYSIS
|
Machado, M
|
|
2009
|
12 |
7 |
p. A518-A519
nvt p.
|
artikel
|
| 867 |
PIN50 MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY
|
Felder, S
|
|
2009
|
12 |
7 |
p. A426-A427
nvt p.
|
artikel
|
| 868 |
PIN81 MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS
|
Endel, G
|
|
2009
|
12 |
7 |
p. A432-A433
nvt p.
|
artikel
|
| 869 |
PIN47 MODELING THE OUTCOMES OF VACCINATION WITH THE 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN SPAIN
|
Mares, J
|
|
2009
|
12 |
7 |
p. A426-
1 p.
|
artikel
|
| 870 |
PIN9 MODELO FARMACOECONÓMICO VORICONAZOL EN ASPERGILOSIS INVASIVA: CASO VENEZUELA
|
Castro Mendez, JS
|
|
2009
|
12 |
7 |
p. A516-
1 p.
|
artikel
|
| 871 |
PIN6 OUTCOME AND RESOURCES USE OF SEVERE BURN INJURY PATIENTS WITH NOSOCOMIAL BLOODSTREAM INFECTION: RESULTS OF A MATCHED COHORT STUDY
|
Brusselaers, N
|
|
2009
|
12 |
7 |
p. A418-
1 p.
|
artikel
|
| 872 |
PIN70 PERCEPTION AND ACCEPTANCE OF INTRADERMAL INFLUENZA VACCINE MEASURED BY THE VACCINEE'S PERCEPTION OF INJECTION (VAPI®) QUESTIONNAIRE
|
Meunier, J
|
|
2009
|
12 |
7 |
p. A430-
1 p.
|
artikel
|
| 873 |
PIN23 POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/ RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS
|
Baran, RW
|
|
2009
|
12 |
7 |
p. A421-
1 p.
|
artikel
|
| 874 |
PIN59 POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG—A DECISION ANALYSIS
|
You, JH
|
|
2009
|
12 |
7 |
p. A428-
1 p.
|
artikel
|
| 875 |
PIN33 POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH
|
Ismaila, AS
|
|
2009
|
12 |
7 |
p. A423-
1 p.
|
artikel
|
| 876 |
PIN3 PREDICTORS OF EFFECTIVENESS WITH LOPINAVIR/RITONAVIR (LPV/R) SINGLE AGENT THERAPY (SAT) TO IMPROVE CLINICAL OUTCOMES IN HIGH RISK HIV+ PATIENTS IN AN URBAN CLINIC
|
Yen, RF
|
|
2009
|
12 |
7 |
p. A417-
1 p.
|
artikel
|
| 877 |
PIN41 PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO: ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION
|
Baca-Muro, VI
|
|
2009
|
12 |
7 |
p. A425-
1 p.
|
artikel
|
| 878 |
PIN68 PSYCHOMETRIC EVALUATION OF THE FUNCTIONAL ASSESSMENT OF HIV INFECTION (FAHl) QUESTIONNAIRE IN TWO CLINICAL PROGRAMMES
|
Gilet, H
|
|
2009
|
12 |
7 |
p. A430-
1 p.
|
artikel
|
| 879 |
PIN67 QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCV-INFECTED PATIENTS IN EUROPE
|
Zhang, HF
|
|
2009
|
12 |
7 |
p. A430-
1 p.
|
artikel
|
| 880 |
PIN71 QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF POLY-L-LACTIC ACID
|
Duracinsky, M
|
|
2009
|
12 |
7 |
p. A431-
1 p.
|
artikel
|
| 881 |
PIN22 QUÉ FACTORES DETERMINAN LOS PRECIOS INTERNACIONALES DE LOS MEDICAMENTOS ANTIRETROVIRALES?
|
Garcia-Gonzalez, A
|
|
2009
|
12 |
7 |
p. A519-
1 p.
|
artikel
|
| 882 |
PIN36 SCREENING OF MIGRANTS FOR CHRONIC HEPATITIS B VIRUS INFECTION: A COST-EFFECTIVENESS ANALYSIS
|
Veldhuijzen, IK
|
|
2009
|
12 |
7 |
p. A424-
1 p.
|
artikel
|
| 883 |
PIN66 SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY
|
Kauf, TL
|
|
2009
|
12 |
7 |
p. A430-
1 p.
|
artikel
|
| 884 |
PIN79 SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS
|
Paladio Duran, N
|
|
2009
|
12 |
7 |
p. A432-
1 p.
|
artikel
|
| 885 |
PIN4 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF EXTERNAL GENITAL WARTS
|
Walczak, J
|
|
2009
|
12 |
7 |
p. A417-A418
nvt p.
|
artikel
|
| 886 |
PIN82 THE APPLICATION OF HEALTH TECNOLOGY ASSESSMENT ON THE NEW PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE IN ITALY
|
La Torre, G
|
|
2009
|
12 |
7 |
p. A433-
1 p.
|
artikel
|
| 887 |
PIN18 THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE
|
Curran, D
|
|
2009
|
12 |
7 |
p. A420-
1 p.
|
artikel
|
| 888 |
PIN54 THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCVI3) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
|
Patel, R
|
|
2009
|
12 |
7 |
p. A427-
1 p.
|
artikel
|
| 889 |
PIN9 THE COST OF PREVENTING INFLUENZA PANDEMIC: MEXICAN ELDERLY POPULATION SCENARIO
|
Soria-Cedillo, IF
|
|
2009
|
12 |
7 |
p. A419-
1 p.
|
artikel
|
| 890 |
PIN17 THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE
|
Curran, D
|
|
2009
|
12 |
7 |
p. A420-
1 p.
|
artikel
|
| 891 |
PIN15 THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA INFECTION
|
Kolbye, A
|
|
2009
|
12 |
7 |
p. A420-
1 p.
|
artikel
|
| 892 |
PIN76 THE PREVALENCE, MORTALITY, AND COST OF CENTRAL LINE BLOOD STREAM INFECTIONS (CLABSI) IN US COMMUNITY HOSPITALS: 2002 TO 2006
|
Dickson, M
|
|
2009
|
12 |
7 |
p. A431-A432
nvt p.
|
artikel
|
| 893 |
PIN80 THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES—LESSONS LEARNED FROM FINLAND
|
Laine, J
|
|
2009
|
12 |
7 |
p. A432-
1 p.
|
artikel
|
| 894 |
PIN77 THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN PHYSICIANS' CARE AND INSTITUTES, BUT NOT HOSPITAL OUTPATIENT CARE)
|
Wilbacher, I
|
|
2009
|
12 |
7 |
p. A432-
1 p.
|
artikel
|
| 895 |
PIN72 TRANSLATION OF THE HIV PATIENT SYMPTOMS PROFILE INTO 5 LANGUAGES SPOKEN IN ISRAEL
|
Brunei, V
|
|
2009
|
12 |
7 |
p. A431-
1 p.
|
artikel
|
| 896 |
PIN19 TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN URBAN CHINA
|
Wang, Z
|
|
2009
|
12 |
7 |
p. A420-A421
nvt p.
|
artikel
|
| 897 |
PIN5 UNDERESTIMATION OF VARICELLA INCIDENCE IN THE NETHERLANDS
|
Pierik, JGJ
|
|
2009
|
12 |
7 |
p. A418-
1 p.
|
artikel
|
| 898 |
PIN30 USE OF NET-BENEFIT REGRESSION FRAMEWORK TO INVESTIGATE THE COST-EFFECTIVENESS OF COMBINATION ANTIVIRAL THERAPY AMONG HCV-INFECTED PATIENTS ENROLLED IN A MANAGED CARE ORGANIZATION
|
Hsu, CN
|
|
2009
|
12 |
7 |
p. A422-A423
nvt p.
|
artikel
|
| 899 |
PMC43 A CONCEPTUAL FRAMEWORK TO APPLY DISCRETE-EVENT SIMULATION TO ESTIMATE THE RESOURCES NEEDED TO PERFORM A POPULATION BASED CANCER SCREENING PROGRAM
|
Comas, M
|
|
2009
|
12 |
7 |
p. A395-
1 p.
|
artikel
|
| 900 |
PMC48 A DYNAMIC MODEL TO MAXIMIZE THE HELATH BENEFITS IN MUTUALLY EXCLUSIVE SUSCEPTIBLE INFECTIOUS POPULATION
|
Chang, CJ
|
|
2009
|
12 |
7 |
p. A395-A396
nvt p.
|
artikel
|
| 901 |
PMC55 AGREEMENT BETWEEN PATIENT AND PROXY ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BEFORE INTENSIVE CARE UNIT ADMISSION
|
Vandijck, D
|
|
2009
|
12 |
7 |
p. A397-
1 p.
|
artikel
|
| 902 |
PMC18 ANALYSIS OF TRANSFERABILITY TOOLS FOR COST-EFFECTIVENESS DATA AND COSIDERATION IN KOREA SETTINGS
|
Jung, S
|
|
2009
|
12 |
7 |
p. A390-
1 p.
|
artikel
|
| 903 |
PMC75 ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR SCIENTIFIC RESEARCH INITIATIVES?
|
Narayanan, S
|
|
2009
|
12 |
7 |
p. A401-
1 p.
|
artikel
|
| 904 |
PMC53 A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS WITH HAND-FOOT SYNDROME
|
Taieb, C
|
|
2009
|
12 |
7 |
p. A396-A397
nvt p.
|
artikel
|
| 905 |
PMC52 ASSESSING THE (DIS) AGREEMENT OF EQ-5D AND SF-6D ACROSS GROUPS WITH INCREASING SEVERITY OF CHRONIC HEART FAILURE
|
Kontodimopoulos, N
|
|
2009
|
12 |
7 |
p. A396-
1 p.
|
artikel
|
| 906 |
PMC15 A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE
|
Baffert, S
|
|
2009
|
12 |
7 |
p. A389-
1 p.
|
artikel
|
| 907 |
PMC2 A STANDARDIZED EVIDENCE BASED APPROACH TO ASSESS NONTRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE DECISION MAKING: THE DIABETES EXAMPLE
|
Badia, X
|
|
2009
|
12 |
7 |
p. A387-
1 p.
|
artikel
|
| 908 |
PMC46 BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER
|
Whyte, S
|
|
2009
|
12 |
7 |
p. A395-
1 p.
|
artikel
|
| 909 |
PMC61 CATALOGUE OF EQ-5D SCORES FOR THE UK
|
Sullivan, PW
|
|
2009
|
12 |
7 |
p. A398-
1 p.
|
artikel
|
| 910 |
PMC70 CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY
|
Lloyd, A
|
|
2009
|
12 |
7 |
p. A400-
1 p.
|
artikel
|
| 911 |
PMC25 CLINICAL HISTORY, RESOURCE UTILIZATION, AND OTHER PATIENTREPORTED OUTCOMES (PROS) IN MIGRAINEURS: AN ADAPTABLE WEB-BASED METHODOLOGY FOR THE DESIGN, IMPLEMENTATION AND CONDUCT OF A MULTI-NATIONAL SURVEY OF PATIENTS
|
Payne, KA
|
|
2009
|
12 |
7 |
p. A391-
1 p.
|
artikel
|
| 912 |
PMC42 COMPARING MARKOV MODEL AND DES—THE EXAMPLE OF COPD
|
Jaburg, AF
|
|
2009
|
12 |
7 |
p. A394-
1 p.
|
artikel
|
| 913 |
PMC37 COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH
|
Baser, O
|
|
2009
|
12 |
7 |
p. A393-
1 p.
|
artikel
|
| 914 |
PMC38 COMPARISON OF TWO METHODS TO DETERMINE COSTS FOR AML PATIENTS IN REMISSION: MODEL VALIDATION FROM A UK PERSPECTIVE
|
Purdy, C
|
|
2009
|
12 |
7 |
p. A394-
1 p.
|
artikel
|
| 915 |
PMC41 CONTROLLING FOR UNOBSERVABLE BIAS: IS THE CURE WORSE THAN THE DISEASE?
|
Baser, O
|
|
2009
|
12 |
7 |
p. A394-
1 p.
|
artikel
|
| 916 |
PMC1 CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH
|
Kamae, I
|
|
2009
|
12 |
7 |
p. A386-A387
nvt p.
|
artikel
|
| 917 |
PMC68 CORRELATION BETWEEN ADHERENCE RATES MEASURED BY MEDICATION EVENT MANAGEMENT SYSTEM AND SELF-REPORTED QUESTIONNAIRES: A META-ANALYSIS
|
Shi, L
|
|
2009
|
12 |
7 |
p. A399-
1 p.
|
artikel
|
| 918 |
PMC36 CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE
|
Baser, O
|
|
2009
|
12 |
7 |
p. A393-
1 p.
|
artikel
|
| 919 |
PMC33 CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES
|
Yi, Y
|
|
2009
|
12 |
7 |
p. A393-
1 p.
|
artikel
|
| 920 |
PMC3 CRITICAL REVIEW OF PUBLISHED COST EFFECTIVENESS ANALYSES OF ORAL TRIPTANS IN THE MANAGEMENT OF ACUTE MIGRAINE: DIFFERENT MEASURES OF EFFICACY EXTRACTED FROM THE SAME META-ANALYSIS
|
Peura, P
|
|
2009
|
12 |
7 |
p. A387-
1 p.
|
artikel
|
| 921 |
PMC59 CULTURAL AND LINGUISTIC ISSUES ASSOCIATED WITH THE TRANSLATION AND LINGUISTIC VALIDATION OF QUESTIONNAIRES FOR USE IN CHINA
|
Houchin, C
|
|
2009
|
12 |
7 |
p. A397-A398
nvt p.
|
artikel
|
| 922 |
PMC22 DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE
|
Daeppen, JB
|
|
2009
|
12 |
7 |
p. A390-A391
nvt p.
|
artikel
|
| 923 |
PMC12 DEVELOPMENT OF COST CATALOGS FOR COST-EFFECTIVENESS ANALYSES IN GERMANY: RESULTS OF A FEASIBILITY STUDY
|
Scheuringer, M
|
|
2009
|
12 |
7 |
p. A389-
1 p.
|
artikel
|
| 924 |
PMC72 DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPS
|
Marant, C
|
|
2009
|
12 |
7 |
p. A400-
1 p.
|
artikel
|
| 925 |
PMC73 DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK OF A COST-BENEFIT ASSESSMENT
|
Dintsios, CM
|
|
2009
|
12 |
7 |
p. A400-
1 p.
|
artikel
|
| 926 |
PMC64 DIFFICULTIES WITH THE APPLICATION OF PRO MEASURES TO CULTURES OUTSIDE OF WESTERN EUROPE AND NORTH AMERICA IN MULTI-NATIONAL TRIALS
|
Furtado, T
|
|
2009
|
12 |
7 |
p. A398-A399
nvt p.
|
artikel
|
| 927 |
PMC3 ESTADO DEL ARTE DE LA EVALUACIÓN DE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD EN VENEZUELA: UNA REVISIÓN SISTEMÁTICA DE LA LITERATURA
|
Bastardo, YM
|
|
2009
|
12 |
7 |
p. A519-A520
nvt p.
|
artikel
|
| 928 |
PMC54 ESTIMATING SOCIAL PREFERENCES FOR EQ-5D IN TURKEY : A NOVEL METHOD BASED ON A VALUATION EXCHANGE-RATE MECHANISM
|
Chuang, LH
|
|
2009
|
12 |
7 |
p. A397-
1 p.
|
artikel
|
| 929 |
PMC40 ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES: A HYPOTHESIS GENERATING STUDY
|
Sauboin, C
|
|
2009
|
12 |
7 |
p. A394-
1 p.
|
artikel
|
| 930 |
PMC19 EVALUATING AN ONLINE INCREMENTAL COST-EFFECTIVENESS CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES
|
McGhan, WF
|
|
2009
|
12 |
7 |
p. A390-
1 p.
|
artikel
|
| 931 |
PMC58 EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE
|
Lin, WL
|
|
2009
|
12 |
7 |
p. A397-
1 p.
|
artikel
|
| 932 |
PMC69 EXAMINING MASLOW'S HIERARCHICAL THEORY OF NEEDS BY USING THE ITEMS OF THE WHOQOL-BREF
|
Yao, G
|
|
2009
|
12 |
7 |
p. A399-A400
nvt p.
|
artikel
|
| 933 |
PMC28 EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLD RANGE IN KOREA: DISCRETE CHOICE EXPERIMENTS
|
Lee, J
|
|
2009
|
12 |
7 |
p. A392-
1 p.
|
artikel
|
| 934 |
PMC30 HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE
|
Schön, H
|
|
2009
|
12 |
7 |
p. A392-
1 p.
|
artikel
|
| 935 |
PMC10 HOW TO MAKE USE OF AVAILABLE SURVIVAL EVIDENCE IN AN INDIRECT COMPARISON
|
Ouwens, M
|
|
2009
|
12 |
7 |
p. A388-
1 p.
|
artikel
|
| 936 |
PMC27 IDENTIFYING ECONOMIC EVALUATIONS IN MEDLINE AND EMBASE: HOW WELL DO PUBLISHED SEARCH FILTERS PERFORM?
|
Glanville, J
|
|
2009
|
12 |
7 |
p. A391-
1 p.
|
artikel
|
| 937 |
PMC29 IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING ADMINISTRATIVE DATABASES
|
Bérard, A
|
|
2009
|
12 |
7 |
p. A392-
1 p.
|
artikel
|
| 938 |
PMC20 IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF PRESCRIPTION DRUGS IN AUSTRIA
|
Heiderer, B
|
|
2009
|
12 |
7 |
p. A390-
1 p.
|
artikel
|
| 939 |
PMC11 IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS
|
Guan, S
|
|
2009
|
12 |
7 |
p. A388-
1 p.
|
artikel
|
| 940 |
PMC13 INDIRECT COST OF ILLNESS IN POLISH ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES
|
Wrona, W
|
|
2009
|
12 |
7 |
p. A389-
1 p.
|
artikel
|
| 941 |
PMC63 IS EXTENDING OF TIME TRADE-OFF EXPERIMENT TO 23 STATES PER RESPONDENT RATIONALIZED? ANALYSIS OF DATA FROM POLISH VALUATION STUDY
|
Golicki, D
|
|
2009
|
12 |
7 |
p. A398-
1 p.
|
artikel
|
| 942 |
PMC4 LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR
|
Vemer, P
|
|
2009
|
12 |
7 |
p. A387-
1 p.
|
artikel
|
| 943 |
PMC67 LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH
|
Ruiz, MA
|
|
2009
|
12 |
7 |
p. A399-
1 p.
|
artikel
|
| 944 |
PMC26 LINKING PERSON-LEVEL INPATIENT DATA TO LONGITUDINAL RECORDS
|
Huse, D
|
|
2009
|
12 |
7 |
p. A391-
1 p.
|
artikel
|
| 945 |
PMC50 MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH EQ-5D
|
Reinders, S
|
|
2009
|
12 |
7 |
p. A396-
1 p.
|
artikel
|
| 946 |
PMC5 MEASURING AND MONITORING THE REAL-WORLD COSTEFFECTIVENESS OF NEW TECHNOLOGIES IN HOSPITALS
|
Neurohr, C
|
|
2009
|
12 |
7 |
p. A387-
1 p.
|
artikel
|
| 947 |
PMC4 METHODS: FOR ACHIEVING AND MAINTAINING ADEQUATE STUDY SUBJECT PARTICIPATION FORA MULTI-SITE TIME-SERIES TRIAL
|
Schoenberger, C
|
|
2009
|
12 |
7 |
p. A520-
1 p.
|
artikel
|
| 948 |
PMC44 MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE TECHNOLOGY: A CRITICAL AND STRATEGIC FEATURE OF BUDGET IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS
|
Ethgen, O
|
|
2009
|
12 |
7 |
p. A395-
1 p.
|
artikel
|
| 949 |
PMC2 MODELO DE ESTIMACIÓN DE LA VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD DEL EQ-5D: CASO DE CHILE
|
Valenzuela, P
|
|
2009
|
12 |
7 |
p. A519-
1 p.
|
artikel
|
| 950 |
PMC32 MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES WITH DIFFERENT SEROTYPES
|
Endel, G
|
|
2009
|
12 |
7 |
p. A392-A393
nvt p.
|
artikel
|
| 951 |
PMC62 ONLINE ADMINISTRATION OF THE TIME TRADE-OFF: A CASE-STUDY AMONG PEOPLE WITH RESTLESS LEGS SYNDROME
|
Aballéa, S
|
|
2009
|
12 |
7 |
p. A398-
1 p.
|
artikel
|
| 952 |
PMC51 PATIENT COMPLETION OF EPROS: TO PHONE OR TO WEB?
|
Miller, KL
|
|
2009
|
12 |
7 |
p. A396-
1 p.
|
artikel
|
| 953 |
PMC76 PATIENT REGISTRIES—A LITERATURE REVIEW OF RECENTLY REPORTED REGISTRY BASED STUDIES
|
Lis, Y
|
|
2009
|
12 |
7 |
p. A401-
1 p.
|
artikel
|
| 954 |
PMC56 PREFERENCES FOR PREFERENCES
|
Greenberg, D
|
|
2009
|
12 |
7 |
p. A397-
1 p.
|
artikel
|
| 955 |
PMC65 QUALITATIVE METHODS IN PRO RESEARCH: DEVELOPMENT OF A METHODS MATRIX
|
Nixon, A
|
|
2009
|
12 |
7 |
p. A399-
1 p.
|
artikel
|
| 956 |
PMC16 QUALITY ASSESSMENT OF PUBLISHED HEALTH ECONOMIC ANALYSES FROM CHINA
|
Kaas, C
|
|
2009
|
12 |
7 |
p. A389-
1 p.
|
artikel
|
| 957 |
PMC1 RANKING HOSPITALS ACCORDING TO QUALITY
|
Baser, O
|
|
2009
|
12 |
7 |
p. A519-
1 p.
|
artikel
|
| 958 |
PMC21 REAL AND THEORETICAL COST OF ABSENTEEISM IN POLAND
|
Macioch, T
|
|
2009
|
12 |
7 |
p. A390-
1 p.
|
artikel
|
| 959 |
PMC9 REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY: AN APPLICATION OF PROPENSITY SCORE MATCHING
|
Exuzides, A
|
|
2009
|
12 |
7 |
p. A388-
1 p.
|
artikel
|
| 960 |
PMC45 REVIEWER'S CHECKLIST FOR ASSESSING THE QUALITY OF DECISION MODELS
|
Zimovetz, E
|
|
2009
|
12 |
7 |
p. A395-
1 p.
|
artikel
|
| 961 |
PMC24 SAMPSON: A HYBRID SIMULATION AND OPTIMIZATION MODEL FOR MANAGING SURGICAL RESOURCES AND REDUCING WAITING TIMES
|
Walker, HD
|
|
2009
|
12 |
7 |
p. A391-
1 p.
|
artikel
|
| 962 |
PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
|
Dragomir, A
|
|
2009
|
12 |
7 |
p. A393-
1 p.
|
artikel
|
| 963 |
PMC49 SENSITIVITY OF 15D, EQ-5D AND SF-6D TO DIABETES COMPLICATIONS: THE CASE OF CORONARY HEART DISEASE
|
Kontodimopoulos, N
|
|
2009
|
12 |
7 |
p. A396-
1 p.
|
artikel
|
| 964 |
PMC34 SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
|
Snedecor, SJ
|
|
2009
|
12 |
7 |
p. A393-
1 p.
|
artikel
|
| 965 |
PMC17 SHOULD INDIRECT COSTS OF ILLNESS BE INCLUDED IN PHARMACOECONOMIC ANALYSIS: SURVEY AMONG POLISH DECISION MAKERS AND EXPERTS
|
Wrona, W
|
|
2009
|
12 |
7 |
p. A389-A390
nvt p.
|
artikel
|
| 966 |
PMC66 THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS: A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI)
|
Anfray, C
|
|
2009
|
12 |
7 |
p. A399-
1 p.
|
artikel
|
| 967 |
PMC14 THE COST OF ABSENTEEISM IN POLAND IN 2007—DIFFERENCES WITHIN THE PROVINCES
|
Macioch, T
|
|
2009
|
12 |
7 |
p. A389-
1 p.
|
artikel
|
| 968 |
PMC71 THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY
|
Schlander, M
|
|
2009
|
12 |
7 |
p. A400-
1 p.
|
artikel
|
| 969 |
PMC31 THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE AS A POPULATION LABORATORY
|
Klungel, OH
|
|
2009
|
12 |
7 |
p. A392-
1 p.
|
artikel
|
| 970 |
PMC6 THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS
|
Singh, N
|
|
2009
|
12 |
7 |
p. A387-
1 p.
|
artikel
|
| 971 |
PMC7 THE NATURE AND SCALE OF INADEQUATE REPORTING OF DICHOTOMOUS OUTCOMES FROM SIX SYSTEMATIC REVIEWS
|
Bhanderi, M
|
|
2009
|
12 |
7 |
p. A388-
1 p.
|
artikel
|
| 972 |
PMC57 TO MAP OR NOT TO MAP? THE OXFORD HIP SCORE AND EQ-5D COMPARED
|
Oppe, M
|
|
2009
|
12 |
7 |
p. A397-
1 p.
|
artikel
|
| 973 |
PMC23 UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES
|
Müller, D
|
|
2009
|
12 |
7 |
p. A391-
1 p.
|
artikel
|
| 974 |
PMC8 USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA OBTAINED IN LITERATURE REVIEWING
|
Stafford, MR
|
|
2009
|
12 |
7 |
p. A388-
1 p.
|
artikel
|
| 975 |
PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA
|
Diva, UA
|
|
2009
|
12 |
7 |
p. A394-
1 p.
|
artikel
|
| 976 |
PMC74 WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISION-MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS
|
Baffert, S
|
|
2009
|
12 |
7 |
p. A400-
1 p.
|
artikel
|
| 977 |
PMC47 WILLINGNESS TO INITIATE THERAPY AND PUBLIC HEALTH POLICY: AN APPLICATION TO THE STRATEGIC DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR HEPATITIS C TREATMENT
|
Kauf, TL
|
|
2009
|
12 |
7 |
p. A395-
1 p.
|
artikel
|
| 978 |
PMC60 WILLINGNESS TO PAY FOR HEALTH INTERVENTIONS: BASED ON SYSTEMATIC REVIEW OF LITERATURES
|
Lee, J
|
|
2009
|
12 |
7 |
p. A398-
1 p.
|
artikel
|
| 979 |
PMH26 A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE
|
Ye, X
|
|
2009
|
12 |
7 |
p. A355-
1 p.
|
artikel
|
| 980 |
PMH60 A CONCEPTUAL MODEL OF 'CLEAR THINKING' RELEVANT TO PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
|
Bridges, JF
|
|
2009
|
12 |
7 |
p. A362-
1 p.
|
artikel
|
| 981 |
PMH30 A DYNAMIC MARKOV APPROACH ASSESSING THE BURDEN OF ILLNESS OF GENERALIZED ANXIETY (GAD) DISORDER IN CANADA
|
Bereza, BG
|
|
2009
|
12 |
7 |
p. A356-
1 p.
|
artikel
|
| 982 |
PMH14 ALZHEIMER'S DISEASE: A PHARMACOEPIDEMIOLOGICAL STUDY
|
Truter, I
|
|
2009
|
12 |
7 |
p. A352-A353
nvt p.
|
artikel
|
| 983 |
PMH10 ANÁLISE DE CUSTO EFETIVIDADE DOS ANTIPSICÓTICOS ATÍPICOS NO TRATAMENTO DA ESQUIZOFRENIA COM BASE NO NNT(NÚMERO NECESSÁRIO TRATAR)
|
Pereira, M
|
|
2009
|
12 |
7 |
p. A521-
1 p.
|
artikel
|
| 984 |
PMH56 A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT
|
Lindström, E
|
|
2009
|
12 |
7 |
p. A361-
1 p.
|
artikel
|
| 985 |
PMH47 ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA AND BIPOLAR DISORDER
|
Sanders, KN
|
|
2009
|
12 |
7 |
p. A359-
1 p.
|
artikel
|
| 986 |
PMH65 ASSOCIATION BETWEEN EARLY ANTIDEPRESSANT RESPONSE AND QUALITY OF LIFE AMONG PATIENT WITH DEPRESSION: RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY
|
Roca, M
|
|
2009
|
12 |
7 |
p. A363-
1 p.
|
artikel
|
| 987 |
PMH9 A SYSTEMATIC REVIEW OF PHARMACOLOGICAL TREATMENTS FOR BIPOLAR I MANIA
|
Parkinson, BT
|
|
2009
|
12 |
7 |
p. A351-A352
nvt p.
|
artikel
|
| 988 |
PMH4 A SYSTEMATIC REVIEW OF THE REAL-WORLD STUDY EVIDENCE COMPARING THE SAFETY AND TOLERABILITY OF DONEPEZIL, RIVASTIGMINE AND GALANTAMINE FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE
|
Lockhart, I
|
|
2009
|
12 |
7 |
p. A350-A351
nvt p.
|
artikel
|
| 989 |
PMH72 BENZODIAZEPINE USE AMONG FREQUENT ATTENDERS TO EMERGENCY DEPARTMENTS: A NATIONWIDE STUDY IN TAIWAN
|
Chou, LF
|
|
2009
|
12 |
7 |
p. A364-
1 p.
|
artikel
|
| 990 |
PMH21 BUDGET IMPACT ANALYSIS OF DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER
|
Gwiosda, B
|
|
2009
|
12 |
7 |
p. A354-
1 p.
|
artikel
|
| 991 |
PMH22 BUDGET IMPACT OF THE USE OF RISPERIDONE LONG ACTING INJECTABLE IN THE GERMAN HEALTH CARE SYSTEM
|
Gaudig, M
|
|
2009
|
12 |
7 |
p. A354-
1 p.
|
artikel
|
| 992 |
PMH33 BURDEN OF BIPOLAR DISORDER: WHAT ARE WE REALLY MEASURING?
|
Gil, E
|
|
2009
|
12 |
7 |
p. A356-
1 p.
|
artikel
|
| 993 |
PMH35 BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
|
Montejano, LB
|
|
2009
|
12 |
7 |
p. A357-
1 p.
|
artikel
|
| 994 |
PMH25 CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY
|
Hong, J
|
|
2009
|
12 |
7 |
p. A355-
1 p.
|
artikel
|
| 995 |
PMH8 CLINICAL EFFICACY AND SAFETY OF DULOXETINE IN COMPARISON WITH PLACEBO IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN POLAND
|
Pankiewicz, O
|
|
2009
|
12 |
7 |
p. A351-
1 p.
|
artikel
|
| 996 |
PMH50 CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES
|
Sicras-Mainar, A
|
|
2009
|
12 |
7 |
p. A360-
1 p.
|
artikel
|
| 997 |
PMH27 COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING
|
Navarro Espigares, JL
|
|
2009
|
12 |
7 |
p. A355-
1 p.
|
artikel
|
| 998 |
PMH12 COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS — ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT
|
Sarlon, E
|
|
2009
|
12 |
7 |
p. A352-
1 p.
|
artikel
|
| 999 |
PMH54 COMPLEX ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PATIENT CHARACTERISTICS, HEALTH CARE UTILIZATION AND COSTS IN A RETROSPECTIVE OBSERVATIONAL CLAIMS STUDY
|
Hess, G
|
|
2009
|
12 |
7 |
p. A361-
1 p.
|
artikel
|
| 1000 |
PMH1 COMPLIANCE WITH ANTIPSYCHOTIC DRUGS AND HOSPITALIZATION: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF PEOPLE WITH SCHIZOPHRENIA
|
Moisan, J
|
|
2009
|
12 |
7 |
p. A350-
1 p.
|
artikel
|
Tijdschrift beschrijving